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Abstract  
 
This review concentrates on the extracellular actions of adenosine, ATP, and 
diadenosine polyphosphates in the human cardiovascular system.  
Adenosine has important cardiovascular actions: it induces vasodilation, inhibits 
noradrenaline release from sympathetic nerve endings, inhibits thrombocyte 
aggregation and has anti-arrhythmic properties. It plays an important role in ischemic 
preconditioning. Adenosine is generated from enzymatic degradation of ATP. The 
formation of adenosine is enhanced during ischemia. In humans, adenosine evokes 
a sympatho-excitatory reflex mediated by chemically sensitive receptors and afferent 
nerves in the kidney, heart and forearm. This reflex may be active during exercise 
and ischemia. New therapies are being developed to harness the tissue-protective 
properties of adenosine against ischemic injury.  
ATP is released from aggregating thrombocytes, endothelium, and from sympathetic 
nerve endings. ATP acts on P2X purinoceptors on vascular smooth muscle cells to 
induce vasoconstriction. Stimulation of P2Y purinoceptors on endothelial cells induces 
vasodilation. The mechanism of ATP-induced vasodilation in humans is not 
elucidated yet. ATP might induce vasospasm at sites of impaired endothelial function 
and thrombus formation.  
Diadenosine polyphosphates are endogenous compounds derived from ATP. They 
are stored and released from thrombocytes, adrenal medulla, and sympathetic 
neurons.The functions of the intact molecules as well as their receptor(s) and second 
messengers are not fully characterized yet. They induce vasodilation as well as 
vasoconstriction depending of the phosphate chain length. Diadenosine 
pentaphosphate has received much attention lately, being a possible mediator in the 
pathogenesis of hypertension, but experimental data are conflicting.  
Currently, purine-agonists and antagonists are being developed as therapies against 
ischemia and other cardiovascular disorders.  
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1. Introduction 
 
Although cardiovascular actions of extracellular purines have been known for many 
years now [1], insight into their interstitial formation, metabolism, and mode of action 
has only recently been acquired [2]. Most of the pharmacologically characterized 
purine receptors have been characterized at a molecular level. Purine-agonists and 
antagonists are being developed as therapies for important cardiovascular diseases 
such as cardiac arrhythmias, heart failure and ischemic syndromes or as a diagnostic 
tool to detect reversible cardiac ischemia or flow reserve. Purines participate in the 
regulation of vascular tone, central nervous system, immune function, and the 
coagulation cascade. They can influence the function of virtually all innervated 
organs by interacting with the autonomic nervous system [3]. 
This article will focus on the cardiovascular actions of extracellular adenosine, ATP, 
and the recently identified class of diadenosine polyphosphates [4]. 
The interested reader is referred to other authors for recent reviews on the potential 
role of purine receptors in the brain with implications for the cardiovascular system 
[5;6].  
 
 
2. FORMATION AND METABOLIC FATE OF PURINES 
 
 
2.1 Adenosine 
 
Extracellular adenosine can originate from both intracellular and extracellular 
sources. The first route of intracellular adenosine-production comprises sequential 
dephosphorylation of intracellular ATP to adenosine-5'-diphosphate (ADP), 
adenosine-5'-monophosphate (AMP) and adenosine. This pathway is accelerated 
when energy demand exceeds supply, and probably represents the main route of 
adenosine formation during ischemia. The hydrolysation of AMP is catalysed by 5`-
nucleotidase, which is present within (cytosolic form) and outside cells (membrane-
bound form) [7;8] and is the rate limiting step in this pathway of adenosine formation 
[9].  
Norepinephrine-induced activation of ecto 5`-nucleotidase may provide a functional 
link between the sympathetic nervous system and adenosine formation [10;11]. A 
second pathway yielding intracellular adenosine comprises hydrolysation of ATP via 
S-adenosylmethionine to S-adenosylhomocysteine (SAH), which is further 
hydrolysed to adenosine and L-homocysteine. This oxygen-insensitive reaction is 
catalysed by S-adenosylhomocysteine-hydrolase and seems to be of minor 
importance during ischemia. During non-ischemic conditions however, the SAH 
pathway may define the transmembrane gradient of adenosine which is the driving 
force of cellular uptake of extracellular adenosine [12;13]. Recent observations in 
hyperhomocysteinemic rats in which the formation of adenosine from SAH is 
inhibited, support this view [14]. 
Adenosine formation also takes place extracellularly, where ATP is rapidly degraded 
to adenosine by widespread ecto-nucleotidases present at the outer surface of 
endothelium and vascular smooth muscle cells [15;16].  
During normoxia, intracellular adenosine and AMP-concentrations are low, and 
extracellular adenosine will be rapidly transported into the cell, where it is 
phosphorylated by adenosine kinase (main route at physiological adenosine-
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concentrations) [17], or it is deaminated to the inactive compound inosine, which is 
further metabolised into hypoxanthine and uric acid [18]. Although an extracellular 
form of adenosine deaminase exists, its role is species-dependant and probably 
plays a minor role in humans [19]. 
Adenosine diffuses through cellular membranes from extracellular to intracellular and 
vice versa, depending on the concentration gradient. This bidirectional transport is 
facilitated by nucleoside transporters located in the plasma membrane of many cells, 
such as endothelial cells, erythrocytes, vascular smooth muscle cells and 
cardiomyocytes [20]. Two types of adenosine transporter can be distuinguished: so-
called secondary active transporters driven by the transmembranous sodium 
gradient, and facilitated-diffusion (equilibrative) carriers. Facilitated-diffusion carriers 
are subdivided based on their sensitivity to the transport inhibitor 
nitrobenzylthioinosine (NBMPR)] into sensitive (es) and insensitive (ei) carriers. 
Dipyridamole and draflazine are more potent inhibitors of the es carrier than of the ei 
carrier. Sodium-dependent adenosine transporters are expressed in the gastro-
intestinal tract and in the kidney [21], but do not play a major role within the 
cardiovascular system. Uptake into erythrocytes and endothelial cells is the major 
mechanism that terminates the cardiovascular effects of luminally applied adenosine 
[13;22]. Therefore, adenosine transport inhibition is a suitable tool to harness the 
tissue-protective properties of adenosine against ischemic injury in a site-and event 
specific way.  
Physiological plasma-concentrations of adenosine in humans are 0.1 to 1 µM. The 
plasma half life of adenosine in this concentration range is very short: less then 10 
seconds [23].  
Evaluation of the pathophysiological role of adenosine in different organs is often 
estimated from plasma concentrations. This requires rapid blood collection with 
immediate addition of enzyme blockers and transport inhibitors, and the 
reproducibility of this method is low in humans in-vivo [13]. The microdialysis 
technique seems a promising new tool to study adenosine metabolism, because cells 
and enzymes are too large to pass the dialysis membrane [24;25]. Once adenosine 
has passed the dialysis membrane, it is protected from degradation. Besides, 
intravascular as well as intramuscular and subcutaneous adenosine concentrations 
can be measured, even simultaneously.  
 
 
2.2 Adenosine-5’-triphosphate 
 
ATP is an ubiquitous intracellular compound, which is released by exocytosis from 
storage granules in aggregating thrombocytes, endothelial cells, the adrenal medulla, 
and from many nerve types, including sympathetic nerve endings [3;26;27]. ATP is 
also released from smooth muscle cells [28], ischemic myocytes [29] and possibly 
from exercising muscle [30]. Triggers for ATP release from endothelial cells are 
shear stress [31;32], sympathetic nerve stimulation [33] and application of 
vasodilators such as acetylcholine and bradykinin [34].  
ATP is co-released with norepinephrine from sympathetic nerves, with acetylcholine 
in some parasympathetic nerves, and with serotonin and dopamine in nerves in the 
brain [35]. Nerves utilizing ATP as their principal transmitter, as determined with 
biochemical or pharmacological techniques, have been named `purinergic` [36].  
ATP is degraded sequentially to ADP, AMP and eventually adenosine by 
ectonucleotidases which are co-released with ATP from sympathetic nerve terminals 
Introduction 
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[37-39], and are expressed on the surface of many cells, among which endothelial 
cells. The resulting adenosine is taken up in cells which is facilitated by the 
nucleoside transporter (see paragraph 2.1).  
 
 
2.3 Diadenosine Polyphosphates 
 
Diadenosine polyphosphates form a recently identified group of naturally occuring 
molecules derived from ATP [40]. They consist of two adenosine molecules linked by 
two to seven phosphate groups, and are commonly abbreviated as APn A [40]. AP4A 
is the most extensively characterized member of this family [41]. Recently described 
polyphosphates in humans are AP7A, identified in thrombocytes [42], and AP2A in 
myocardial granules [43]. Diadenosine polyphosphates can be released from storage 
granules in thrombocytes [44-46], from chromaffin cells in the adrenal gland [47;48] 
and from autonomic nerves [49-51], and have been identified in human [43] and 
guinea pig hearts [52]. It is known that they are synthesized intracellularly from amino 
acids and ATP, a reaction catalysed by aminoacyl-tRNA synthetases [41] and other 
ligases [53] and their degradation involves asymmetrical specific and non-specific 
hydrolases primarily yielding AMP and the remaining APn-1 as products [15;54]. 
These hydrolases are inhibited by mononucleotides, and depend on bivalent cations 
for their activity. An alternative degradation route is catalysed by phosphorylases 
introducing orthophosphate, yielding two APn-moieties [54]. APn-moieties can be 
degraded by specific hydrolases as well as alkaline phosphatases, 
phosphodiesterases, and some diadenosine polyphosphate hydrolases. These 
enzymes are not only abundantly present in the vascular wall, but they can be 
cleaved from the plasma membrane and circulate as active enzymes. 
Ectohydrolases degrading diadenosine polyphosphates have been described on 
endothelial cells [55-57] vascular smooth muscle cells [57] and on the surface of 
many other cells [58]. 
The current view is that APnA are relative stable compounds in the extracellular 
space compared to mononucleotides, with half lives of several minutes [41;59]. They 
seem to derive this stability from the absence of specific degratory enzymes on blood 
cells. In contrast, ectoenzymes that degrade mononucleotides are present on 
erythrocytes, leucocytes, and thrombocytes [59]. The half-life of diadenosine 
polyphosphates is further extended by co-released ATP and ADP, which 
competitively inhibit APnA hydrolases [59].  
Diadenosine polyphosphates do not penetrate intact membranes of healthy cells [56] 
but uptake of AP4A into tumor cells has been reported [60]. 
The physiological concentration of APnA can be expected to be between the nM and 
low µM range [61]. Local concentrations at sites of platelet aggregation could 
potentially rise to 100 µM initially [41]. As described below, it is still a matter of debate 
whether responses to diadenosine polyphosphates are mediated by the intact 
molecules or by their metabolites. A simplified overview of extracellular purine 
metabolism is provided in figure 1. 
 
 
3. PURINERGIC RECEPTORS  
 
Extracellular purines mediate their effects via membrane-bound receptors (see table 
1 for an overview). These receptors are divided into two families [62]. P1 or 
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adenosine receptors have a potency order of adenosine > AMP > ADP > ATP. P2 
receptors have a potency order of ATP > ADP > AMP > adenosine. P1- but not P2 
receptors are antagonised by xanthine derivates such as caffeine and theophylline 
[63].  
 
 
3.1 P1 receptors 
 
Adenosine receptors are subdivided into four subtypes based on pharmacological 
and molecular profiles, i.e. A1, A2A, A2B and A3 -receptors, all of which are G protein-
coupled [2]. As outlined in tabel 1, many celltypes express various types of P1 
receptors, which often mediate opposite actions. The final action of adenosine is 
determined by the relative expression of these receptors, differences between P1 
subtype receptors in affinity for adenosine and differences between various cell types 
in coupling of P1 receptors to second messenger systems. This diversity even exists 
at the level of a single cell [64] which complicates the extrapolation of in vitro 
observations to the effects of adenosine in an intact organism.  
A1-receptors are coupled to adenylate cyclase via Gi -proteins, resulting in decreased 
intracellular levels of the second messenger cAMP. Stimulation of A1-receptors also 
activates intracellular phospholipase C [65;66] and opens KATP-channels that are 
located in both the plasma membrane and the inner mitochondrial membrane [67]. A1 
-receptor-induced opening of mitochondrial KATP channels mediate the protective 
effects of adenosine in the phenomenon of ischemic preconditioning [68;69]. 
Opening of KATP channels in the plasma membrane is involved in adenosine-
mediated vasodilation [67;70].  
A2 receptors, linked to Gs-proteins, stimulate adenylate cyclase activity, which results 
in a subsequent increase in intracellular cAMP levels. A2A and A2B receptors are 
expressed on vascular smooth muscle and endothelial cells [71-73], where both 
mediate vasodilation. In comparison to A2B receptors, the affinity of A2A receptors for 
adenosine is relative high and they have a wider tissue distribution. The physiological 
importance of this pharmacological subdivision in A2 receptors is not yet known.  
The signal transduction mechanism of the A3 receptors comprises inhibition of 
adenylate cyclase activity [74] as well as stimulation of phospholipase C [75], 
resembling the A1 receptor. A3 receptors are typically xanthine-resistant. The 
physiological significance of the A3 receptor is not well understood, but there is 
increasing evidence for a role in ischemic preconditioning [76]. 
 
 
3.2 P2 receptors 
 
On the basis of their specific transduction pathways, P2 receptors are subdivided into 
two families: the P2x ionotropic ligand-gated ion-channel receptors and the P2y 
metabotropic G-protein-coupled-receptors [77;78]. P2x receptors were originally 
cloned in excitable cells and mediate fast permeability changes to cations [79;80]. 
Signal transduction from P2y receptors occurs by activation of phospholipase C 
and/or stimulation or inhibition of adenylate cyclase. To date, at least seven 
mammalian P2x- and six P2y receptor subtypes have been cloned [2]. The most 
recently cloned P2y-12 receptor plays an important role in platelet aggregation [81]. 
This platelet P2y receptor is currently the only P2 receptor for which a specific 
antagonist (clopidogrel) is available for human use [82;83]. 
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The P2x receptors are present in vascular smooth muscle cells (VSMC) and mediate 
vasoconstriction [2]. Recently, the expression of P2x receptors in human endothelial 
cells was reported [84]. Their functional significance remains to be elucidated, they 
appear to be associated with cell adhesion and permeability [35] and may play a role 
in shear stress-mediated vasodilation [84;85]. P2y receptors are present on vascular 
endothelial cells and on VSMC and mediate relaxation [2].  
The lack of specific antagonists hinders investigation of the (patho)physiological 
sigificance of the various P2 receptor subtypes. The drug suramin acts as a P2 
receptor antagonist with limited specificity and efficacy [86]. It does not antagonise all 
P2 receptors, and it does not discriminate between P2x and P2y receptors. 
Furthermore, suramin inhibits ecto-nucleotidase [87] and neural diadenosine 
polyphosphate hydrolases [88], which further complicates the interpretation of ligand-
binding studies. Its carcinogenic properties hinder its use in human in-vivo studies. 
Pyridoxal-5-phosphate (P5P) and pyridoxalphosphate-6-azophenyl 2`,4`-disulfonic 
acid (PADS) are often used to block P2x receptors, but these antagonists are not 
selective [89].  
 
 
3.3 Binding sites for diadenosine polyphosphates 
 
The receptor(s) for diadenosine polyphosphates and their second messengers have 
yet to be fully characterized. Consequently, at present it is preferable to avoid the use 
of terms such as P4, P2yAP4A or dinucleotide receptors in favour of more general 
terms such as binding sites [90]. APnA can activate subclasses of P2x- and P2y 
receptors, as well as specific binding sites [2;91]. A binding site specific for AP4A has 
been reported in mouse brain [92], mouse heart [93] and in rat brain [94]. It was 
shown recently that diadenosine polyphosphates activate calcium-dependent 
potassium conductance in smooth mucle cells derived from porcine aorta. This action 
is most likely mediated via P2y-receptors and possibly also partially by a specific 
receptor for AP4A [95]. 
 
 
4. CARDIOVASCULAR EFFECTS OF PURINES 
 
 
4.1 Vascular tone 
 
Depending on the site of adenosine formation (luminal versus interstitial) [96], 
adenosine stimulates A2-receptors [97] on either endothelial [71] or vascular smooth 
muscle cells [2], resulting in endothelium dependent [71;98] or independent 
vasorelaxation [99].  
In humans, adenosine infusion into brachial or coronary arteries causes a dose-
dependent vasodilation [100;101] which is mediated by P1-receptors, because it can 
be blocked by either caffeine or theophylline. Forearm vasodilation induced by intra-
brachial adenosine-infusion is, at least partially, mediated by nitric oxide [102] 
supporting the importance of the endothelium in the vasodilator response to luminal 
adenosine. 
Stimulation of A1-receptors in renal glomerular afferent arterioles [103] results in 
vasoconstriction which may play a role in tubuloglomerular feedback [104]. In other 
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vascular beds, vascular A1 receptors may mediate vasorelaxation by opening ATP-
dependent potassium channels [105-107].  
 
ATP is capable of inducing both vasoconstriction or vasodilation, depending on the 
experimental conditions and the integrity of the endothelial cells. In general, P2x and 
P2y receptors on vascular smooth muscle cells mediate vasoconstriction, whereas 
P2y receptors on endothelial cells mediate vasodilation [77]. P2x receptors on 
vascular smooth muscle cells are stimulated by ATP released from perivascular 
sympathetic nerve endings, while ATP acting on endothelial receptors is derived from 
endothelial cells and aggregating thrombocytes. This dual vasomotor-action of ATP 
may have important clinical consequences: during thrombocyte aggregation at sites 
of severe atherosclerosis, locally released ATP might induce vasoconstriction 
mediated by P2x receptors on vascular smooth muscle cells, unopposed by P2y 
receptor-mediated vasodilation because of endothelial damage. It was recently 
shown that activation of endothelial P2y receptors induces release of EDHF, the 
vasodilator action of which can be counteracted functionally by smooth muscle cell 
P2x receptor stimulation [108;109]. The vasomotor action of intra-arterially infused 
ATP in the forearm of healthy volunteers is dominated by vasodilation which can not 
be explained by stimulation of P1 receptors. The mechanism of this ATP-induced 
vasodilation in humans has not been elucidated yet but does not seem to involve 
endothelial nitric oxide release [110;111].  
 
The effects of diadenosine polyphosphates on vascular tone are a function of the 
number of phosphate groups in the molecule, the species and the origin of the 
vascular bed that is studied, and the presence or absence of intact endothelial cells. 
For example, Ralevic et al. demonstrated that diadenosine-polyphosphate-induced, 
P2x -receptor-mediated vasoconstriction in the isolated perfused rat mesenteric 
artery increases with the length of the phosphate chain [112]. Generally, in intact 
animals or vessels AP2A, AP3A and AP4A are vasodilators and AP5A and AP6A are 
vasoconstrictors.  
AP3A and AP4A have been shown to induce vasodilation in rabbit mesenteric and 
rabbit coronary vascular beds [113;114]. Continuous intravenous administration of 
AP4A in anesthetized dogs induced hypotension by primarily dilating the arterial 
resistance vessels, without eliciting reflex tachycardia [115]. Endothelial release of 
nitric oxide and/or prostacyclin are involved in this vasodilator response 
[113;116;117]. 
AP5A and AP6A induce vasoconstriction in human umbilical vessels in vitro [118]. In 
rats, these dinucleotides may induce a rise in blood pressure and may be involved in 
the pathogenesis of essential hypertension [45].  
Until recently data concerning the vasoactive properties of APnA in the human 
vasculature in-vivo were scarce. We recently demonstrated that intra-arterial infusion 
of AP5A into the brachial artery of healthy volunteers evoked a dose-dependent 
forearm vasodilator response, equal to adenosine but less than ATP at equimolar 
doses [22]. This vasodilator action was inhibited by theophylline and augmented by 
dipyridamole, which implies involvement of P1-receptors. Kikuta et al. used a stable 
analogue of AP4A in humans to induce controlled hypotension during surgical 
procedures [119]. It has been suggested that some diadenosine polyphosphates are 
involved in blood-pressure regulation [45] or the pathogenesis of essential 
hypertension [120], but direct evidence for these concepts is currently lacking. 
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4.2 Heart 
 
In the heart, adenosine receptors are expressed in the sinus node, atrioventricular 
(AV) node, atrial and ventricular myocardial cells, coronary circulation and autonomic 
nerve endings. For the coronary circulation and autonomic nerve endings, the reader 
is refered to paragraph 4.1 and 4.5 respectively.  
Within the sinus node, stimulation of A1 receptors and subsequent reduction in 
intracellular cAMP and opening of potassium channels results in hyperpolarization of 
the cell membrane which reduces the spontaneous depolarization and subsequent 
firing rate. Likewise, in the AV-node A1 receptor stimulation results in 
hyperpolarization and a subsequent reduction in AV-nodal conduction velocity which 
is responsible for adenosine-induced termination of AV-nodal tachycardias [19]. In 
atrial myocardial cells, A1 receptor stimulation and subsequent sarcolemmal 
hyperpolarisation prevents calcium influx which reduces contractility, irrespective of 
sympathetic tone [121;122]. This direct negative inotropic action of adenosine is not 
observed in ventricular myocardial cells, where stimulation of A1 receptors reduces 
contractility only in the presence of β-adrenoceptor stimulation. This interaction of 
adenosine with the sympathetic nervous system involves inhibition of β-
adrenoceptor-induced activation of adenylate cyclase [19;123]. Finally, A1 and A3 
receptor stimulation prevents ischemia-induced arrhythmias and cell death [124] (see 
chapter 5).  
Intravenous infusion of ATP in humans exerts its negative chronotropic and 
dromotropic effects on the heart after degradation to adenosine [124]. In isolated cell 
and tissue preparations, ATP has a direct positive inotropic effect on atrial and 
ventricular myocardial cells, which is mediated by a P2x receptor mediated increase 
in intracellular calcium [125].  
Diadenosine polyphosphates have been shown to influence both coronary blood flow 
and cardiac electrical activity [126]. AP3-6A exert a negative inotropic effect in canine 
and guinea pig myocardium, probably mediated by P1-receptors, but a yet undefined 
receptor may also be involved [127-129]. Recent reports suggest a role for 
diadenosine polyphosphates in cardioprotection against ischemia [130;131]. The role 
of degradation products of APnA must be clarified first however, as well as whether 
specific APnA-receptors on endothelial cells and VSMC exist.  
 
 
4.3 Kidney 
 
The vascular effects of adenosine in the kidney (glomerular afferent vasoconstriction 
and efferent vasodilation) have been reviewed [132]. Other adenosine mediated 
renal effects include A1-receptor-mediated inhibition of renin release [133], mediation 
of tubuloglomerular feedback [104], and increased salt reabsorption in the proximal 
tubule [134]. Acting in concert, these actions of adenosine reduce diuresis by 
reducing glomerular filtration rate and increasing tubular salt reabsorption. However, 
medullary A2 receptor-mediated vasodilation and subsequent increased diuresis may 
override A1 receptor-mediated salt and water retention [135]. 
ATP induces vasoconstriction in rat afferent glomerular arterioles, and has no effect 
on the efferent arterioles [136]. For rabbit and human renal arteries, it has been 
shown that exogenous ATP mainly acts after degradation to adenosine [137]. 
The renal vascular effects of APnA are not completely clear [138-140]. Apart from 
differences in models and species, differences in metabolism may be basis of 
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discrepancies (see paragraph 4.1). Diadenosine polyphosphates also have a 
mitogenic effect on mesangial cells, which leaves a possible role for them open in 
accelerating the process of glomerulosclerosis [141]. 
 
 
4.4 Haemostasis 
 
Adenosine inhibits platelet aggregation [142], whereas [143] adenosine-5’-
diphosphate (ADP) induces thrombocyte aggregation mediated by a thrombocyte 
specific P2y-12 receptor. ATP is an endogenous antagonist for the P2y-12 receptor 
[81]. The clinical importance of this action is underlined by results from recent clinical 
trials which show additional benefit of P2y-12 receptor antagonists on survival in 
patients with unstable angina (see chapter 6). AP3A is a potent stimulator of platelet 
aggregation, mediated by its metabolite ADP [144]. In contrast, AP4A and AP5A 
inhibit ADP-induced platelet aggregation [145;146]. ATP strongly induces release of 
the anti-thrombotic factor tissue-type plasminogen activator (tPA) from the intact 
human vascular bed in vivo [145;147]. The clinical relevance of this finding is not 
known yet. 
 
 
4.5 Adenosine and the sympathetic nervous system 
 
 
4.5.1 Adenosine and sympathetic afferents 
 
In conscious humans and some larger animals such as dog, adenosine stimulates 
carotid chemoreceptors [148] and sympathetic afferent nerves in heart [149], kidney 
[150] and forearm muscle [151;152]. In the carotid body of the rat and rabbit, both A1 
and A2 receptors are expressed [153;154]. The A2 receptor is most likely involved in 
adenosine-induced carotid body excitation [155] but human in-vivo data are lacking. 
Adenosine-sensitive afferent nerves in heart, kidney and skeletal muscle are possibly 
involved in the sympatho-excitation that accompanies ischemia in these organs. The 
receptor subtype that is involved in adenosine-mediated activation of these 
sympathetic afferents is largely unknown, but studies in the dog heart suggest the 
involvement of A1 receptors [156].  
Since adenosine is rapidly taken up by erythrocytes, the site and mode of adenosine 
administration determine which adenosine sensitive afferents are stimulated. During 
continuous intravenous infusion of adenosine as performed during adenosine-
Thallium stress testing, the stimulation of carotid body chemoreceptors are probably 
solely responsible for the sympatho-excitation [157]. This results in stimulation of the 
sympathetic nervous system and the respiratory system [151;158], and a subsequent 
increase in systolic blood pressure, plasma renin activity and ventilation [159]. These 
effects are not elicited during anesthesia, because an intact autonomic reflex loop is 
essential [160]. The rise in systolic blood pressure is not always observed during 
intravenous adenosine infusion in healthy volunteers, due to differences in the 
degree of caffeine abstinence [161].  
Several mechanisms for involvement of adenosine-induced sympatho-excitation in 
the (patho)physiology of the cardiovascular system have been put forward. First, 
adenosine may be an important trigger of the exercise-induced pressor reflex [162]. 
This hypothesis is supported by the observation that theophylline blunts the 
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sympatho-excitation that is evoked by isometric exercise [163] and increased levels 
of forearm interstitial adenosine during isometric handgrip as determined using 
microdialysis. However, this last observation may be confounded by mechanical cell 
rupture due to the presence of a microdialysis probe in a contracting muscle and 
subsequent increases in interstitial adenosine.  
Second, adenosine may be an afferent signal for sympatho-excitation in heart failure 
which is an important marker of reduced survival in this condition [164]. Patients with 
heart failure have increased levels of adenosine in proportion to disease severity 
[165], as well as an augmented sympathetic response to isometric exercise which 
can be partially reversed by the adenosine receptor antagonist caffeine [166]. In 
healthy subjects, the angiotensin II receptor antagonist losartan blunts the 
generalized sympatho-excitation that is induced by forearm infusion of adenosine 
[152]. These results suggest that the beneficial effect of inhibition of the renin-
angiotensin system in patients with heart failure is partially mediated by inhibition of 
the adenosine-induced sympatho-excitation. 
Third, ischemia-induced formation of interstitial adenosine and subsequent 
sympatho-excitation could potentially be involved in remote ischemic preconditioning: 
a phenomenon in which ischemia of a remote organ such as kidney, gut, or skeletal 
muscle protects the heart against subsequent ischemic injury [167;168] (see chapter 
5).  
Fourth, sympatho-excitation in response to intravenous adenosine infusion may play 
a role in the pro-arrhythmic action of adenosine that sometimes occurs a few minutes 
after a bolus injection of adenosine when used to terminate AV-nodal tachycardias 
[169]. 
Finally, adenosine may be involved in hypoxia-induced stimulation of peripheral 
chemoreceptors and the subsequent increase in ventilation [170].  
Recently, adenosine-induced activation of hepatic sympathetic afferents have been 
suggested, which may be implicated in sympathetic nervous system-mediated renal 
salt retention. Whether this reflex is clinically important and involved in salt retention 
in patients with liver cirrhosis remains to be elucidated [171;172]. 
 
 
4.5.2. Adenosine and central regulation of sympathetic outflow 
 
At the area postrema, circulating adenosine can easily access the nucleus tractus 
solitarius [173]. Micro-injections of adenosine in the caudal part of the nucleus tractus 
solitarius of the rat induce contrasting effects on blood pressure, depending on the 
adenosine receptor type that is stimulated: A1 receptor activation induces an increase 
in blood pressure whereas A2a receptor activation reduces blood pressure and 
sympathetic outflow [174;175]. The role of these central actions of adenosine in the 
hemodynamic effects of intravenous infusion of adenosine is not known. 
 
 
4.5.3. Adenosine and sympathetic efferents 
 
Adenosine inhibits norepinephrine release by stimulating A1 receptors on sympathetic 
nerve endings [176]. This local action of adenosine on sympathetic efferents 
functionally counteracts the central or reflex-mediated increase in sympathetic nerve 
traffic and subsequent release of norepinephrine. This action has been demonstrated 
in various in vitro and in vivo models including in humans in vivo [152;177]. Human in 
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vivo data on the involved adenosine receptor subtype are lacking. This action of 
adenosine is possibly involved in the local sympatholysis in exercising muscle [178] 
which contributes to the local vasodilation in exercising muscle. In the heart, this 
sympatho-inhibitory action of adenosine at sympathetic nerve terminals may 
contribute to the anti-arrhythmic action of adenosine in the ischemic myocardium 
[179]. In vitro, an A2a receptor mediated increase in sympathetic norepinephrine 
release has been described, but the functional significance of this modulation is not 
known [180;181].  
 
 
4.6 Integrated cardiovascular action of adenosine in humans 
 
The cardiovascular effect of parenteral adenosine administration in conscious 
humans depends on the route of administration (intra-arterial versus intravenous) 
and the velocity of infusion (bolus versus continuous infusion) [148;158]. These 
differences are explained by the kinetics of extracellular adenosine (rapid uptake by 
endothelial cells and erythrocytes) and the relative contribution of sympatho-
excitation as elicited by adenosine sensitive sympathetic afferents [13]. In addition, 
the period of caffeine abstinence is critical for the evaluation of cardiovascular 
responses to adenosine [161].  
After a typical intravenous bolus injection of 6-12 mg, the inhibitory actions of 
adenosine on sinus node firing rate and AV conduction velocity predominate the 
response [148]. Therefore, this method of administration is prefered when adenosine 
is used to terminate supraventricular tachycardias [182]. When adenosine is infused 
continuously at a frequently used infusion rate of 140 µg·kg-1·min-1, bradycardias or 
AV block are only rarely observed. In stead, an increase in heart rate is the typical 
response which is frequently accompanied by some chest discomfort, an increase in 
tidal volume, sympatho-excitation and, if caffeine is abstained for at least 24 hours, 
an increase in systolic blood pressure [157;161;183]. Of note, continuous intravenous 
administration of adenosine does not result in forearm vasodilation [184]. Apparently, 
these conditions facilitate stimulation of carotid chemoreceptors as supported by its 
inhibition during 100% oxygen breathing and observations in patients in whom the 
carotid chemoreceptors have been removed surgically [157;183].  
Continuous infusion of adenosine into the brachial artery at rates < 0.5 mg·min-1 
induces forearm vasodilation and inhibits norepinephrine release in the forearm. 
Although heart rate and blood pressure are not affected under these conditions, 
careful monitoring reveals generalized sympathoexcitation probably resulting from 
stimulation of metabolic afferents in the forearm skeletal muscle [152;185]. Bolus 
injections of adenosine into the brachial artery result in more profound sympatho-
excitation as reflected by an increase in heart rate and peroneal muscle sympathetic 
nerve activity possibly resulting from the higher local peak concentrations as 
compared with continuous infusions [186]. Injection of adenosine into the femoral 
artery also results in sympatho-excitation but this does probably not represent local 
stimulation of muscle sympathetic afferents but rather reflects local vasodilation with 
a subsequent decrease in blood pressure and baroreflex activation or originates from 
systemic spillover of locally infused adenosine [187]. 
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5. INVOLVEMENT OF ADENOSINE IN ISCHEMIC PRECONDITIONING 
 
Extracellular formation of adenosine is increased during hypoxia and ischemia [188]. 
Adenosine is a protective agent in the setting of ischemia-reperfusion: in the heart, 
adenosine reduces oxygen-demand by its negative inotropic and chronotropic effects 
and improves oxygen supply by coronary vasodilation. Its electrophysiological effects 
reduce the risk of ischemia-induced arrhythmias. Adenosine also inhibits 
noradrenaline release and sympathetic neurotransmission during ischemia, which 
could limit catecholamine-induced arrhythmogenesis and vasoconstriction [179]. 
Additionally, during ischemia and reperfusion adenosine inhibits thrombocyte 
aggregation [143] and adhesion of neutrophil cells, inhibits cytokine release and free 
radical formation [189].  
Ischemic preconditioning, i.e. the concept that brief periods of ischemia and 
reperfusion reduce the rate of cell death during a subsequent prolonged period of 
ischemia, was first described in the dog myocardium by Murry et al. [190], but has 
been observed in skeletel muscle [191], liver and brain [192;193]. In humans in vivo, 
this phenomenon is likely to occur as well [194;195]. However, definite prove is 
difficult to obtain due to the lack of a good model to study ischemic injury in humans 
in vivo (see table 2).  
Endogenous adenosine, acting through its A1-receptors, triggers and mediates the 
process of ischemic preconditioning in various animal models and human in-vitro 
experiments with myocardial cell cultures or isolated atrial tissue preparations 
[76;196;197]. The second messenger system includes protein kinase C activation 
and subsequent opening of mitochondrial KATP channels [198;199]. The final 
mechanism of retarded cell death is not known but may involve inhibition of 
ischemia/reperfusion-induced apoptosis [200-203].  
 
 
6. POTENTIAL CLINICAL APPLICATIONS OF PURINES 
 
Adenosine is the drug of first choice for treatment of atrio-ventricular node re-entry 
tachycardia, for which it has FDA approval. Nowadays, selective and stable 
adenosine A1 receptor agonists are being developed, in order to slow atrioventricular 
conduction at concentrations that do not cause the significant coronary vasodilation 
or systemic hypotension, that is associated with bolus injections of adenosine [204]. 
In addition, these compounds are not expected to cause chemoreceptor mediated 
sympatho-excitation although this property of A1 agonists has not been studied in 
humans yet. 
The vasodilator properties of adenosine are exploited in the adenosine-Thallium 
stress test. The advantage of adenosine over dipyridamole is its short lasting action 
which improves its tolerability [205].  
A1 receptor antagonists may prove valuable in the prevention of radiocontrast-
mediated renal injury [206;207]. Furthermore, these agents have diuretic properties 
which may be promising in patients with congestive heart failure. In these patients A1-
antagonists may prevent prerenal failure because their diuretic properties are 
associated with renal vasodilation that is limited to the afferent arterioles [208]. A1 -
and A 3 receptor agonists may also exert tissue-protection in the setting of cardiac 
bypass graft surgery, limb ischemia, and reconstructive surgery.  
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Systemic side effects (sympatho-excitation, AV block, vasodilation) are the major 
problems when systemic administration of adenosine is used to exploit its protective 
actions against ischemic injury. In theory, various strategies are possible to 
circumvent these drawbacks among which are the use of selective adenosine 
receptor agonists, the administration of a nucleoside transport inhibitor or the local 
infusion of adenosine. Before selective A1- or A3 receptor agonists can be used for 
this purpose, more research is needed to determine the involvement of the various 
adenosine receptor subtypes in the systemic actions of adenosine in humans. 
Because extracellular adenosine is also formed in non-ischemic conditions, high 
grade inhibition of nucleoside transport also results in systemic side effects that are 
similar to the effects of intravenous infusion of adenosine [13]. Therefore, systemic 
administration of a nucleoside transport inhibitor needs carefull dose titration to 
exploit the benficial effects of endogenous adenosine in the setting of ischemia 
without inducing undesired systemic actions. An alternative approach to prevent 
systemic side effects is the local, intra-arterial, administration of adenosine or a 
nucleoside transport inhibitor. Several trials in humans have shown cardioprotective 
actions of intracoronary infusion of adenosine in the setting of (acute) coronary 
angioplasty [209-211]. Likewise, intracoronary infusion of the nucleoside transport 
inhibitor dipyridamole reduced the ischemia-induced decrease in left ventricular 
function and ischemia-induced changes in ECG [212;213]. 
The antithrombotic drugs clopidogrel and ticlopidine, acting as antagonist on the 
platelet P2y-12 receptor have proven their capacity to reduce the risk of recurrent 
heart attacks and strokes [82;83].  
Stable and potent analogues of APnA are being developed for different purposes 
such as inhibition of platelet aggragation [214-216].  
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Table 1: Cardiovascular distribution and effects of purine receptors 
 
 
Class 
 
 
 
Sub- 
type 
 
Second messenger 
system(s) 
 
Tissue distribution 
 
Cardiovascular effects 
P1 A1 Gi/o coupled, ↓cAMP 
↑ PLC, ↑ IP3, ↑PKC, 
↑ KATP-conductance, 
↑ MAP kinase 
↑ IP3K/Akt pathway 
Brain stem 
Carotid chemoreceptors 
Sympathetic efferents 
Sinus and AV node  
 
Atrial cardiomyocytes 
 
 
Ventricular cardiomyocytes 
 
 
Endothelial cells 
 
Vascular smooth muscle cells  
 
Juxtaglomerular cells 
Renal tubular cells 
Increased sympathetic outflow [217]  
Functional significance unknown [154] 
Inhibition of norepinephrine release [176] 
Sinus bradycardia; AV conduction delay 
(AV blockade) [19] 
Decrease in contractile force both in the 
absence and presence of catecholamines 
[121;122]; ischemic preconditioning [218] 
Decrease in contractile force only in the 
presence of catecholamines [19;123]; 
ischemic preconditioning [194]  
NO release, vasodilation; ischemic 
preconditioning [219;220]  
vasoconstriction in glomerular afferents 
[221;222] 
Reduced renin release [133] 
Sodium retention (A2 mediated medullary 
vasodilation overrides this tubular effect of 
adenosine) [135;223] 
 
 A2a Gs coupled, ↑ cAMP 
↑ KATP conductance 
Brain stem 
Carotid body chemoreceptors 
 
Endothelium 
 
Vascular smooth muscle cell 
Platelets 
Hypotension [217] 
Increase in sympathetic afferents, reflex 
mediated sympatho-excitation [155] 
Hyperpolarization and NO release, 
vasodilation [102;107;224] 
Vasodilation [225] 
Inhibition of thrombocyte aggregation [226] 
 
 A2b As A2a As A2a As A2a (functional significance not well 
known, probably similar to A2a) 
 
 A3 Gi Gq coupled, as A1 Widely distributed Physiological significance largely 
unknown. Involved in ischemic 
preconditioning [227].  
May serve as a ‘backup’ for the A1 receptor 
 
P2 P2X1 Ion channel,  
↑ intracellular Ca2+ 
Vascular smooth muscle cell 
Brain stem 
 
 
Cardiac myocytes 
Vasoconstriction [228;229] 
Increase in sympathetic outflow (rostral 
VLM) or decrease in sympathetic outflow 
(caudal VLM) [230] 
Increased contractility [231] 
 
 P2X4,5,7 Ion channel, 
↑ intracellular Ca2+ 
Endothelial cells Functional significance not well known, 
role in shear stress induced vasodilation? 
[232-234] 
 
 P2Y1, 2 Gq/11 coupled, PLC, 
PKC activation, IP3 
formation, 
↑intracellular 
calcium 
Endothelial cells 
Smooth muscle cells 
 
Cardiac myocytes 
Vasodilation [235] 
P2Y1: vasodilation, proliferation; P2Y2: 
vasoconstriction, proliferation [236]  
Increased contractity [237] 
 
 
P2Y12 ↓ cAMP Platelets Thrombocyte aggregation [81] 
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Table 2: Evidence for ischemic preconditioning in humans 
 
Author Method Observation Limitations 
 
Ikonomidis et al [194] 
 
 
 
Cultured non- beating 
ventricular cells 
 
IPC increases 
survival 
 
Highly artificial 
conditions 
Speechly-Dick et al 
[218] 
 
 
 
 
 
 
 
 
Isolated, superfused, 
isometrically 
contracting atrial 
trabeculae 
Hypoxia + glucose 
deprivation reduces 
contractile 
dysfunction; role for 
adenosine, 
subsequent PKC 
activation and 
opening of KATP-
channels 
No direct 
measurement of cell 
death 
Cleveland et al [238] 
 
 
 
Idem Idem, sulphonylurea 
derivatives prevent 
‘IP’ 
Idem 
Yellon et al [76] 
 
 
 
 
Coronary artery 
bypass surgery/aortic 
cross clamping 
Repeated global 
myocardial ischemia 
reduces intracellular 
ATP loss. 
Idem 
Deutsch et al [239] 
 
 
 
 
 
 
Coronary angioplasty 
with ECG monitoring 
and venous lactate 
measurements 
The increase in 
coronary venous 
lactate and ECG 
changes are reduced 
after repeated 
ischemia 
Idem 
Tomai et al [240;241] 
 
 
 
Coronary angioplasty 
with ECG monitoring 
Glibenclamide and 
bamiphylline prevent 
‘IP’. 
Idem 
Napoli et al [242] 
 
 
 
Epidemiological 
observation 
Predromal angina 
reduces infarct size 
Possible confounding 
by reduced time to 
reperfusion 
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Introduction 
 
The first report about the cardiovascular effects of nucleosides and nucleotides dates 
back from amply seventy years ago (Drury and Szent-Gyorgi, 1929). Nowadays, 
endogenous purines are known to exert a multitude of cardiovascular effects. These 
were briefly outlined in chapter 1A, with a focus on adenosine. The endogenous 
purine adenosine acts on cell surface receptors, resulting in numerous cardio- and 
vasoprotective effects, like modulation of vascular tone, presynaptic inhibition of 
noradrenaline release, ischaemic preconditioning, and inhibition of platelet 
aggregation. Many details about the cardiovascular pharmacology of purines in 
humans remain to be answered, however, and the following chapters deal with some 
of them.  
 
This thesis deals with the following study questions: 
 
1. What is the effect of intra-arterially infused dipyridamole and adenosine on 
interstitial and intravascular adenosine concentrations (chapter 2). 
As outlined in chapter 1, adenosine plays an important role in the 
pathophysiology of ischemia and reperfusion. In particular, its protective 
actions against the sequels of ischemia are of therapeutic interest in humans. 
However, it is still not known how these effects could optimally be exploited in 
a clinical context. Furthermore, adenosine is frequently used as a 
pharmacological tool to detect reversible perfusion defects in the heart.  
The biological availability of intravenously or intra-arterially infused adenosine 
has not been well characterized in humans in vivo. Since the pharmacological 
actions of adenosine will vary depending on its site of action, this knowledge 
could improve the clinical application of adenosine and dipyridamole as tools 
to diagnose ischemia and prevent ischemia-reperfusion injury. 
2. What is the role of adenosine in the pressor response to exercise in healthy 
volunteers (chapter 2). 
Several lines of evidence suggest a role for adenosine in the exercise-pressor 
reflex. This reflex is augmented in patients with heart failure and may play a 
role in the deleterious activation of the sympathetic nervous system in these 
patients. Therefore, we studied the possible role of adenosine in this reflex in 
healthy volunteers. 
3.  Is there a difference in the mechanism of vasodilation between interstitial and 
intravascular adenosine (chapter 2 and 3).  
Partially based on observations in chapter 2 and previous observations with 
another adenosine uptake inhibitor draflazine, we argued that dipyridamole 
and adenosine may both induce vasodilation by stimulating adenosine 
receptors. However, these agents could differ in the involved cell populations 
that are responsible for vasodilation: adenosine could stimulate endothelial 
cells whereas dipyridamole could preferentially stimulate vascular smooth 
muscle cells. This difference could result in differences in post-receptor 
pathways that are involved in vasodilation with potential importance for the 
clinical use of these drugs to detect reversible perfusion defects in the heart. 
In particular the interaction with glibenclamide, a blocker of ATP-sensitive 
potassium channels could differ between dipyridamole and adenosine with 
important consequences for patients with type 2 diabetes mellitus who are 
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treated with glibenclamide and scheduled for a pharmacological stress-
thallium scan.  
4. What is the vasomotor action of AP5A in humans, and what is the role of 
adenosine in AP5A-induced changes in vascular tone (chapter 4). 
 Animal studies suggest a vasoconstrictor action of the complex endogenous 
diadenosine AP5A. Furthermore, platelet derived AP5A has been suggested to 
cause hypertension. However, these studies do not definitely exclude 
confounding by vascular actions of degradation products of AP5A such as 
adenosine. Furthermore, human in-vivo data are lacking. Therefore, we 
decided to study the effect of AP5A on forearm vascular tone in healthy 
volunteers.  
5. Do benzodiazepine-derivates inhibit cellular adenosine uptake in the human 
forearm (chapter 5). 
 Clinically, benzodiazepines are frequently used in the setting of an acute 
myocardial infarction. In-vitro studies suggest that these substances inhibit 
nucleoside transport which could theoretically improve tolerance to ischemia-
reperfusion injury by augmenting the protective action of endogenous 
adenosine that is released in ischemic cardiac tissue. This study was 
performed to explore a possible effect of benzodiazepines on adenosine 
uptake in humans in vivo. 
6. What is the mechanism of ATP-induced vasodilation in the human forearm 
(chapter 6). 
 Although the potent endothelium-dependent vasodilator action of adenosine-
5’-triphosphate (ATP) is known for some time, its mechanism of action in 
humans in vivo is still not completely resolved. Since ATP, released from 
aggregating thrombocytes, may induce paradoxical vasoconstriction at sites of 
dysfunctional endothelium, it is of potentially clinical importance to elucidate 
the mechanism of ATP-induced vasodilation as it may reveal new targets for 
pharmacological treatment of patients with atherosclerosis. In this chapter, the 
role of cyclo-oxygenase products and various key molecules that mediate 
vasodilation by endothelium-derived hyperpolarizing factors (ATP-sensitive 
potassium channels, Ca2+-sensitive potassium channels, Na+/K+-ATPase) is 
investigated. 
7. Is the vasodilator response to adenosine reduced in patients with 
uncomplicated insulin dependent diabetes mellitus (chapter 7). 
Diabetes mellitus is associated with increased cardiovascular morbidity. The 
vascular effects of adenosine are impaired in animal models of diabetes. Is the 
presence of type 1 diabetes perse associated with a reduced action of 
adenosine? To answer this question, we evaluated the vasodilator response to 
adenosine in patients with uncomplicated insulin dependent diabetes mellitus 
and compared these observations with a matched control group. 
 
 
Chapter 2 up to chapter 5 inclusive are centered around nucleoside transport. 
Nucleoside transport is characterized both biochemically -using microdialysis- and 
pharmacologically, using dipyridamole as a nucleoside transport inhibitor and the 
vasodilator response to intra-arterially infused adenosine as a biomarker of 
adenosine receptor stimulation. Chapter 5 focuses on a possible adenosine-transport 
inhibiting effect of two different compounds; diazepam and midazolam. Chapter 6 
involves the vasodilatory mechanism of the nucleotide ATP. Chapter 7 deals with a 
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more clinical issue: the vasodilator response to adenosine in patients with 
uncomplicated insulin dependent diabetes mellitus. The last chapter provides a 
summary of the thesis.  
 
 
Methods applied 
 
 
The perfused forearm technique 
 
In the experimental studies described in this thesis, the perfused forearm technique 
was applied to quantify actions of endogenous or exogenous substances on vascular 
tone. The brachial artery is cannulated for infusion of purines and other vasoactive 
compounds and for blood pressure recording. Intra-arterial infusion of vaso-active 
substances allows the use of very low cumulative doses that reach local 
concentrations in the infused forearm that are sufficient to induce a local effect 
without relevant systemic spill-over to induce confounding systemic actions. 
Calibrated strain-gauges are attached around the forearms at the level of maximal 
diameter to measure forearm blood flow (FBF; venous occlusion plethysmography). 
The rate of swelling of the forearm during occlusion of venous return is used to 
assess the rate of arterial inflow. To confine the measurement to the muscular 
vascular bed as much as possible, the hand circulation is impeded by pediatric cuffs 
around the wrists. Concomitant measurement of FBF in both arms enables detection 
of relevant systemic effects on forearm vascular tone. The ratio of FBF in both 
forearms is sometimes used to correct for generalized random fluctuations in 
vascular tone that are not directly related to the intra-arterial infusions. Alternatively, 
to correct for small changes in blood pressure that sometimes occur during the 
experiment, Forearm Vascular Resistance (FVR) can be calculated from the quotient 
of mean arterial blood pressure (MAP) and FBF and is expressed in Arbitrary Units 
(AU).  
 
 
Microdialysis 
  
After local anesthesia, a small double-lumen catheter is inserted into the musculus 
flexor digitorum superficialis or in a cubital vene. The tip of the probe is constituted of 
a semi-permeable membrane. The probe is perfused with NaCl 0.9% by a small 
pump. Small molecules (<20.000 KD) in the interstitial space or in blood, such as 
adenosine, can diffuse through the membrane but cells and enzymes can not. 
Adenosine within the probe is therefore protected against degradation. Samples were 
collected every 15 minutes and frozen until analysis by HPLC. After finishing the 
protocol, the dialysis catheters were brought to the laboratory for in vitro calibration of 
adenosine recovery (see chapter 2 for a more detailed description). 
 
 
Finally: the perfused forearm technique is the basis for all studies described in this 
thesis. The microdialysis technique was applied -as described in chapter 2- to gain 
more insight into the compartmentalization of adenosine.  
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Abstract 
 
In the present study, microdialysis was used to study the effects of the nucleoside 
uptake inhibitor dipyridamole on interstitial and intravascular adenosine kinetics. We 
hypothesized that dipyridamole [1] augments the exercise-pressor reflex by interstitial 
adenosine uptake inhibition and [2] improves extravasation of intra-arterially infused 
adenosine. Firstly, interstitial adenosine was measured with a microdialysis probe in 
the forearm flexor muscle of healthy volunteers, during rhythmic handgripping. 
Infusion of dipyridamole into the brachial artery (12 µg·min-1·dl-1 forearm) potentiated 
the exercise-induced rise in dialysate adenosine (from 0.30 ± 0.08 to 0.48 ± 0.10 
nmol·ml-1, n=9, P<0.05) but not the exercise-induced rise in blood pressure 
(SBP/DBP 9.6 ± 2.4 / 4.5 ± 2.0 versus 10.4 ± 2.2 / 7.0 ± 1.3 mmHg, n=9, P>0.1). 
Secondly, a microdialysis probe was inserted into forearm muscle and antecubital 
vein for simultaneous measurement during infusion of adenosine into the brachial 
artery (5.0, 15 and 50 µg·min-1·dl-1). Adenosine infusion did not significantly increase 
dialysate adenosine from either probe. However, co-infusion of adenosine (5.0 
µg·min-1·dl-1) and dipyridamole (100 µg·min-1·dl-1) increased dialysate adenosine from 
the intravascular probe (0.07 ± 0.02 to 0.39 ± 0.14 nmol·ml-1, n=9, P<0.05), without 
affecting muscle interstitial adenosine. 
Conclusions: (1) Dipyridamole significantly inhibits intravascular as well as interstitial 
adenosine uptake, without potentiating the exercise-pressor response, indicating that 
interstitial adenosine is not involved in the pressor response in these healthy 
volunteers. (2) There is a strong blood-muscle barrier for adenosine, which is not 
significantly reduced by inhibition of dipyridamole-sensitive nucleoside transport. This 
observation supports the concept that the pharmacological actions of intra-arterially 
infused adenosine are mediated by endothelial or circulating cells. 
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Introduction 
 
The endogenous nucleoside adenosine exerts several physiological effects via 
stimulation of specific membrane-bound adenosine receptors [1]. Adenosine receptor 
stimulation induces vasodilation in most vascular beds, inhibits noradrenaline release 
from sympathetic nerve endings, inhibits thrombocyte-aggregation and induces anti-
arrhythmic effects [2-5]. It plays an important role in ischemic preconditioning, a 
naturally occuring phenomenon in which ischemia-induced cell death is reduced by a 
previous non-lethal bout of ischemia [6;7]. Acting in concert, these effects of 
adenosine provide this molecule with unique protective properties against the 
sequelae of ischemia. In addition, adenosine may prevent the development of 
atherosclerosis by preventing proliferation of vascular smooth muscle cells and by 
inhibition of vascular inflammation [8;9]. Finally, adenosine is considered a potential 
trigger for the exercise-pressor reflex, which is defined as a reflex rise in blood 
pressure resulting from isometric exercise, by stimulation of muscle afferent fibers 
after release during exercise [10-12]. Infusion of adenosine into the brachial artery of 
healthy volunteers results in forearm vasodilation, inhibition of noradrenaline release 
from local sympathetic nerve endings and generalized activation of the sympathetic 
nervous system by activating local metabolic afferents [4;12;13]. Although there is 
not much doubt that these actions are mediated by adenosine receptors, there is an 
ongoing debate about the cell types that mediate the effects of intravascular 
adenosine. For example, vasodilation may occur by stimulation of adenosine 
receptors on endothelial cells or vascular smooth muscle cells and the relative 
contribution of these cell types on adenosine-induced vasodilation is not known 
[14;15]. Indeed, a recent report from our group suggests a difference in vasodilator 
mechanism between circulating and interstitial adenosine (Glibenclamide inhibits 
dipyridamole-induced forearm vasodilation but not adenosine-induced forearm 
vasodilation, Bijlstra and van Ginneken et al, Clin Pharm Ther 2004). Similarly, it is 
unknown whether intra-arterial infusion of adenosine directly stimulates metabolic 
afferents or, alternatively, stimulates the endothelium to release a substance that 
subsequently triggers generalized sympatho-excitation. The same uncertainty exists 
for the inhibiting action of intravascular adenosine on local release of noradrenaline: 
does adenosine act directly on presynaptic nerve endings or is this action mediated 
by an endothelium-derived factor. Likewise, the protective effect of intra-arterially-
infused adenosine against ischemic cell death, as shown in various models [7;16;17], 
may result from a direct effect on interstitial cells or from the increased release of an 
endothelium-derived factor. 
To provide more insight in the contribution of the various cell types in the action of 
endogenous or infused adenosine, it is important to be accurately informed about the 
kinetics of extracellular adenosine in interstitial as well as intravascular 
compartments. Although much has been learned from animal experiments and in 
vitro studies, human in vivo data are scarse. Recently, the microdialysis technique 
has been introduced to determine tissue adenosine concentrations in humans. Using 
this method, previous studies showed an increase of muscle interstitial adenosine 
concentration during exercise [12;18-21]. The present studies were conducted to 
characterize the effect of dipyridamole, a nucleoside transport inhibitor, on the 
kinetics of interstitial and circulating adenosine. In addition, intra-arterial infusion of 
dipyridamole in combination with intramuscular and intravascular monitoring of 
adenosine was performed to test two hypotheses: (1) adenosine receptor stimulation 
mediates the pressor response to exercise and therefore, this pressor response is 
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augmented by inhibition of cellular uptake of adenosine; (2) dipyridamole sensitive 
cellular uptake of adenosine prevents the passage of intravascular adenosine into 
the interstitial compartment.  
 
 
Methods 
 
 
Subjects 
 
The study-protocols were approved by the local ethics comittee, and each subject 
gave written informed consent before participation. The demographic data of the 26 
participants of the substudies are shown in table 1. The subjects were normotensive 
nonsmokers and were not taking any medications except for oral contraceptives. The 
subjects underwent a physical examination including an ECG before entering the 
study. Subjects with a history of pulmonary or cardiovascular disease were excluded. 
Participants were asked to abstain from food-intake 2 hours prior to the study. For 
subjects participating in protocol 1, caffeine-containing beverages were not allowed 
24 hours before the start of each study. Protocol 2 was performed without caffeine 
abstinence to prevent systemic side effects from the adenosine infusion in the 
presence of a high dose of intra-arterially infused dipyridamole.  
 
 
Table 1: demographic characteristics (mean ± SD) 
 
 Study 1 
Dipyridamole 
Study 1 
Time control 
Study 2 
Number (M/F) 9 (1/8) 8 (5/3) 9 (5/4) 
Age (years) 20.5 ± 1.7 21.0 ± 1.2 23.7 ± 2.8 
BMI (kg m
2
) 22.9 ± 2.3 21.9 ± 2.6 22.9 ± 2.1 
SBP (mmHg)* 120.0 ± 5.2 123.5 ± 11.4 122.7 ± 5.3 
DBP (mmHg)* 73.0 ± 7.8 72.8 ± 6.2 73.9 ± 8.0 
HR (bpm)
§
 61.8 ± 10.8 63.5 ± 9.7 66.9 ± 9.7 
Cholesterol (mmol·l
-1
)  4.6 ± 0.5 4.0 ± 0.7 4.0 ± 0.7 
Triglycerides(mmol·l
-
1) 1.0 ± 0.2 0.9 ± 0.5 1.0 ± 0.4 
Glucose (mmol·l
-1
) 4.5 ± 0.4 4.6 ± 0.4 4.7 ± 0.3 
 
* Auscultatory measurement after 5 minutes rest in supine position 
§ Measured by pulse frequency counting after 5 minutes of supine rest 
 
 
Dipyridamole and exercise pressor reflex 
 39 
 
General outline of the procedure 
 
The experiments started in the morning in a quiet room with stable temperature 
(23°C), with the subjects in supine position. Heart rate was monitored continuously 
with surface ECG. After local anaesthesia (xylocaine 2%), the brachial artery of the 
non-dominant arm was cannulated (Angiocath, 20 gauge, Deseret Medical, Becton 
Dickinson Sandy, UT, USA) for drug infusion (syringe infusion pump, type STC-521, 
Terumo Corp., Tokyo, Japan) and blood pressure recording (Hewlett Packard GmbH, 
Böblingen, Germany). In the first protocol, blood pressure was measured at two-
minute intervals at the dominant arm, using an automated device (Dinamap). Drug- 
and volume infusion rates (50 µl·min-1·dl-1 forearm) were adjusted to forearm volume, 
which was measured for each person by water displacement.  
The rate of infused volume and the amount of connected syringes was kept constant 
throughout each experiment.  
After local anesthesia, a microdialysis probe (CMA 70 brain microdialysis catheter, 
Stockholm, Sweden) was inserted into the flexor digitorum superficialis muscle  
of the non-dominant arm, guided by a venflon cannula (14 G, Ohmeda, Sweden). 
The probe had a dialysis tubing of 10 x 0.6 mm with a membrane cut-off of 20.000 
Dalton. In the second experiment (‘protocol 2’) a second, identical probe was inserted 
retrogradely into a deep antecubital vein of the same arm, guided by a venflon 
cannula (16 G, Ohmeda, Sweden). The probes were continuously perfused with 
NaCl 0.9% (perfusate) with a microdialysis pump (CMA 107, Stockholm, Sweden) at 
a rate of 2 µl·min-1. The effluent (dialysate) was collected at 15 minute intervals to 
obtain 30 µl samples. Dialysate collections were shifted with 2.5 minutes in relation to 
the exercise period because of lag time due to the volume of the collecting tube. 
Samples were kept on ice and protected from light before they were stored at –20 oC 
untill analysis. 
After finishing the second protocol, the dialysis catheters were brought to the 
laboratory for in vitro callibration of adenosine recovery, as described before (see 
also ‘analytical procedures’) [18].  
 
Study 1: Interstitial adenosine measurements during repeated handgrip with and 
without dipyridamole 
 
Maximal force of handgrip was determined after insertion of the microdialysis probe 
(Baseline Hydrolic Hand Dynamometer, Fabrication Enterprise Inc., Irvington, NY, 
USA). Sampling of microdialysate started immediately after insertion of the 
microdialysis probe. Immediately after insertion of the probe, interstitial levels of 
adenosine are known to be particularly high, likely due to insertion-related muscle 
fiber injury. In a pilot study (data not shown), we found that dialysate concentrations 
of adenosine returned to a stable baseline level within 1.5 hours. Therefore, baseline 
resting values were determined in 2 consecutive 30 µl dialysate samples that were 
obtained 1.5 hours after insertion of the microdialysate probe. Thereafter, subjects 
performed intermittent handgrip during 15 minutes, with 5-second contractions at 
50% of maximal force every 10-seconds while dialysate sampling continued. One 
hour later, this procedure was repeated in the absence (n=8) or presence (n=9) of 
dipyridamole infusion into the brachial artery (12 µg·min-1·dl-1) which started 15 
minutes prior to the second period of contractions and was continued throughout the 
exercise.  
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Study 2: Simultaneous intramuscular and intravascular adenosine measurements 
during intra-brachial infusion of adenosine with and without dipyridamole 
 
In a separate group of 9 volunteers, 1.5 hours after instrumentation, baseline 
samples were obtained during intra-brachial infusion of NaCl 0.9%. Thereafter, 
increasing doses of adenosine (5, 15 and 50 µg·min-1·dl-1) were co-infused with 
saline. Each infusion lasted 20 minutes and the succeeding infusions were 
interrupted by a 5 min drug free interval. After one hour, recontrol values were 
obtained during infusion of NaCl 0.9% followed by dipyridamole 100 µg·min-1·dl-1. 
Subsequently, the lowest dose of adenosine was repeated together with 
dipyridamole. Infusion of the two higher doses of adenosine appeared to be 
impossible in the presence of dipyridamole, due to the occurance of systemic side 
effects that resemble the action of intravenous infusion of adenosine such as chest 
pain, hyperventilation and an increase in heart rate. 
 
 
Analytical procedures 
 
Dialysate samples were analyzed for concentrations of adenosine using high 
performance liquid chromatography, equipped with a UV detector set at 254 nm. The 
nucleotides were separated on a Lichrosorb RP18-column. A binary low-pressure 
gradient elution was used with eluent A consisting of di-potassium-hydrogen-
phosphate (0.1 M) and tetra-butyl-ammonium-hydrogen-sulfate (10 mM) as the ion-
pair forming agent. The pH was adjusted to 6.5 with HCl. Solvent B contained, in 
addition, 40% (v/v) methanol. In addition, in the time-control study of protocol 1 
creatine and phosphocreatine were measured spectrophotometrically with Merck kit 
nr. 12320, without use of creatininase. In protocol 2, in vitro recovery of the purines 
was measured in 9 intramuscular catheters and in 6 intravenous catheters (3 
catheters were damaged due to removal). After the experiment was finished, the 
catheters were removed from the arm and placed in a homogeneously mixed solution 
that contained 0.8 µM adenosine. The catheters were perfused with NaCl 0.9% at a 
rate of 2 µl·min-1. The dialysate was collected in two 10-minute fractions. The 
percentage recovery was calculated by dividing the measured dialysate adenosine 
concentration by the concentration from a sample taken directly from the solution.  
 
 
Drugs and solutions 
 
All solutions were freshly prepared. Adenosine (Adenocor, Sanofi-Synthelabo) and 
dipyridamole (Persantin, Boehringer Ingelheim) were diluted in NaCl 0.9% to reach 
the necessary concentrations.  
 
 
Statistical analysis 
 
Blood pressure was measured at two-minute intervals at the dominant arm, using an 
automated device (Dinamap). All blood pressure values during the 15 minute-
contraction periods were averaged to one value. This value was compared with the 
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mean value of a baseline period of 15 minutes immediately before contraction. All 
results are expressed as mean ± SE, unless indicated otherwise. 
T-tests on absolute values of adenosine concentrations and blood pressure were 
used to explore the effects of exercise with and without dipyridamole. To avoid 
multiple comparison, the effect of dipyridamole on interstitial versus intravascular 
adenosine concentrations was assessed with repeated measures ANOVA. The 
presence of dipyridamole and adenosine doses were used as within subject factors. 
P<0.05 (two sided) was considered statistically significant. 
 
 
Results 
 
 
Study 1: Interstitial adenosine measurements during repeated handgrip with and 
without dipyridamole 
 
Two cycles of handgrip without intra-arterial infusion of dipyridamole increased 
dialysate-adenosine by 0.25 ± 0.10 and 0.15 ± 0.07 nmol·ml-1 respectively (p<0.05 for 
the effect of exercise; p> 0.1 for the comparison between the first and the second 
period of contractions; n=8, see figure 1). Creatine (C) en creatine-phosphate (CP) 
(summed as (phospho)creatine) concentrations were measured in seven from the 
eight volunteers as indicator of muscle cell damage. Due to insertion-damage, 
dialysate (phospho)creatine was high immediately after insertion (330.1 ± 82.3 
nmol·ml-1, n=7). One and a half hour later, (phospho) creatine had stabilized (64.6 ± 
11.4 nmol·ml-1). During subsequent exercise, dialysate (phospho)creatine increased 
by 150.5 ± 58.1 nmol·l-1. Prior to the second bout of exercise, (phospho)creatine had 
returned to baseline (78.4 ± 14.3 nmol·ml-1) and increased by 44.5 ± 18.8 nmol·ml-1 
during the second period of exercise. The ratio of dialysate (phospho)creatine to 
adenosine just after insertion did not significantly differ from the ratio during the 
exercise periods (1291 ± 477 vs 1033 ± 434 and 805 ± 181, P>0.1).  
The handgrip-induced rise in blood pressure (SBP/DBP) was 15.1 ± 2.8 / 9.8 ± 2 for 
the first contraction period and 17.3 ± 3.7 / 14.3 ± 1.6 mm Hg for the second 
contraction period (p=NS for SBP, p<0.05 for DBP for comparison between first and 
second period of contractions; see figure 2).  
In a separate group of 9 volunteers, infusion of dipyridamole 12 µg·min-1·dl-1 into the 
brachial artery significantly potentiated the exercise-induced increase in dialysate-
adenosine from 0.30 ± 0.08 to 0.48 ± 0.10 nmol·ml-1 (p<0.05 for effect of 
dipyridamole). There was a significant difference in exercise-induced increase in 
dialysate-adenosine between the group with and without dipyridamole (p=0.01; 
unpaired t-test). As opposed to the dialysate adenosine concentration, dipyridamole 
did not potentiate the exercise-induced increase in blood pressure; 9.6 ± 2.4 / 4.5 ± 
2.0 and 10.4 ± 2.2 / 7.0 ± 1.3 mm Hg in the presence and absence of dipyridamole, 
respectively (see figure 2). 
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Figure 1. Course in dialysate adenosine (µM) and creatine + creatine phosphate (µM),  
during study 1 (repeated hangrip without dipyridamol infusion, n=8). 
 
 
 
 
 
Figure 2. Delta dialysate adenosine (µM), delta Systolic Blood Pressure, delta Diastolic 
Blood Pressure and delta Heart Rate during repeated handgrip with (black, n=9) and without 
(white, n=8) intra-arterial infusion of dipyridamole 12 µg·min-1·dl-1.  
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Study 2: Simultaneous intramuscular and intravascular adenosine measurements 
during intra-brachial infusion of adenosine with and without dipyridamole 
 
In the absence of dipyridamole, intra-arterial infusion of adenosine did not 
significantly affect dialysate adenosine concentrations from either intravascular and 
intramuscular probe (see figure 3). Likewise, infusion of dipyridamole alone (100 
µg·dl-1·min-1) did not significantly affect dialysate adenosine concentration from either 
probe. However, infusion of adenosine together with dipyridamole significantly 
increased adenosine in dialysate from the intravascular probe from 0.07 ± 0.02 to 
0.39 ± 0.14 nmol·ml-1 (p<0.05; n=9), without affecting adenosine in the dialysate from 
the intramuscular probe (0.08 ± 0.02 nmol·ml-1 during dipyridamole versus 0.08 ± 
0.02 nmol·ml-1 during dipyridamole plus adenosine; p>0.1, n=9).  
The in vitro adenosine-recovery from the intramuscular and intravenous catheter was 
measured in 6 from 9 persons and mounted 42 ± 4 versus 49 ± 6%, respectively 
(p>0.1). 
 
 
 
Figure 3. Course in dialysate adenosine during study 2 (n=9); p<0.05 for IV vs IM, p<0.05 for 
IV-adenosine with versus without dipyridamole. *:p<0.05 IV vs. IM. #: p<0.05 vs. ADO 5. 
 
 
Discussion  
 
In this study we report three main findings in man: intra-arterial infusion of 
dipyridamole significantly inhibits the cellular uptake of both interstitial and circulating 
adenosine; the pressor response to rhythmic handgrip is not affected by inhibition of 
cellular uptake of interstitial adenosine, indicating a minor role for adenosine in this 
hemodynamic response to exercise in healthy volunteers; finally, circulating 
adenosine does not significantly enter the interstitial compartment and this barrier 
does not depend on an intact dipyridamole-sensitive equilibrative nucleoside 
transporter.  
 
 
Base 1 ADO5 ADO15 ADO50 Base 2 Dipy ADO5/Dipy
0.0
0.1
0.2
0.3
0.4
0.5
IM
IV
A
d
e
n
os
in
e
 (
µM
)
*
#
Chapter 2 
 
 
 
44 
The pressor response to rhythmic handgrip is not mediated by adenosine. 
 
The exercise-pressor reflex is defined as a sympathoneural activation and a 
subsequent rise in blood pressure in response to exercise. This reflex contributes to 
a redistribution of blood flow in favor of exercising muscle. Afferent signals from the 
exercising muscle that trigger this reflex originate from stimulated mechano- and 
metaboreceptors. Several substances that locally accumulate during exercise have 
been implicated in the stimulation of metaboreceptors, including adenosine, 
potassium and lactate [12;21]. Experimental evidence for adenosine as a trigger of 
the exercise-pressor reflex are threefold: first, infusion of adenosine into the brachial 
artery stimulates local afferents which results in a generalized sympatho-excitation 
[10;12;13]. Second, infusion of theophylline, an adenosine receptor antagonist, into 
the brachial artery inhibits the forearm exercise-induced sympatho-excitation and 
increase in blood pressure [11]. Finally, graded hand-grip exercise results in a 
graded increase in interstitial adenosine as measured with microdialysis which 
correlates with the sympathetic arousal [12]. An increase in hand-grip intensity from 
15% to 50% of maximal force resulted approximately in a doubling of the exercise-
induced increase in interstitial adenosine as well as of the increase in sympathetic 
arousal. This observation triggered us to perform the first study in this report. Our 
observation indicates that, in contrast to the reported effect of graded exercise, 
pharmacological augmentation of the exercise-related increase in adenosine 
concentration did not potentiate the pressor response to exercise. Based on this 
finding, we further hypothesized that the previously reported correlation between 
interstitial adenosine and exercise-induced sympatho-excitation is confounded by 
mechanical injury which is associated with exercise-intensity and which is limited to 
muscle fibers that are located near the microdialysis probe. To further assess the role 
of muscle fiber injury as a source of interstitial adenosine during exercise, creatine 
and creatine phosphate were measured in microdialysate that was obtained during 
the time-control study. Creatine and creatine phosphate are found in high intracellular 
concentrations in muscle cells and cannot diffuse freely out of these cells [22] but 
easily pass the semipermeable microdialysis membrane. We assumed an increase of 
these substances in the microdialysate to indicate muscle fiber rupture. Since 
exercise results in dephosphorylation of creatine phosphate, the sum of creatine and 
creatine phosphate (refered to as (phospho)creatine) was used as a marker of 
muscle fiber injury. Immediately after insertion of the microdialysis probe, dialysate 
levels of adenosine and (phospho)creatine are elevated, reflecting pure mechanical 
injury of muscle fibers. During exercise, a similar increase in (phospho)creatine and 
adenosine occured and the ratio of (phospho)creatine to adenosine did not 
significantly differ between samples obtained during exercise and those obtained 
immediately after insertion of the probe. This observation indicates that mechanical 
injury of muscle fibers significantly contributes to the increase of adenosine in the 
microdialysate during exercise and reflects an artefact that is due to the presence of 
a microdialysis probe in the exercising muscle. Dipyridamole significantly potentiated 
this exercise-induced increase in dialysate adenosine concentration, indicating 
significant inhibition of cellular uptake of interstitial adenosine. Nevertheless, 
dipyridamole did not potentiate the exercise-induced increase in blood pressure. 
Thus, in healthy volunteers, muscle interstitial adenosine is not involved as a trigger 
of the pressor response to exercise. This conclusion is supported by a recent study in 
healthy volunteers and patients with heart failure. In this study, systemic infusion of 
the adenosine receptor antagonist caffeine inhibited the sympatho-excitation during 
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post handgrip ischemia in patients with heart failure but had no effect in healthy 
volunteers [23] suggesting that adenosine may play a more important role in the 
exercise-pressor reflex in patients with reduced skeletal muscle perfusion as 
compared with healthy volunteers. In this context, it is important to note that the 
isometric exercise in the present study, as in previous studies with microdialysis, was 
performed rhythmically to allow volunteers to sustain the exercise for a sufficient 
period of time to complete microdialysis sampling. Therefore, skeletal muscle 
perfusion was restored during each 5 second interval of relaxation. This experimental 
set-up differs from studies in which caffeine or theophylline were used to block 
adenosine receptors during exercise. In these studies, sustained isometric exercise 
was used and sometimes combined with occlusion of forearm circulation. Isometric 
exercise in combination with circulatory arrest produced a greater increase in muscle 
sympathetic nerve activity than isometric exercise alone [11]. The resulting ischemia 
probably augmented adenosine release and accumulation which increased the 
involvement of adenosine as a trigger of the exercise-pressor reflex. The intermittent 
restoration of muscle perfusion in the present study prevented accumulation of 
metabolites such as adenosine and explains why our conclusion differs from a 
previous report by others [11]. In the present setting, stimulation of 
mechanoreceptors probably fully accounts for the observed pressor response to 
exercise.  
 
 
The blood-muscle barrier for adenosine is not reduced by dipyridamole. 
 
Since the biological importance of circulating and interstitial adenosine differs and the 
concentration of adenosine may vary between these two compartments, it is 
important to be informed about the adenosine concentration in both compartments. 
Microdialysis could serve this goal. However, insertion of a microdialysis probe 
disrupts the microcirculation. Subsequent access of circulating blood to the 
intramuscular microdialysis probe could complicate the separate determination of 
interstitial and intravascular adenosine. The results from study 2 demonstrate that a 
significant increase in intravascular adenosine was not accompanied by an increase 
in adenosine in dialysate from the intramuscular probe, indicating that traumatic 
admixture of circulating blood with interstitial fluid does not occur. This finding 
supports extrapolation of previous observations in animal in vitro models to the 
human in vivo (micro)circulation that circulating adenosine has only minor access to 
the interstitial space [24-26]. Our observation is also in accordance with a study by 
Costa et al. in which they showed that 15 minutes of forearm ischemia significantly 
increased the intravenous adenosine concentration but did not affect the muscle 
interstitial concentration [27]. Interestingly, intravascular administation of adenosine 
has repeatedly been shown to prevent ischemia/reperfusion injury of myocardial and 
skeletal muscle cells [7;16;17]. Our present observations indicate that intravascular 
adenosine does not sufficiently reach the muscle cells to stimulate adenosine 
receptors on these cells and therefore suggest an important role for the endothelium 
or circulating blood cells in mediating this beneficial action of adenosine. 
Despite significant inhibition of cellular uptake of circulating adenosine, dipyridamole 
did not improve access of infused adenosine to the interstitial compartment.This 
finding contrasts with a recent report from Gamboa et al. [28]. An important 
difference between the two studies is that we infused dipyridamole into the brachial 
artery, whereas Gamboa administered this substance intravenously. The intravenous 
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administration of a relatively high dose of the nucleoside transport inhibitor probably 
resulted in a generalized sympatho-excitation [29-31]. Consequently, the 
experimental design that was applied by Gamboa et al. may have resulted in a more 
pronounced perivascular release of noradrenaline and sympathetic co-transmitters 
such as adenosine-5'-triphosphate (ATP) [32] as compared to our present 
experimental set-up. Due to the abundent presence of ecto-phosphatases [33], this 
ATP is rapidly metabolized to adenosine and provides an alternative source for the 
rise in interstitial concentration of adenosine that was observed by Gamboa when 
intra-arterial infusion of adenosine is combined with intravenous administration of 
dipyridamole.  
 
In conclusion, intra-arterial infusion of dipyridamole inhibits uptake of both interstitial 
and intravascular adenosine. Dipyridamole did not affect the blood pressure 
response to exercise nor the blood-muscle barrier for intravascular adenosine. These 
observations indicate that interstitial adenosine is not the trigger of the pressor 
response to rhythmic handgrip in healthy volunteers and that the dipyridamole-
sensitive nucleoside transporter is not critically involved in the blood-muscle barrier 
for adenosine.  
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Abstract 
 
The mechanism of the vasodilator response to adenosine has not been elucidated in 
humans. Stimulation of adenosine receptors on endothelial and vascular smooth 
muscle cells with subsequent endothelial release of nitric oxide and opening of ATP-
sensitive potassium (KATP) channels has been suggested. Aim of the study: to 
investigate the involvement of KATP channels in the vasodilator response to adenosine 
and the nucleoside transport inhibitor dipyridamole. 
In healthy male volunteers, adenosine (0.6, 1.9, 5.6, 19, 57 and 190 nmol·min-1·dl-1) as 
infused into the brachial artery and forearm blood flow (FBF) was measured using strain 
gauge plethysmography. Adenosine increased the ratio in FBF (FBF-ratio = FBF 
experimental arm / FBF control arm) from 1.3 ± 0.2 to 1.2 ± 0.2, 1.5 ± 0.2,  
2.8 ± 0.4, 7.3 ± 2.3, 11.1 ± 4.1 and 12.9 ± 3.7 for the 6 increasing adenosine doses 
respectively. Simultaneous infusion of glibenclamide, a blocker of KATP-channels, did 
not affect this response (from 1.7 ± 0.4 to 1.5 ± 0.2, 2.2 ± 0.3, 4.0 ± 1.0, 9.3 ± 4.0, 
13.5 ± 6.4 and 15.9 ± 5.3 for the six increasing doses of adenosine respectively; 
p=0.439, N=6). The increase in FBF-ratio during infusion of the nucleoside transport 
inhibitor dipyridamole (20, 60 and 200 nmol·min-1·dl-1) was significantly reduced by 
glibenclamide: from 1.2 ± 0.1 to 1.7 ± 0.2, 2.4 ± 0.5 and 2.9 ± 0.4 during saline 
versus from 1.6 ± 0.2 to 1.8 ± 0.2, 2.1 ± 0.3 and 2.2 ± 0.4 during glibenclamide 
(p=0.010 for effect of glibenclamide on response from baseline, ANOVA for repeated 
measures; N=8). The vasodilator response to dipyridamole was significantly inhibited 
by the adenosine receptor antagonist theophylline. 
Opening of vascular KATP channels is involved in the forearm vasodilator response to 
dipyridamole but not to adenosine. Differences in stimulated cell type (endothelium 
for adenosine versus smooth muscle cells for dipyridamole) may underly this 
divergent pharmacological profile.  
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Introduction 
 
Extracellular adenosine stimulates specific adenosine receptors, which are classified as 
A1, A2a, A2b and A3 receptors [1]. Stimulation of A1 adenosine receptors triggers and 
mediates ischemic preconditioning of cardiac and skeletal muscle, a naturally occuring 
adaptive process that delays ischemia-induced cell death [2-4]. Furthermore, adenosine 
inhibits thrombocyte aggregation and leucocyte activation [5;6], it modulates 
sympathetic noradrenaline release [7;8], and it is a potent vasodilator [9]. With respect 
to the vasodilator action of adenosine, animal studies suggest an important role for the 
A2a receptor on vascular smooth muscle cells and endothelial cells, with subsequent 
opening of ATP-sensitive potassium (KATP) channels and stimulation of endothelial 
release of nitric oxide [10;11]. 
The mechanism of the vasodilator action of adenosine in humans is less well 
characterized. In the human forearm vascular bed of healthy male volunteers, 
adenosine-induced vasodilation is inhibited by the non-selective A1 and A2 receptor 
antagonists caffeine and theophylline [12;13] and potentiated by the nucleoside 
transport inhibitor draflazine [14] indicating the involvement of specific adenosine 
receptors on the cell membrane. Furthermore, its vasodilator action is inhibited by the 
NO-synthase inhibitor NG-monomethyl-L-arginine (L-NMMA) but not by the KATP 
channel blocker tolbutamide [15]. These initial observations suggested the involvement 
of endothelial nitric oxide but not KATP channels in adenosine-induced forearm 
vasodilation [15]. However, this study has some limitations. First, intra-arterially infused 
adenosine may not reach the vascular smooth muscle cells due to rapid endothelial 
uptake and metabolism of adenosine [16]. Adenosine receptors on endothelial and 
smooth muscle cells may differ in their capacity to open KATP channels [11]. Second, 
glibenclamide is a more potent blocker of vascular KATP channels than tolbutamide in 
the human forearm [17]. Therefore, the negative findings in our initial studies with 
tolbutamide do not exclude the involvement of vascular KATP channels in adenosine-
induced forearm vasodilation. 
We hypothesize that the nucleoside transport inhibitor dipyridamole increases 
endogenous levels of adenosine at the adventitial side of the endothelium (see figure 
1). Consequently, intraluminally applied dipyridamole (as opposed to adenosine) will 
indirectly stimulate adenosine receptors on vascular smooth muscle cells, while 
intraluminally applied adenosine (as opposed to dipyridamole) stimulates endothelial 
adenosine receptors. This hypothesis is supported by previous observations with the 
nucleoside transport inhibitor draflazine: its hemodynamic actions resembled that of 
adenosine without increasing plasma adenosine concentrations [14] and it is able to 
modulate sympathetic release of norepinephrine presynaptically [8]. Further support 
comes from in vitro studies that emphasize the important barrier function of the 
endothelium for adenosine between the interstitial and intravascular compartment 
[16;18]. Based on this model of action of adenosine and dipyridamole, we asked 
ourselves the following questions:  
1. Does the involvement of KATP channels differ between adenosine and  
dipyridamole? 
2. Is the forearm vasodilator action of dipyridamole mediated by  
stimulation of adenosine receptors?  
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To answer the first question, glibenclamide was used as a blocker of KATP channels in  
the human forearm [19]. To assess the second question, we used the A1 and A2-
adenosine receptor antagonist theophylline [12;13].  
 
 
 
 
 
 
 
Figure 1: Schematic presentation of our working hypothesis for this study. 
Intra-arterial infusion of adenosine will stimulate endothelial adenosine receptors (ADOr) 
resulting in (endothelium-dependent) vasodilation. Intraluminal adenosine is rapidly taken up 
by erythrocytes, endothelial cells and possibly also vascular smooth muscle cells (VSM). 
This process of facilitated diffusion is mediated by nucleoside transporters (NT) and prevents 
intraluminal adenosine from stimulating ADOr on VSM. Intraluminal infusion of dipyridamole, 
an inhibitor of NT, will result in accumulation of endogenous adenosine that may originate 
from endothelial cells and sympathetic nerve endings. This accumulated endogenous 
adenosine will stimulate ADOr on VSM.
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Methods 
 
 
Subjects 
 
The study protocol was approved by the local ethics committee, and all participants 
gave written informed consent before entering the study. All experiments were 
performed in healthy male non-smoking volunteers with a normal history, physical 
examination and blood pressure. The characteristics of the subsets of volunteers are 
listed in Table 1. Each volunteer participated in only one experiment and was 
instructed to abstain from caffeine-containing beverages and alcohol for at least 24 
hours before the experiment. Furthermore, they were asked to use a light meal at 
least 2 hours before the experiment was started and to abstain from further food 
intake until after the experiment.  
 
 
Table 1: Characteristics of the healthy volunteers 
 
Experiment 
involving: 
Adenosine x 
glibenclamide 
Dipyridamole 
Time-control 
Dipyridamole x 
Theophylline 
Dipyridamole x 
Glibenclamide 
Adenosine (+ 
Dipyridamole)x 
Glibenclamide 
N 
 
6 7 8 8 6 
Age (years) 
 
22 ± 4 27 ± 10 27 ± 7 21 ± 4 22 ± 3 
Weight (kg) 
 
69 ± 6 74 ± 14  76 ± 5 75 ± 4 68 ± 10 
Height (m) 
 
1.82 ± 0.07 1.81 ± 0.05 1.84 ± 0.09 1.83 ± 0.07 1.74 ± 0.09 
SBP (mm Hg)* 
 
109 ± 3 125 ± 9 122 ± 8 118 ± 3 124 ± 5 
DBP (mm Hg)* 
 
83 ± 6 73 ± 6 67 ± 5 63 ± 10 79 ± 4 
Heart rate 
(bpm) 
60 ± 4 65 ± 14 63 ± 5 61 ± 7 60 ± 7 
 
Data are presented as means (± SD).*Sphygmomanometrically obtained blood pressure 
after 5 minutes supine rest. SBP: Systolic blood pressure; DBP: diastolic blood pressure. 
 
 
General outline of the procedures 
 
The experiments were performed with the subjects supine in a quiet temperature 
controlled room (22oC). A cannula was inserted into the brachial artery (Angiocath, 
20 gauge, Deseret Medical Inc., Becton Dickinson and Comp., Sandy, Utah) for intra-
arterial blood pressure measurement (Hewlett Packard monitor, type 78353B, 
Hewlett Packard GmbH, Böblingen, Germany) and infusion of drugs (automated 
syringe infusion pump, type STC-521, Terumo Corp., Tokyo, Japan). Deep 
antecubital veins of the left and the right arm were cannulated for blood sampling.  
During intra-arterial infusion of saline (NaCl 0.9%) or drugs, forearm blood flow (FBF) 
was measured three times per minute at both arms simultaneously, using ECG-
triggered venous occlusion mercury-in-silastic strain-gauge plethysmography  
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(Hokanson EC4, D.E. Hokanson, Inc., Issaquah, Washington, USA). During all FBF 
recordings, the hand circulation was completely occluded using a wrist cuff which 
was inflated 100 mmHg above the systolic blood pressure to confine FBF 
measurements to the forearm skeletal muscle vascular bed [20].  
At least 45 minutes after all cannulations were done, intra-arterial infusion of saline 
was started. Ten minutes thereafter, the vasodilator agonist (adenosine or 
dipyridamole) was infused at incremental doses. After a subsequent wash-out period 
to allow parameters to return to baseline levels, measurements during intra-arterial 
infusion of placebo were repeated. Then, the agonist was infused again, but now with 
concomitant infusion into the brachial artery of the antagonist (theophylline or 
glibenclamide) instead of saline. Drugs or saline were infused at a constant rate of 50 
µl·min-1·dl-1.  
 
 
 
Vasodilator response to adenosine 
 
 
Adenosine-glibenclamide study 
 
In 6 subjects, the effect of glibenclamide on the adenosine-mediated vasodilation 
was studied. After baseline measurements of blood pressure, heart rate and bilateral 
FBF were performed during intra-arterial infusion of saline, incremental doses of 
adenosine were infused (0.6, 1.9, 5.6, 19, 57 and 190 nmol·min-1·dl-1 forearm), 4 
minutes per dose. After a subsequent equilibration period of 60 minutes, baseline 
measurements were repeated. Then, intra-arterial infusion of adenosine was 
recommenced, but now with concomitant infusion of glibenclamide instead of saline. 
Glibenclamide was administered at a rate of 0.7 nmol·min-1·dl-1 forearm. We have 
previously shown in the same experimental set up that this dose leads to local 
therapeutic concentrations of glibenclamide equivalent to concentrations reached in 
type 2 diabetes on oral glibenclamide therapy and significant blockade of vascular 
KATP channels without systemic effects [19]. 
Venous blood samples were collected from the non-experimental arm to determine 
insulin and C-peptide concentrations at start, after 30 minutes and at the end of 
glibenclamide infusion. Blood glucose and glibenclamide concentrations were 
monitored in venous blood from the experimental arm at regular intervals during the 
glibenclamide infusion. 
 
 
 
Vasodilator response to the nucleoside transport inhibitor dipyridamole 
 
 
Time-control study 
 
In order to detect possible carry-over effects, dipyridamole was infused into the 
brachial artery at 20, 60 and 200 nmol·min-1·dl-1 forearm, 5 minutes per dose during 
the concomitant administration of saline. This procedure was repeated after an 
equillibration period of 120 minutes. Originally, this experiment was performed in 8  
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volunteers. For unknown reasons, one volunteer showed a reproducible reduction in 
FBF-ratio in response to dipyridamole. This vasoconstrictor response was not 
observed in any other volunteer in this study, including those who participated in the 
other substudies with dipyridamole. Since inclusion of this outlier would hinder a valid 
comparison of the vasodilator action of dipyridamole between the three substudies, 
we decided to exclude this volunteer from further analysis. 
 
 
Dipyridamole-theophylline study 
 
In 8 subjects, the involvement of adenosine receptors in the vasodilator action of 
dipyridamole was studied. The same protocol as for the time-control study was 
performed but saline in the second part was substituted by the adenosine receptor 
antagonist theophylline. We administered theophylline at a rate of 130 nmol·min-1·dl-1 
forearm, which is sufficient to inhibit adenosine-induced forearm vasodilation [12;21] 
 
 
Dipyridamole-glibenclamide study 
 
As for adenosine, the role of vascular KATP channels in dipyridamole-induced 
vasodilation was studied using glibenclamide. We repeated the above mentioned 
protocol with glibenclamide instead of theophylline. Blood samples were drawn as for 
the adenosine-glibenclamide study. Glibenclamide concentrations were not 
determined in this set of experiments. 
 
 
 
The vasodilator response to adenosine in the presence of dipyridamole 
 
 
First, the vasomotor action of 7.4, 14.8 and 22.2 nmol dipyridamole ·min-1·dl-1 was 
studied in 8 volunteers (dose-finding study). Each dose was infused for 15 minutes. 
The lowest dose appeared to lack a significant vasomotor action (data not shown). 
This dose was used in 7 volunteers to test its ability to potentiate the vasodilator 
action of adenosine. Adenosine was infused at a dose of 0.6 and 6 nmol·min-1·dl-1. 
One hour later, these doses were repeated in the presence of dipyridamole (7.4 nmol 
min/dl). These two substudies have been published previously [21]. 
In a separate group of 6 volunteers, the effect of glibenclamide was studied on 
adenosine-induced forearm vasodilation in the presence of dipyridamole. We 
hypothesized that inhibition of endothelial nucleoside transport would increase the 
biological availability of intra-arterially-infused adenosine to stimulate adenosine 
receptors on vascular smooth muscle cells. First, adenosine (0.6, 1.9, 5.6, 19, 57 and 
190 nmol·min-1·dl-1 forearm, 4 minutes per dose) was infused in the presence of 
dipyridamole (7.4 nmol·min-1·dl-1). Sixty minutes later, these infusions (adenosine 
plus dipyridamole) were repeated in the presence of glibenclamide (0.7  
nmol·min-1·dl-1).  
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Analysis of blood samples 
 
For determinations of plasma glibenclamide concentrations venous blood samples  
were collected in glass tubes without additives. After 20 minutes the blood was 
centrifuged at 3000 r.p.m. for 10 minutes. Then serum was frozen at -20oC. In these 
serum samples drug concentrations were determined at the laboratories of Hoechst 
AG, Frankfurt, Germany. Glibenclamide was determined, using a validated specific 
radioimmunoassay (RIA) [22]. The detection limit was 1-3 ng·ml-1 and concentrations 
higher than 200 ng·ml-1 were diluted before measured according to the standard 
procedure. Insulin and C-peptide concentrations were determined in venous blood 
samples collected in chilled glass tubes coated with lithium-heparin. The blood was 
centrifuged at 3000 r.p.m. for 10 minutes. Then plasma was frozen at -20oC. In these 
samples insulin and C-peptide were determined in our laboratories using specific 
RIAs. C-Peptide was measured with a standard kit (D.P.C., Los Angeles, CA, USA)  
and insulin with a procedure using standard and tracer prepared from 
monocomponent human insulin (NOVO, Zoeterwoude, The Netherlands). Blood 
glucose was measured using an Accutrend glucose analyzer (type 1284851, 
Boehringer, Mannheim, Germany). 
 
 
Drugs and solutions 
 
All solutions were freshly prepared on the study day. Dipyridamole (10 ml ampoules 
containing 5 mg dipyridamole ·ml-1; Boehringer Ingelheim, Alkmaar, the Netherlands), 
adenosine (10 ml ampoules containing 20 mg of adenosine with NaCl 0.9% as 
solvent; Sigma Chemical Co., St Louis, MO) and theophylline (EuphyllinR, 10 ml 
ampoules containing 24 mg·ml-1 aminophyllinum-hydricum; BYK Nederland, 
Zwanenburg,The Netherlands) were diluted in NaCl 0.9%. Lyophilized glibenclamide 
(2 mg per vial, Aventis Pharma, Frankfurt, Germany) was reconstituted with NaCl 
0.9% on each study day.  
 
 
Statistical analysis 
 
Mean arterial pressure was measured continuously during each recording of forearm 
blood flow (FBF) and averaged per FBF registration. Experimental and control arms 
were analyzed separately. Since blood pressure gradually increased during the 
course of the experiment without relation to any intra-arterial drug infusion, forearm 
vascular resistance (FVR) was calculated as the quotient of simultaneously 
measured mean arterial pressure (MAP) and forearm blood flow (FBF) and 
expressed as arbitrary units (AU). Since intra-arterial drug infusions did not affect 
FVR in the control arm, random changes in forearm vascular tone were filtered out 
using the ratio of FBF in experimental and control arm which was taken as the main 
study parameter [23;24]. 
Based on previous experience in our laboratory with repeated infusion of intra-arterial 
adenosine [14], we calculated that a group of 6 volunteers would allow us to detect a 
minimal difference of 0.6 in absolute response or 61% in percentage response to 5.6 
nmol adenosine min/dl, expressed as FBF ratio, with a power of 80% and alpha of 
0.05. Similarly, a minimal difference of 6 in absolute response or 250% in percentage 
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response to 190 nmol adenosine min/dl can be detected with a power of 80% and 
alpha of 0.05. 
Baseline parameters were compared by student t-tests. A two-way analysis of 
variance (ANOVA), with type of agonist (adenosine versus dipyridamole) as  
between group factor and presence of antagonist and agonist dose as within-subject 
factors, was used to test the hypothesis that the interaction with glibenclamide 
differed between adenosine and dipyridamole. For this test, only the first three 
adenosine doses were included since these doses induced an equal vasodilator 
response as compared with the three dipyridamole doses. Additionally, the effect of 
antagonists (or infusion order for the time-control study) on vasodilator responses 
were analysed by ANOVA for repeated measures with the used antagonist (or 
infusion order) and agonist dose as within-subject factors. A p-value of <0.05 was 
considered statistically significant. Results are presented as means ± SEM unless 
indicated otherwise. 
 
 
Results 
 
None of the infused drugs significantly affected forearm vascular resistance in the 
non-infused arm, blood pressure or heart rate, indicating the absence of a relevant 
systemic action of the intra-arterial drug infusions. Therefore, the data are presented 
as absolute (text) and percentage (figures) change in FBF ratio from control values.  
 
 
 
Vasodilator response to adenosine  
 
 
Adenosine-glibenclamide study 
 
Adenosine increased the FBF ratio from 1.3 ± 0.2 at baseline to 1.2 ± 0.2, 1.5 ± 0.2, 
2.8 ± 0.4, 7.3 ± 2.3, 11.1 ± 4.1 and 12.9 ± 3.7 during the six increasing adenosine 
doses. Sixty minutes later the FBF ratio had almost returned to baseline (1.9 ± 0.3; 
p=0.026 vs baseline). Repeated infusion of adenosine with glibenclamide increased 
FBF ratio from 1.7 ± 0.4 (glibenclamide alone; p=0.074 vs baseline and p=0.364 vs 
recontrol) to 1.5 ± 0.2, 2.2 ± 0.3, 4.0 ± 1.0, 9.3 ± 4.0, 13.5 ± 6.4 and 15.9 ± 5.3 during 
the six incremental doses of adenosine (p=0.439 for effect of glibenclamide; N=6). 
Similar results were obtained when percentage changes in FBF ratio were calculated 
(see figure 1). Intra-arterial glibenclamide did not affect blood glucose (from 4.6 ± 0.2 
mmol·l-1 before to 4.4±0.4 mmol·l-1 at the end of glibenclamide infusion), plasma 
insulin (from 7.5 ± 1.2 to 8.8 ± 0.9 mU·ml-1) or plasma C-peptide concentrations (from 
0.4 ± 0.1 to 0.4 ± 0.1 ng·ml-1). At the end of a 10 minute infusion of glibenclamide, the 
regional serum concentration averaged 162 ± 14 ng·ml-1. During simultaneous intra-
arterial infusion of glibenclamide and adenosine, serum glibenclamide concentrations 
dropped to 43 ± 8 ng·ml-1 and 21 ± 4 ng·ml-1 at the end of 5.6 and 190 nmol 
adenosine ·min-1·dl-1 respectively, reflecting adenosine-induced increases in forearm 
blood flow with subsequent dilution of glibenclamide. 
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Figure 2. The effect of glibenclamide on the vasodilator response to adenosine expressed as 
percentage changes in forearm bloodflow (FBF) ratio from baseline. The p-value represents 
the level of significance for the effect of glibenclamide (ANOVA for repeated measures). 
 
 
 
Vasodilator response to the nucleoside transport inhibitor dipyridamole 
 
 
The vasodilator action of dipyridamole (pooled data of 23 volunteers). 
 
Experimental conditions were similar during the first set of dipyridamole infusions for 
three subgroups (N=23). In this entire group, dipyridamole increased FBF-ratio from 
1.2 ± 0.7 at baseline to 1.5 ± 0.1, 1.9 ± 0.2, and 2.3 ± 0.3 during the three increasing 
dipyridamole doses (p=0.000 for dipyridamole effect). When expressed as 
percentage changes form baseline similar results were obtained: 31.5 ± 4.2, 65.0 ± 
15.4 and 101.4 ± 16.1% for the three subsequent dipyridamole doses respectively 
(p=0.000 for dipyridamole effect). 
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Time-control study 
 
Dipyridamole increased FBF ratio from 0.9 ± 0.1 at baseline to 1.1 ± 0.1, 1.3 ± 0.3 
and 1.5 ± 0.3 during the 3 increasing doses respectively. Two hours after the last 
dipyridamole infusion, FBF ratio returned to baseline (1.2 ± 0.1; p=0.160 vs baseline). 
During repeated infusion of dipyridamole, FBF ratio increased to 1.4 ± 0.2, 1.8 ± 0.3 
and 2.1 ± 0.4 for the three incremental doses respectively (p=0.026  
for dipyridamole effect; p=0.186 for time effect and p=0.266 for interaction between 
dipyridamole and time; N=7). Likewise, results expressed as percentage change in 
FBF ratio did not reveal a significant carry-over effect (p=0.021 for vasodilator effect 
of dipyridamole, p=0.819 for time effect and p=0.449 for interaction between 
dipyridamole and time; N=7). 
 
 
Dipyridamole-theophylline study 
  
Dipyridamole increased FBF ratio from 1.3 ± 0.1 at baseline to 1.7 ± 0.2, 1.8 ± 0.2 
and 2.6 ± 0.4 during the three subsequent dipyridamole infusions. Two hours after 
the highest dipyridamole dose, FBF ratio returned to baseline (1.4 ± 0.2; p=0.510 vs 
baseline, N=8). During simultaneous infusion of theophylline, dipyridamole increased 
FBF ratio from 1.5 ± 0.2 (theophylline alone; p=0.325 vs recontrol) to 1.8 ± 0.4, 1.7 ± 
0.3 and 2.1 ± 0.4 during the three subsequent dipyridamole doses (effect of 
theophylline: p=0.081; N=8). When results were expressed as percentage change in 
FBF ratio, theophylline significantly reduced the vasodilator response to dipyridamole 
(p=0.032 for effect of theophylline, see figure 3). 
 
 
Dipyridamole-glibenclamide study 
 
Dipyridamole increased FBF ratio from 1.2 ± 0.1 at baseline to 1.7 ± 0.2, 2.4 ± 0.5 
and 2.9 ± 0.4 respectively. Two hours after the last dipyridamole infusion, FBF ratio 
returned to baseline (1.7 ± 0.3; p=0.196 vs baseline). During intra-arterial infusion of 
glibenclamide, FBF ratio increased from 1.6 ± 0.2 during glibenclamide alone 
(p=0.162 vs baseline and p=0.418 vs recontrol, N=8), to 1.8 ± 0.2, 2.1 ± 0.3 and 2.2 ± 
0.4 during the three incremental dipyridamole doses respectively (effect of 
glibenclamide: p=0.010; N=8). Likewise, when results were expressed as percentage 
change in FBF ratio, glibenclamide significantly reduced the vasodilator response to 
dipyridamole (p=0.006 for effect of glibenclamide, see figure 2).  
During these experiments blood glucose did not change (4.9 ± 0.2 mmol·l-1 at the 
start versus 4.8±0.2 mmol·l-1 at the end of the protocol). Likewise, insulin and C-
peptide concentrations remained stable (10.7 ± 2.3 vs 9.2 ± 1.3 pmol·l-1 for insulin 
and 0.69 ± 0.11 vs 0.54 ± 0.05 nmol·l-1 for C-peptide; p>0.1 for both comparisons, 
N=8). 
The two-way ANOVA for repeated measures showed that the percentage response 
in FBF ratio to the lowest three adenosine doses and the three dipyridamole doses 
significantly differed with respect to the effect of glibenclamide (p=0.024 for group x 
glibenclamide interaction). The vasodilator effect of dipyridamole and the lowest 
three adenosine doses in the absence of glibenclamide did not significantly differ  
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(p=0.212). However, in the presence of glibenclamide, the vasodilator response to 
dipyridamole was significantly less as compared with adenosine (p=0.035). Similar 
results were obtained with absolute responses in FBF ratio. 
 
 
Vasodilator response to adenosine in the presence of dipyridamole 
 
First, the functional significance of intra-arterial infusion of dipyridamole at a dose 
that does not result in forearm vasodilation was confirmed. In the absence of 
dipyridamole, adenosine increased the FBF ratio from 1.1 ± 0.1 at baseline to 1.2 ± 
0.2 and 3.0 ± 0.7 during infusion of 0.6 and 6 nmol adenosine min/dl respectively. 
Subsequently, in the presence of dipyridamole (7.4 nmol·min-1·dl-1), adenosine 
increased the FBF ratio from 1.1 ± 0.1 (recontrol with dipyridamole; p=0.936 vs 
baseline, N=7) to 2.1 ± 0.2 and 4.9 ± 1 for 0.6 and 6 nmol adenosine min/dl 
respectively (p=0.002 for the effect of dipyridamole; N=7). Similar results were 
obtained when results were expressed as percentage change in FBF ratio.  
Next, in a separate group of 6 volunteers, the effect of glibenclamide was studied on 
the adenosine-induced vasodilation in the presence of dipyridamole. In the absence  
of glibenclamide, adenosine increased the FBF ratio from 1.0 ± 0.1 (baseline with 
dipyridamole) to 1.3 ± 0.1, 2.0 ± 0.2, 3.7 ± 0.7, 4.9 ± 0.7, 9.7 ± 1.6 and 14.9 ± 2.6 for 
the six increasing adenosine doses respectively. In the presence of glibenclamide, 
adenosine increased the FBF ratio from 1.0 ± 0.2 (dipyridamole plus glibenclamide) 
to 1.6 ± 0.3, 2.7 ± 0.8, 5.6 ± 1.7, 7.1 ± 0.9, 12.1 ± 2.5 and 18.3 ± 3.6 for the six 
increasing adenosine doses respectively (p=0.240 for the effect of glibenclamide, 
p=0.550 for the interaction between adenosine dose and glibenclamide, N=6). Similar 
results were obtained when results were expressed as percentage change in FBF 
ratio. 
 
 
 
 
Figure 3. The effect of theophylline (middle panel) and glibenclamide (right panel) on the 
dipyridamole-induced vasodilation expressed as percentage changes in forearm bloodflow 
(FBF) ratio from baseline. The left panel shows the results of the time-control study (black 
bars: first set of dipyridamole infusions; grey bars: second set of dipyridamole infusions). P-
values represent the level of significance for the effect of repeated infusion (left panel), 
theophylline (middle panel) and glibenclamide (right panel) on dipyridamole-induced 
vasodilation as analysed with ANOVA for repeated measurements. 
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Discussion 
 
The main finding of this study is that glibenclamide inhibits the vasodilator response 
to dipyridamole but not to adenosine in the human forearm vascular bed. 
Furthermore, theophylline, an adenosine receptor antagonist, significantly inhibited 
the vasodilator response to dipyridamole. These observations support our working 
hypothesis that dipyridamole-induced inhibition of nucleoside transport results in 
increased levels of endogenous adenosine with subsequent stimulation of adenosine 
receptors and opening of vascular KATP channels. The inhibitory action of 
dipyridamole on nucleoside transport was confirmed in vivo by the augmenting effect 
of dipyridamole on adenosine-induced vasodilation. This discussion will focus on the 
observed difference in sensitivity to glibenclamide between adenosine- and 
dipyridamole-induced vasodilation.  
 
Possible differences in local glibenclamide concentration  
 
The last three adenosine doses induced more vasodilation than dipyridamole which 
may have resulted in more dilution of glibenclamide in this part of the adenosine 
experiment as compared with dipyridamole or the lower adenosine infusions. This 
could potentially have reduced the blockade of vascular KATP channels during the 
three highest adenosine infusion rates. However, glibenclamide could not inhibit the 
vasomotor response to adenosine doses that were equipotent to dipyridamole. 
Furthermore, we have previously shown in the same experimental set up that 
glibenclamide at similar local concentrations as observed during adenosine infusion 
in the present study, sufficiently blocked KATP channels in the forearm vascular bed 
[19]. Therefore, differences in forearm kinetics of glibenclamide between the two 
study protocols do not explain the divergent action of glibenclamide on the 
vasodilator effect of adenosine and dipyridamole. Nevertheless, we can not exclude 
the possibility that the infusion of a higher dose of glibenclamide would have inhibited 
the vasodilator response to adenosine.  
 
Dipyridamole-induced vasodilation may not be related to stimulation of adenosine 
receptors 
 
Apart from inhibition of adenosine transport, dipyridamole may have non-specific 
actions such as release of prostacycline [25] or inhibition of phosphodiesterases 
resulting in intracellular increases of cAMP and cGMP [26]. However, theophylline at 
a dose that did not affect basal tone and therefore did probably not inhibit intracellular 
phosphodiesterases, inhibited the vasodilator response to dipyridamole. This 
observation provides strong support for our notion that the vasomotor action of 
dipyridamole in the forearm is mediated by adenosine-receptor stimulation and that 
non-specific actions of dipyridamole are not involved in the observed interaction 
between dipyridamole and glibenclamide.  
In isolated small subcutaneous arteries from humans, glibenclamide did not inhibit 
dipyridamole-induced vasodilation [27]. A difference in endogenous adenosine 
formation between our in vivo model and this in vitro preparation could explain this 
contrasting result. For example, sympathetic denervation may have reduced 
endogenous adenosine formation in the in vitro isolated blood vessel model [8;28].  
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Dipyridamole and adenosine may stimulate adenosine receptors on different cells 
 
Adenosine receptors are found on both endothelium and vascular smooth muscle 
cells and stimulation by adenosine of either cell type results in vasodilation [29;30]. 
Apart from adenosine receptors, the endothelium expresses a dipyridamole-sensitive 
equilibrative nucleoside transport protein [18]. Because intracellular adenosine 
concentrations are low during normoxic conditions, the concentration gradient favors 
rapid endothelial uptake of luminally applied adenosine and subsequent metabolism 
of adenosine. Thus, the endothelium functions as a metabolic barrier that prevents 
intraluminally applied adenosine from reaching the vascular smooth muscle cells as 
documented in large arteries [18]. However, it is not known whether this barrier 
function also occurs at the level of arterioles. At high doses of intra-arterially infused 
adenosine, some adenosine may have reached vascular smooth muscle cells. 
Nevertheless, it is likely that at lower doses, the endothelial cell is completely 
responsible for the vasodilator response to intra-arterial adenosine [15] although the 
exact nature of the involved endothelium-derived relaxing factor is still a matter of 
debate in humans in vivo [31-34]. Therefore, the lack of effect of glibenclamide 
suggests that KATP channels are not involved in the endothelial mechanism of 
adenosine-induced vasodilation. In contrast to adenosine, dipyridamole-induced 
stimulation of adenosine receptors is dependent on endogenous formation of 
adenosine which occurs at both the adventitial and luminal side. Therefore, 
adenosine receptors on vascular smooth muscle cells are likely to be involved in the 
dipyridamole-induced vasodilator response. The observed difference between 
adenosine and dipyridamole in their susceptibility to glibenclamide suggests that 
ATP-dependent potassium channels in smooth muscle cells but not in endothelial 
cells are involved in the dipyridamole-induced vasodilation.  
Based on this hypothesis, we predicted that dipyridamole-induced inhibition of 
endothelial nucleoside transport would enhance the availability of intraluminally 
applied adenosine for adenosine receptors on vascular smooth muscle cells. 
Therefore, we studied the effect of glibenclamide on adenosine-induced vasodilation 
in the presence of dipyridamole. Since dipyridamole-induced vasodilation would 
prevent a correct interpretation of an interaction between adenosine and 
glibenclamide, we used a low dose of dipyidamole that did not induce vasodilation 
itself. This dose potentiated the vasodilator response to adenosine, indicating 
functionally significant nucleoside transport inhibition. Nevertheless, this low dose of 
dipyridamole did not reveal an interaction between adenosine and glibenclamide. 
The most obvious explanation for this negative finding is that the low dose of 
dipyridamole augmented the vasodilator response to intra-arterial adenosine by 
significant inhibition of nucleoside transporters on erythrocytes but did not sufficiently 
block vascular nucleoside transporters to increase the availability of adenosine at the 
vascular smooth muscle cells. Alternatively, our primary hypothesis that 
glibenclamide reduces dipyridamole-induced vasodilation by inhibition of adenosine-
induced opening of KATP channels may be false. Theoretically, glibenclamide may 
have reduced formation of endogenous adenosine which could have reduced the 
ability of dipyridamole to increase the concentration of endogenous adenosine. Since 
interstitial adenosine concentrations were not measured in this study, this possibility 
can not be excluded.  
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Clinical relevance 
 
Regardless its mechanism, the observed interaction between glibenclamide and 
dipyridamole is of potential clinical relevance because adenosine and dipyridamole are 
clinically used as pharmacological tools to detect reversible cardiac ischemia [35]. 
Glibenclamide is often used in patients with type 2 diabetes who are at increased risk 
for the development of coronary atherosclerosis. Intra-arterially infused glibenclamide 
reached a local concentration of 43 ± 8 ng·ml-1 which is well within the minimally 
effective concentration range to reduce plasma glucose in patients with type 2 diabetes 
(30-50 ng·ml-1). In these patients, the use of glibenclamide could negate dipyridamole 
thallium stress-tests as demonstrated previously for the adenosine receptor antagonist 
caffeine [36]. Therefore, our data suggest that adenosine in stead of dipyridamole 
should be used as a pharmacological tool to detect insufficient coronary blood supply in 
patients who use glibenclamide. However, our forearm data can not be extrapolated 
directly to the heart and therefore, this important implication needs further confirmation 
in the coronary circulation during dipyridamole-thallium stress testing. 
 
In conclusion, like adenosine, the dipyridamole-induced forearm vasodilation is inhibited 
by theophylline which indicates that it is mediated by stimulation of adenosine 
receptors. In contrast to adenosine, the vasodilator response to equipotent doses of 
dipyridamole is inhibited by glibenclamide. Although these observations do not provide 
definite prove, they support our working hypothesis that dipyridamole and intraluminally 
applied adenosine act on different cells in the vascular wall. Furthermore, it indicates 
the involvement of ATP-sensitive potassium channels in the vasodilator response to 
dipyridamole.  
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Abstract  
 
In rats, diadenosine pentaphosphate (AP5A) has been implicated in the pathogenesis 
of essential hypertension. This study describes for the first time the vasomotor action 
of AP5A in humans, using the ‘perfused forearm technique’. 
Diadenosine pentaphosphate evoked a dose-dependent forearm vasodilator 
response equal to adenosine but less than adenosine-5`-triphosphate (ATP) at 
equimolar doses. The P1-purinoceptor antagonist theophylline (0.28 µmol·min
-1
·dl-1) 
reduced the percentage decrease in forearm vascular resistance (FVR) to AP5A (0.6, 
6 and 20 nmol·min-1·dl-1): -8 ± 6, -50 ± 6, -68 ± 4% during saline versus -7 ± 4, -33 ± 5 
and - 45 ± 6% during theophylline (ANOVA for repeated measures; p<0.05 for the 
interaction between purine dose and theophylline; n=10). The inhibitor of equilibrative 
nucleoside transport dipyridamole (7.4 µmol·min-1·dl-1) augmented the AP5A - (0.6 
and 6 nmol·min-1·dl-1) induced decrease in FVR: -34 ± 6 and -67 ± 5 % during saline 
versus -49 ± 5 and -80 ± 3 % during dipyridamole (p<0.05 for the effect of 
dipyridamole; n=6). The bivalent cation chelator ethylene diamine tetra acetic acid 
(EDTA), inhibited the rapid degradation of AP5A in vitro. In vivo, the highest tolerated 
intra-arterial EDTA dose (0.76 µmol·min-1·dl-1) was not sufficient to inhibit AP5A-
metabolism. 
Thus, intra-arterial AP5A reduces forearm vascular tone dose-dependently. This is, at 
least in part, mediated by its degradation product adenosine. Our data do not support 
an in vivo vasoconstrictor action of AP5A, and as such AP5A seems not likely to 
contribute to the pathogenesis of primary hypertension in man.  
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Introduction 
Diadenosine polyphosphates (APnA, n=2-7) are newly recognized endogenous 
compounds, consisting of two adenosine molecules bridged by two to seven 
phosphate groups [1;2]. Diadenosine polyphosphates occur in thrombocyte dense 
granules [3], in chromaffin granules of the adrenal medulla and in nerve terminals, 
where they are co-stored with neurotransmitters like adenosine-5`-triphosphate 
(ATP) [4;5]. They could potentially be involved in modulation of vascular tone [3], 
thrombocyte aggregation [6] and neurotransmission [4]. In 1989, Zidek et al. cross-
circulated spontaneously hypertensive and normotensive rats, which induced a 
significant rise in blood pressure in the normotensive rats [7]. They observed a 
vasoconstrictor action of plasma from hypertensive patients in isolated rat aortic 
strips [8]. Based on these findings, a circulating hypertensive factor was postulated. 
Agha et el. isolated substances from human platelets which increased the perfusion 
pressure of isolated rat kidneys [9]. These substances were present at higher 
concentrations in hypertensive subjects as compared to normotensive controls. 
Subsequently, Schlüter et al. identified these vasopressor agents as AP5A and AP6A 
[3]. Both AP5A and AP6A induced vasoconstriction in perfused rat kidneys and aortic 
rings, and an increase in blood pressure after intra-aortic injection in rats [3]. Thus, 
Schlüter and colleagues hypothesized that AP5A and AP6A may play a part in local 
vasoregulation and possibly in the pathogenesis of hypertension [3]. However, 
animal data are not unequivocal with respect to the vasomotor action of dinucleotide 
polyphosphates. Furthermore, important interspecies differences in purine 
pharmacology exist [10;11]. Therefore, we characterized the effect of AP5A on 
forearm vascular tone in human volunteers. We chose for AP5A , because this 
dinucleotide appeared to be the most potent vasoconstrictor in vitro [12-15]. 
The following questions were posed: [1] What is the effect of AP5A on forearm 
vascular tone? and [2] What is the involvement of P1-purinergic receptors in the 
vascular response to AP5A? 
Our results indicate that AP5A dilates the forearm vascular bed, which involves 
adenosine-induced stimulation of P1-purinoceptors. In-vitro experiments further 
support rapid degradation of AP5A. 
 
 
Methods 
 
 
Subjects  
 
After approval of this study by the local ethics committee, 49 normotensive 
nonsmoking healthy Caucasian male and female volunteers signed informed consent 
to participate. Two people took part in two studies. The volunteers had no history of 
hypertension, diabetes mellitus, or hyperlipidemia. Before participation, they 
underwent a physical examination, electrocardiagraphy, and laboratory investigation 
of cholesterol, triglycerides and glucose. Medication was not allowed except for oral 
contraceptives. Subjects did not use caffeine-containing beverages and alcohol for 
24 hours prior to the study (caffeine acts as an adenosine-receptor antagonist), and 
participants abstained from food two hours before testing. To confirm compliance to 
the caffeine abstinence, blood was sampled for the measurement of plasma caffeine 
concentration before each experiment. 
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General outline of the procedure 
 
The experiments were performed in the afternoon in a quiet, temperature-controlled 
room (23° C) and lasted approximately 4 hours. The vasomotor actions of AP5A and 
other substances were studied with the ‘perfused forearm technique’ as described 
before [16;17]. Briefly, the brachial artery was cannulated for measurement of intra-
arterial blood pressure and infusion of substances. Forearm blood flow was 
measured using ECG triggered mercury-in-silastic strain gauge plethysmography. 
Within each protocol the total infusion rate was kept constant at 50 µL·min-1·dl-1 of 
forearm tissue for the first protocol and 100 µL·min-1·dl-1 for the other protocols. 
Baseline recordings were always performed during saline (NaCl 0.9%) infusion for 5 
minutes. Each purine dose was infused for 5 minutes. 
 
 
Comparison of the vasomotor action of AP5A with equimolar doses of adenosine and 
ATP. 
 
In 6 subjects, the vasomotor action of equimolar doses of intra-arterially infused 
AP5A, adenosine and ATP were compared. After baseline measurements, three 
increasing doses of each purine (0.6, 6 and 20 nmol·min-1·dl-1) were infused. The 
purines were infused in a fixed order: first AP5A, followed by adenosine and ATP. 
The different purines were infused with a thirty minute interval to prevent any carry-
over effect.  
 
 
The effect of the P1-(adenosine) receptor antagonist theophylline on the AP5A-
induced forearm vasodilator response.  
 
In 10 volunteers, the effect of intra-arterially infused theophylline, a competitive P1-
receptor antagonist of both A1- and A2- receptors [18;19], was studied on the 
vasodilator response to AP5A and adenosine. After baseline measurements with 
saline-infusion, two increasing doses of adenosine (6 and 20 nmol·min-1·dl-1) were co-
infused with saline into the brachial artery. After a 15 minute drug-free interval 
baseline recordings were repeated, followed by three doses of AP5A (0.6, 6 and 20 
nmol·min-1·dl-1) co-infused with saline. This scheme was repeated with theophylline 
(0.28 µmol·min-1·dl-1) instead of saline.  
 
 
The effect of an inhibitor of equilibrative nucleoside transport, dipyridamole, on the 
forearm vasodilator response to AP5A.  
 
First, the vasomotor action of 7.4, 14.8 and 22.2 µmol dipyridamole ·min-1·dl-1 was 
studied in 8 volunteers (dose-finding study). Each dose was infused for 15 minutes. 
The lowest dose appeared to lack a significant vasomotor action. This dose was 
used in two groups of volunteers to test its ability to potentiate the vasodilator action 
of adenosine (positive control; n=7) and AP5A (n=6). Each purine was infused at a 
dose of 0.6 and 6 nmol·min-1·dl-1. In five volunteers AP5A was measured in the 
venous effluent at the end of the infusion of the highest dose of AP5A in the absence 
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and presence of dipyridamole. For this purpose, 3 ml blood was collected in 
prechilled tubes containing EDTA at a final concentration of 4 mmol·L-1 blood.  
 
 
Effect of EDTA on AP5A metabolism in human blood in vitro.  
 
From two healthy volunteers, 30 ml blood was collected using heparin as 
anticoagulant. AP5A was added to whole blood at a final concentration of 
approximately 3.5 nmol·ml-1 plasma in the absence or presence of EDTA (0.5 and 5 
mM). This AP5A concentration was based on the calculated AP5A concentration in 
the forearm vascular bed, assuming no degradation. AP5A was measured in plasma 
directly and after 30 and 180 minutes of incubation at 37°C. In addition the half-life of 
AP5A added to plasma was measured in 2 healthy volunteers.  
 
 
Characterization of EDTA as an inhibitor of AP5A metabolism in human blood in vivo.  
 
First we studied the tolerability and the vasomotor effect of increasing doses of intra-
arterially infused ethylene diamine tetra acetic acid (EDTA): 0.19, 0.38, 0.76, 1.52 
and 3.04 µmol·min-1·dl-1, resulting in calculated forearm concentrations of 0.1, 0.3, 
0.5, 1 and 2 mmol EDTA·L-1 plasma (n=6). Each dose was infused for 15 minutes 
with 15 minute drug free intervals between subsequent doses. The dose of 0.76 
µmol·min-1·dl-1 EDTA was the highest tolerated dose: higher doses EDTA caused 
stinging pain at the infusion site, radiating to the forearm. This dose did not affect 
baseline tone itself, in contrast to the higher doses. Therefore, in the final experiment, 
AP5A (0.6 and 6 nmol·min
-1
·dl-1) was infused with saline and repeated during EDTA 
(0.76 µmol·min-1·dl-1; n=8). Venous catheters were inserted in a deep antecubital vein 
of both arms to sample blood for analysis of ionized calcium. 
 
 
Drugs and solutions 
 
AP5A solutions were prepared from vials containing 5.3 mg lyophilized powder 
(synthesized for this study by Clinalfa, Switzerland). Adenosine solutions were 
prepared from 2-ml ampoules containing 6 mg adenosine (Adenocor, Sanofi 
Winthrop, the Netherlands). ATP solutions were prepared from 2-ml ampoules 
containing 20 mg ATP (Striadyne, Wyeth, France). Theophylline solutions were 
prepared from 10-ml ampoules containing 175.7 mg theophylline (Byk bv, the 
Netherlands). Dipyridamole solutions were prepared from 10 ml ampoules containing 
50 mg (Boehringer Ingelheim bv, Germany). A sterile EDTA stock solution was 
prepared at the hospital pharmacy and kept in cool storage until further dilution 
before the experiment. NaCl 0.9% was used as solvent for all drug solutions.  
 
 
Analytical methods 
 
AP5A: In vitro studies on AP5A metabolism with/without EDTA were performed in 
freshly collected plasma. Venous plasma collected during intra-arterial AP5A 
infusions was stored at -80 º. Sample pretreatment was as follows: 0.5 ml plasma 
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was mixed with 100 µL 0.01 M phosphate buffer and 100 µL 4 M HCL04. After 
standing for 5 min, the tube was centrifugated for 10 min on 2700 RPM. In the 
supernatant, 1.5 ml sodium phosphate buffer was added and AP5A was measured 
using HPLC with spectophotometric detection. The chromatographic system 
consisted of a Spectra Physics (Breda, the Netherlands) P2000 binary gradient 
pump, a 5 µm ODS Hypersil guard column (20x2.1mm), a Hewlett Packard 
(Amsterdam, the Netherlands) 5 µm BDS Hypersil C18 analytical column (200x4.6 
mm) and a Spectra Physics AS 3000 autosampler with a built-in column heater. The 
mobile phase, acetonitrile 0.02 M phosphate buffer, pH 6.0 was delivered with a flow-
rate of 1 ml·min-1. The column effluent was monitored with a Spectra Physics 
UV1000 variable wavelength detector set at 258 nm. The signal was processed by a 
Spectra Physics SP4400 integrator. The column heater was set at 40ºC and the 
injection volume was 10 µL.  
The retention time of AP5A in the chromatogram was 8.8 min for AP4A and 10.9 min 
for AP5A. The limit of detection of the method was 0.1 µmol AP5A·L
-1. The inter-day 
coefficient of variation was 9% at a concentration of 3.6 nmol AP5A·ml
-1. 
Caffeine: Samples were analyzed by HPLC [20]. 
Free ionised Calcium: this was measured with an ion-selective electrode on a Chiron 
bloodgas-analyzer. 
 
 
Statistical analysis 
 
Mean arterial BP (MAP) was measured continuously during each recording of FBF 
and averaged per FBF measurement. Forearm vascular resistance (FVR) was 
calculated as the quotient of simultaneously measured MAP and FBF and expressed 
in arbitrary units (AU). For saline infusion, data obtained during the last four minutes 
were averaged to one value, and for drug infusion, data from the last two minutes 
were averaged to ensure a steady state condition. The vascular response was 
expressed as percentage change from baseline in forearm vascular resistance. 
Analyses were performed on infused and non-infused arm separately, to detect 
possible systemic effects of the drug infusions on forearm vascular tone [17]. All 
results were expressed as mean ± SE. In the first study, the effects of the three 
purine receptor agonists were compared with an ANOVA for repeated measures, 
with agonist and agonist dose as within subject factors. Effects of interventions on 
purine receptor agonists were analyzed by an ANOVA for repeated measures with 
intervention and agonist dose as within subject factors. Two-sided P-values <0.05 
were considered to indicate statistically significant differences.  
Based on previous studies [16], a theophylline- or dipyridamole- induced difference of 
16% or 23% in FVR- response to adenosine can be detected with 10 or 6 
experiments respectively at a power of 0.8, acccepting an α-error of 0.05. These 
calculations are based on a paired-t-test on a single dose. In fact, we performed a 
repeated measures ANOVA which increases the power of the analysis. 
 
 
Results 
 
The demographic data of the participants are shown in table 1. 
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Plasma caffeine levels could not be detected in all but one of the participants, 
indicating excellent compliance to caffeine abstinence. 
 
Table 1. Demographic characteristics 
 
N= 49 (39 M / 10 F)  mean ± SD 
Age (years) 
 
23 ± 4 
BMI (kg·m
-2
) 
 
22.5 ± 2.1 
SBP (mmHg)*  
    
22 ± 8 
DBP (mmHg)* 
 
75 ± 7 
HR (beats·min
-1
)
 ¶
 
 
62 ± 9 
Cholesterol (mmol·L
-1
) 
 
4.0 ± 0.6 
Triglycerides (mmol·L
-1
) 
 
0.8 ± 0.3 
Glucose (mmol·L
-1
) 4.7 ± 0.4 
 
* Auscultatory measurement after 5 minutes of rest in a supine position.  
¶ Measured by pulse frequency counting after 5 minutes of supine rest 
 
 
Comparison of the vasomotor action of AP5A with equimolar doses of adenosine and 
ATP (n=6).  
 
AP5A reduced FVR from 30±2 AU at baseline to 26±3, 14±2 and 9±1 AU for three 
increasing doses, respectively (p<0.05). Likewise, equimolar doses of adenosine 
reduced FVR from 24±3 AU at baseline to 27±3, 16±2 AU and 9±1 AU. Similarly, 
ATP reduced FVR from 34±5 AU to 12±1, 7±1 and 6±1 AU. Baseline FVR did not 
significantly differ between the three purines. The vasodilator response to AP5A 
significantly differed from ATP (p<0.05), but not from adenosine (p>0.1). Thus, the 
rank order of vasodilator potency was ATP>AP5A = adenosine (figure 1). Purine 
infusions did not significantly affect FBF or FVR in the non-infused arm, blood 
pressure or heart rate (data not shown).  
 
 
The effect of the P1-(adenosine) receptor antagonist theophylline on the AP5A-
induced forearm vasodilator response (n=10).  
 
During saline, AP5A reduced FVR from 26±4 AU to 22±2, 12±1 and 8±1 AU. During 
theophylline, AP5A reduced FVR from 21±2 AU to 20±2, 14±1 and 11±2 AU. Baseline 
vascular tone did not differ significantly between theophylline and saline. For both 
adenosine and AP5A, the ANOVA for repeated measurements revealed a significant 
interaction between theophylline and purine-dose (figure 2). The effect of 
theophylline alone was not significant (for AP5A: p=0.075, for adenosine: p>0.1). 
Thus, the effect of theophylline was dependent on the purine-dose. Purine infusions 
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did not significantly affect FBF or FVR in the control arm, blood pressure or heart rate 
(data not shown).  
 
 
Figure 1. Comparison of forearm vasodilator response (percentage change in forearm 
vascular resistance, n = 6) to equimolar doses of diadenosine pentaphosphate (AP5A, black 
bars), adenosine (gray bars), and adenosine triphosphate (ATP, hatched bars) (0.6, 6 and 20 
nmol·min-1 per deciliter). Levels of significance for comparisons of percentage change in 
forearm vascular resistance (FVR) between purines are as follows: p<0.05, AP5A versus 
ATP; P<0.05, adenosine versus ATP.  
 
 
 
 
Figure 2. Effect of theophylline (0.28 µmol·min-1·dl-1) on the vasodilator response to 
adenosine and AP5A. P-values indicate level of significance for the interaction between 
theophylline and purine-dose.  
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The effect of dipyridamole, an inhibitor of equilibrative nucleoside transport, on the 
forearm vasodilator response to AP5A (n=6). 
  
In a pilot study 22.2 µmol dipyridamole ·min-1·dl-1 caused significant vasodilation: the 
FVR was reduced from 28±2.5 during saline to 23±2.6 AU during the last 5 minutes 
of dipyridamole infusion (p<0.05, n=8). At a dose of 7.4 µmol·min-1·dl-1 dipyridamole 
did not affect baseline tone but significantly potentiated the vasodilator response to 
both adenosine and AP5A (figure 3). In the control arm, vascular tone was not 
significantly affected by any drug infusion. Likewise, blood pressure and heart rate 
were not affected by the drug infusions (data not shown).  
At the end of the infusion of 6 nmol AP5A 6 ·min
-1
·dl-1, the AP5A-concentration in the 
venous effluent was 0.36 ± 0.1 µmol·L-1 (n=5). Assuming a calculated forearm 
concentration of 3.75 µmol·L-1 plasma, the extraction and/or degradation of AP5A 
during one transit time through the arm is 90%. In the presence of dipyridamole, the 
AP5A-concentration in the venous effluent was 0.27±0.1 µmol·L-1 (n=5) indicating that 
the augmenting effect of dipyridamole on AP5A-induced vasodilation did not result 
from changes in local AP5A concentrations. 
 
 
Characterization of EDTA as an inhibitor of AP5A-metabolism in human blood in vitro.  
 
Plasma half-life of AP5A added to plasma was 3.3 min (95% confidence interval: 2.7- 
4). In the presence of 5 mM EDTA, degradation of AP5A was completely blocked. 
However, at 0.5 mM, recovery of AP5A was reduced, indicating preserved 
metabolism (table 2).  
 
Table 2. Time course in recovery of diadenosine pentaphosphate (AP5A, micrograms per 
milliliter) in plasma and whole blood in absence and presence of ethylene diaminetetra-acetic 
acid (EDTA) (mean ± SE, n=2) 
 
    Whole Blood  
Time   0-mmol/L  0.5-mmol/L  5-mmol/L 
(min)  Plasma  EDTA  EDTA  EDTA 
0   3.7 ± 0.1  3.8 ± 0.3  3.8 ± 0.3  3.8 ± 0.3 
5  1.3 ± 0.01    
10  0.5 ± 0.03  2.2 ± 0.2  1.1 ± 0.3  3.6 ± 0.3 
15  0.1 ± 0.01    
20     
30     
40   0  0  3.3 ± 0.1 
190   0  0  3.4 ± 0.1 
 
Values at time zero indicate calculated concentrations of AP5A, assuming absent metabolism 
 
 
Characterization of EDTA as an inhibitor of AP5A-metabolism in human blood in vivo 
(n=8). 
 
In the pilot study, EDTA 0.76 µmol·min-1·dl-1 was tolerated by 5 out of 6 subjects. This 
dose had no influence on baseline vascular tone, but reduced ionized Ca2+ 
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concentration in the infused arm to 0.95 ± 0.1 mmol·L-1 during infusion of EDTA 
versus 1.24 ± 0.03 in the control arm, indicating a local reduction of 23% (n=3). 
EDTA in a dose of 1.52 µmol·min-1·dl-1 was tolerated by 3 out of 6 volunteers and 
increased FBF from 2.1±0.27 (baseline) to 4.6±1.1 µmol·dl-1 forearm volume 
(FAV)·min-1, although this difference was not statistically significant (p=0.07; 
Wilcoxon signed ranks test).  
At the dose of 0.76 µmol·dl-1 FAV·min-1, the AP5A-induced reduction in FVR (0.6 and 
6 nmol·dl-1 FAV·min-1) was not affected (figure 4). During co-infusion of AP5A 6 
nmol·min-1·dl-1 with EDTA the ionized calcium in the infused arm decreased from 
1.24±0.01 at baseline to 1.13±0.04 mmol·L-1 (mean±SE; n=7), indicating 8.9 % 
reduction in Ca2+ (p<0.05 for relative change). In the control arm, ionized calcium did 
not change: 1.27±0.01 at baseline and 1.27±0.03 during AP5A 6 nmol·dl
-1 FAV·min-1 
with EDTA (p>0.1).  
 
 
 
Figure 3. Effect of dipyridamole (7.4 µmol·min-1·dl-1) on AP5A (upper panel)- and adenosine 
(lower panel)-induced forearm vasodilation. P-values indicate level of significance for effect 
of dipyridamole on purine-induced % change in FVR (ANOVA for repeated measurements). 
The interaction between dipyridamole and purine dose was not statistically significant 
(ANOVA for repeated measurements p>0.1 for AP5A and p>0.05 for adenosine). 
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Figure 4. Effect of ethylene diamine tetra acetic acid (EDTA; 0.76 µmol·min-1·dl-1) on AP5A-
induced forearm vasodilation. P-value indicates level of significance for effect of EDTA on 
AP5A-induced % change in FVR 
 
 
 
Discussion 
 
This study shows for the first time that intra-arterial infusion of AP5A dilates the 
forearm vascular bed in humans in vivo. Theophylline inhibits the vasodilator effect of 
both adenosine and AP5A, suggesting the involvement of P1 purinoceptors. 
Therefore, we hypothesized that adenosine, one of the breakdown products of AP5A 
[21;22], contributes to the AP5A-induced vasodilation.  
 
 
Metabolism of AP5A in the human forearm 
 
Diadenosine pentaphospate is degraded by hydrolases on endothelium yielding ATP, 
AMP and adenosine as vasodilating metabolites [1;23]. The vasoactive effect and 
degradation of the metabolite AP4 is unknown [1]. 
To further support the hypothesis that AP5A induces vasodilation through its 
breakdown products, we used three approaches. First, we used dipyridamole to 
inhibit equilibrative nucleoside transport (ENT) in the forearm [24]. Dipyridamole 
inhibits adenosine uptake without having a known effect on AP5A metabolism. To 
prevent a possible vasomotor action of increased concentrations of endogenous 
adenosine [25], a dipyridamole dose was used that did not significantly affect 
baseline vascular tone. This dose augmented the vasodilator response to exogenous 
adenosine, indicating significant inhibition of ENT. Likewise, dipyridamole augmented 
AP5A-induced vasodilation, indicating increased formation of adenosine during AP5A 
infusion. This observation confirms rapid metabolism of AP5A to adenosine in the 
human forearm in vivo. 
Second, we studied the stability of AP5A in human blood in vitro and in the forearm in 
vivo. Only a small portion of AP5A added to human blood could be recovered, 
confirming rapid degradation. Furthermore, the measured concentration of AP5A in 
venous plasma collected from the infused arm, during intra-arterial administration of 
AP5A supports degradation of most of the infused AP5A during one transit time. 
P > 0.1
AP5A – NaCl 0.9%
AP5A – EDTA
-100
-75
-50
-25
0
25
∆ Forearm vascular resistance (%)
0.6 6
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EDTA, a known inhibitor of enzymes that are involved in AP5A- and ATP breakdown 
[22;26;27], significantly inhibited the degradation of AP5A in vitro and improved 
recovery, indicating the validity of our method to detect AP5A. 
Third, in an attempt to inhibit the degradation of AP5A in vivo, we investigated the 
effect of EDTA on AP5A-induced vasodilation in the forearm. EDTA reduced the free 
calcium concentration in the infused but not in the control arm, indicating local 
chelation of divalent cations. Furthermore, EDTA induced a small vasodilator 
response. As far as we know, this is the first description of a direct vasodilator action 
of EDTA. This observation probably reflects reduced availability of calcium to 
maintain adrenergic- and endotheline- mediated contraction of vascular smooth 
muscle cells. In patients with hyperparathyroidism, an increased forearm vascular 
tone has been reported [28]. Our observation suggests that an increased serum 
calcium concentration contributes to the altered forearm vasomotor state in these 
patients. This is supported by others showing that calcium infusion increases blood 
pressure and total vascular resistance in healthy volunteers [29]. 
Unfortunately, pain at the site of infusion prevented the use of a dose of EDTA that 
would be sufficient to inhibit ectonucleotidases, which explains why EDTA failed to 
affect AP5A-induced vasodilation significantly. This is confirmed by the reduced 
recovery of AP5A in vitro at an EDTA concentration of 0.5 mM, that was estimated to 
occur in vivo during infusion of the highest tolerated dose into the brachial artery.  
Our experimental design does not directly allow us to draw conclusions about the 
contribution of nitric oxide (NO) in AP5A induced forearm vasodilation, because we 
did not co-infuse AP5A with a NO-antagonist. Adenosine but not ATP has been 
shown to stimulate NO release in the human forearm [30;11]. Since the vasodilator 
response on AP5A at least partially depends on formation of adenosine, it is expected 
that NO is also involved in AP5A-induced vasodilation. 
 
 
Comparison of this study with previous observations in animals 
 
Our observation that AP5A reduces forearm vascular tone at physiologically relevant 
concentrations [31], is at variance with a human in vitro study which showed 
vasoconstriction of isolated umbilical arteries in response to AP5A [32], and with 
animal in vitro studies which demonstrated vasoconstriction in isolated renal 
resistance arteries [2;3;9;12], isolated perfused mesenteric arteries [14] and isolated 
rat aortic strips [33]. However, more recently also a vasodilator response to AP5A has 
been observed in animal preparations in vitro [15;34]. How can these discrepancies 
be explained? 
In vitro, enzymatic degradation of AP5A may be reduced for several reasons. First, 
the abundant amount of the substrate AP5A relative to the small amount of enzymes 
in the isolated blood vessel wall contrasts with the in vivo situation. Second, in these 
in vitro preparations AP5A can easily reach the vascular smooth muscle cells without 
the need to pass the endothelium, which is a rich source of ectonucleotidase activity 
[23;35]. Apart from differences in ectonucleotidase activity, differences between 
species or vascular beds may exist. For example, AP5A gives rise to vasodilation in 
the isolated guinea pig heart [36], while it elicits a vasoconstrictor response in the 
isolated perfused rat kidney [12]. However, these results obtained in perfused organ 
preparations do not exclude degradation of AP5A to adenosine and ATP, because 
adenosine is known to induce vasoconstriction in the afferent glomerular arteriole 
[37]. Furthermore, a P2x purinoceptor was hold responsible for the vasoconstrictor 
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response to AP5A in the perfused rat kidney [12]. Finally, methodological differences 
may explain some of the differences between in vitro studies. For example, Ralevic 
et al. observed vasoconstriction in isolated perfused mesenteric arteries of the rat 
[14], which differs from a report from Steinmetz et al. who studied precontracted 
isolated rat mesenteric resistance arteries in a Mulvany wire myograph and observed 
only a transient vasoconstriction, followed by sustained dilation. This discrepancy 
may find its origin in the use of bolus injections in the first study and steady state 
agonist concentrations in the second.  
Results from in vivo studies on the pressor effect of AP5A in intact rats are conflicting: 
both a reduction in blood pressure [38;39] as well as an increase in blood pressure 
[3] have been reported. 
 
 
Implications of this study for the role of AP5A in the pathogenesis of hypertension 
 
Schlüter et al. originally hypothesized that thrombocyte- or plasma- derived AP5A and 
AP6A are involved in the pathogenesis of hypertension [3]. However, our observation 
that luminal AP5A is rapidly metabolized and, through its degradation products, elicits 
a vasodilator response in the human forearm, does not support a pathogenic role of 
plasma- or thrombocyte-derived AP5A in the development of hypertension in humans. 
Furthermore, our observations provide an explanation for some contrasting results 
from in-vitro and animal studies. 
Three limitations of our study should be mentioned. First, we studied AP5A in the 
forearm vascular bed. An increased forearm vascular resistance has been observed 
in patients with essential hypertension, supporting the contribution of this vascular 
bed in the pathogenesis of hypertension [40]. However, regional differences in the 
vasomotor action of AP5A may exist. Our study does not exclude constriction of renal 
resistance arteries in response to AP5A which could cause hypertension. Second, we 
studied AP5A in a healthy vascular bed with normal endothelial function. Therefore, 
our results do not exclude a vasoconstrictor action in atherosclerotic vessels where 
the metabolism of this purine could possibly be reduced, and where it may have 
direct access to the vascular smooth muscle cells. However, if AP5A causes 
hypertension as suggested by the cross circulation experiments in rats, it should be 
able to increase vasoconstriction in an otherwise healthy vascular bed. Third, our 
results do not exclude a vasoconstrictor action of adventitially released AP5A as may 
occur during activation of the sympathetic nervous system.  
 
In conclusion, our results indicate that intra-arterial infusion of AP5A induces forearm 
vasodilation, which at least in part is mediated by its breakdown product adenosine. 
Our observations do not support a role for luminal AP5A in the pathogenesis of 
hypertension.  
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Abstract  
 
Adenosine is an endogenous purine with vasodilating and cardioprotective 
properties. Animal experiments have shown that some benzodiazepine-induced 
effects can be explained by potentiation of adenosine effects, via inhibition of the 
nucleoside transport system. The objective of this study was to determine whether 
the frequently used benzodiazepines diazepam and midazolam increase adenosine-
induced vasodilation in the human forearm vascular bed, measured by venous 
occlusion plethysmography. 
Adenosine (0.6, 6, 20 and 60 nmol·min-1·dl-1 Fore Arm Volume) was infused into the 
brachial artery with and without concomitant separate infusion of diazepam (21 
nmol·min-1·dl-1, n=9) and midazolam (23 nmol·min-1·dl-1, n=8). Plasma concentrations 
of diazepam resp. midazolam at the end of the infusion protocol averaged 0.5 ± 0.2 
µg·ml-1 plasma (1.6 µM) for diazepam versus 1.2 ± 0.4 µg·ml-1 plasma (3 µM) for 
midazolam. Intra-arterial infusion of the benzodiazepines did not alter baseline 
vascular tone, and had no significant influence on the forearm vasodilator response 
to adenosine. The adenosine-induced relative change in Forearm Vascular 
Resistance (FVR) was -3 ± 7, -48 ± 8, -75 ± 6 and -85 ± 3% in the absence and 3.5 ± 
11, -54 ± 5, -74 ± 5 and -82 ± 3% res. in the presence of diazepam (p>0.1, repeated 
measures ANOVA, n=9). Likewise, in the absence resp. presence of midazolam FVR 
fell by 1 ± 6, 55 ± 5, 74 ± 3 and 84 ± 2% resp. 11 ± 11, 59 ± 2, 80 ± 3 and 87 ± 2% 
(p>0.1, n=7). 
Intra-brachial infusion of diazepam- and midazolam resulting in forearm 
concentrations in the high-therapeutic range does not augment adenosine-induced 
forearm vasodilation. A possible interaction at supra-therapeutic levels of the 
benzodiazepines can not be excluded from the present study, but lacks clinical 
significance. 
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Introduction 
 
Adenosine is involved in autoregulation of cerebral- and coronary blood flow and is a 
mediator in the process of ischemic preconditioning [1]. Adenosine-induced 
vasodilation is mediated by specific membane receptors, the so-called adenosine A2 
-receptors [2]. The A1-receptor is responsible for the central depressant action of 
adenosine, and for its antiarrhythmic and anti-ischemic properties. Adenosine has a 
half-life of a few seconds [3]. Inhibition of its metabolism offers a unique possibility to 
harness the tissue -protective properties of adenosine in a site- and event specific 
manner. 
Benzodiazepines are widely prescribed for their anxiolytic, anticonvulsant and 
sedative effects. These properties of benzodiazepines are often used in patients with 
acute cardiac events. Most of these clinical effects can be explained by 
benzodiazepine-induced enhancement of synaptic transmission of the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA) [4]. An intriguing alternative mechanism 
for its therapeutic actions is the capacity of benzodiazepines to inhibit adenosine 
uptake. This results in increased extracellular adenosine levels and potentiation of 
adenosine-effects [5]. Phillis initially observed that diazepam potentiates the 
depressant action on cerebral neurons evoked by adenosine [6]. Moreover, the 
adenosine receptor antagonists theophylline and caffeine have been shown to 
antagonize several central actions of diazepam, while adenosine and its analogues 
elicit many effects corresponding to those of benzodiazepines [5]. Although most 
studies on the adenosine-benzodiazepine interaction focused on the central effects 
of adenosine, several studies on peripheral tissues have confirmed the potentiation 
of adenosine by micromolar concentrations of diazepam. For example, diazepam 
potentiates adenosine responses by inhibiting adenosine uptake in rat vas deferens, 
guinea pig hearts, trachea and taenia coli [7-10], rat coecum [11], rat ventricle [12], 
and mouse diaphragm [13]. To our knowledge, human in-vivo studies about the 
adenosine-benzodiazepine interaction are lacking so far. We hypothesized that 
diazepam and midazolam in high-therapeutic forearm concentrations might augment 
adenosine-mediated vasodilation in the forearm skeletal muscle vascular bed in 
healthy human volunteers. Studies were performed with the perfused forearm 
technique. This experimental set up has been validated previously to demonstrate 
adenosine uptake inhibition in humans in vivo [14;15]. 
 
 
Methods 
 
 
Subjects 
 
Studies were performed in 24 healthy, non-smoking volunteers. Demographic data 
are shown in table 1. Participants did not use concomitant medication except for oral 
contraceptives, and all subjects were normotensive. All participants underwent a 
physical examination, laboratory screening (total cholesterol, triglycerides and 
glucose) and electrocardiography before entering the study. The study protocol was 
approved by the hospital ethics comittee, and all participants signed written informed 
consent before their participation. Participants were asked to abstain from caffeine-
containing beverages and alcohol for 24 hours before the experiment, and to abstain 
from food-intake 2 hours prior to the study.  
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Table 1. Demographic characteristics 
 
N = 24 ( 8M / 16 F) mean ± SD 
Age (years) 
 
21 ± 2 
BMI (kg·m
-2
) 
 
22 ± 2 
SBP (mmHg)* 
 
118 ± 9 
DBP (mmHg)* 
 
73 ± 7 
HR (bpm) 
¶ 
 
64 ± 9  
Cholesterol (mmol·L
-1
) 
 
4.1 ± 0.6 
Triglycerides (mmol·L
-1
) 
 
0.7 ± 0.2 
Glucose (mmol·L
-1
) 4.6 ± 0.3 
 
* Auscultatory measurement after 5 minutes of rest in supine position 
¶ Measured by pulse frequency counting after 5 minutes of supine rest 
 
 
 
General outline of the procedure 
 
The experiments were performed in the morning with the subjects supine in a quiet 
temperature -controlled room (23-24°C). After local anesthesia (xylocaine 2%), the 
brachial artery of the non-dominant arm was cannulated (Angiocath, 20 gauge, 
Deseret Medical, Becton Dickinson Sandy, UT, USA) for drug infusion (syringe 
infusion pump, type STC-521, Terumo Corp., Tokyo, Japan) and intra-arterial blood 
pressure measurement (Hewlett Packard monitor, type 78353B, Hewlett Packard 
GmbH, Böblingen, Germany). A deep antecubital vein was cannulated bilaterally for 
blood sampling to determine plasma benzodiazepine-concentrations. Drug- and 
volume infusion rates were calculated per deciliter of forearm tissue, which was 
measured by the water displacement method. Bilateral Forearm Blood Flow (FBF) 
was measured by electrocardiogram triggered mercury-in-silastic strain gauge 
plethysmography, as described before [15], while the hand circulation was occluded 
using wrist cuffs [16]. After intra-arterial cannulation, at least 30 minutes of 
equilibration were included to obtain a steady state before baseline measurements. 
Pilot studies with intra-brachial infusions of diazepam (n=3) and midazolam (n=4) 
alone were performed first, for safety and dose-finding. Baseline values were 
recorded during infusion of saline (NaCl 0.9%). Diazepam (Diazemuls) was infused 
ino the brachial artery in three increasing doses: 1.2, 3.5 (each during ten minutes) 
and 10.5 (during thirty minutes) nmol·min-1·dl-1 (n=3). Each dose was preceded by a 
five-minutes measurement of baseline values during infusion of NaCl 0.9%. During 
the last minute of diazepam infusion, venous blood samples were drawn for 
measurement of local plasma diazepam concentrations. Midazolam pilot experiments 
with 0.8, 2.5 and 7.5 nmol·min-1·dl-1 were performed using the same infusion 
schedule (n=4).  
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The final experiments started with infusion of saline (NaCl 0.9%) to obtain baseline 
recordings (see figure 1 for the infusion schedule). Thereafter, four increasing doses 
of adenosine (0.6, 6, 20 and 60 nmol·min-1·dl-1) were co-infused with saline during 5 
minutes per dose. The succeeding adenosine-doses were interrupted once by a 5 
minutes drug free interval during which the wrist cuffs were deflated to allow recovery 
of the hand circulation. After a subsequent equilibration period of 45 minutes to allow 
parameters to return to baseline levels, baseline recordings were repeated during 
infusion of saline followed by separate infusion of diazepam (21 nmol·min-1·dl-1) resp. 
midazolam (23 nmol·min-1·dl-1). After 15 minutes of benzodiazepine-infusion, 
subsequent infusions of adenosine were started. Diazepam and midazolam 
administration was continued during the adenosine infusions. The rate of infused 
volume and the amount of connected syringes was kept constant throughout each 
experiment. Venous benzodiazepine plasma concentrations from both arms were 
measured at baseline, after the second and after the last adenosine dose.  
  
 
 
 
Figure 1. Infusion schedule 
 
 
 
Drugs and solutions 
 
Adenosine was prepared for each experiment by diluting Adenocor (6 mg/2ml, Sanofi 
Winthrop) vials in NaCl 0.9% to reach the necessary concentrations. Diazemuls 
(Dumex, Baarn) and midazolam (Dormicum, Roche, Mijdrecht, The Netherlands) 
were diluted in saline to reach maximal syringe-concentrations of 0.06 and 0.09 
mg·ml-1 respectively. We used the emulsion preparation Diazemuls for diazepam 
administration because it proved to be not arterio-toxic in animal experiments [17] in 
contrast to the regular preparation. All solutions were freshly prepared.  
 
Blood samples: diazepam / midazolam↓
diazepam / midazolam
Adenosine (nmol/min/dl FAV)
NaCl 0.9%
Time after cannulation (minutes) 
cannulation
30 40 50
↓ ↓
0.6 0.6
60
20
6
60
20
6
↓ ↓
0 120 14013060 110 150
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Analytical procedures 
 
Plasma levels of midazolam were determined using a specific HPLC method with UV 
detection at 220 nm as described elsewhere [18]. In brief, the method included a 
liquid-liquid extraction of alkalized plasma with cyclohexane-dichloromethane (55-45 
v/v) followed by evaporation of the organic layer. Separation was achieved on a 
Inertsil ODS-3 C-18 column (15 X 0.46 cm) with an isocratic mobile phase of 0.1M 
phosphate buffer (pH7.0) -acetonitrile (65-35% v/v). The inter- and intra-day 
coefficients of variation of the assay were less than 7% over the range till 0.4 µg·ml-1. 
A good linearity for midazolam was obtained till a concentration of 10 µg·ml-1 
(R2=0.9999). The limit of quantification was 0.5 ng·ml-1. 
Plasma levels of diazepam were determined with a routine High Pressure Liquid 
Chromatography method for benzodiazepines with UV detection at 313 nm. This 
modified method of Meijer [19] included an automatic solid phase extraction with an 
ASPEC (Gilson) on Isolute C18 (100 mg) SPE columns. After conditioning of the 
SPE columns with 2 ml of methanol and 2 ml of ultrapure water the system added 1.0 
ml of plasma with 0.2 ml internal standard of 10 µg·ml-1 chlorodesmethyldiazepam 
onto the SPE columns. After washing the columns with 2.0 ml of 0.05M K2HPO4 and 
1 ml of ultrapure water, the benzodiazepines were eluted with 0.35 ml acetonitrile. 
The eluate was mixed with 0.75 ml water before injection of 0.2 ml into the 
chromatograph. Analyses were performed on a Sperisorb 3ODS2 column (12.5 X 
0.46 cm) with an isocratic mobile phase of 0.02M phosphate buffer (pH 7.0) - 
acetonitrile (62-38% v/v) at a flow of 1 ml·min-1. The inter- and intra-day coefficients 
of variation for diazepam and the desmethyldiazepam were less than 7% at a 
concentration of 0.1 µg·ml-1. The limit of quantification was less than 0.02 µg·ml-1. 
 
 
Statistical analysis 
 
All results are mean ± SE, unless indicated otherwise. P<0.05 (two sided) was 
considered statistically significant. Mean arterial blood pressure (MAP) was 
calculated from the electronically integrated area under the brachial arterial pulse-
wave curve and averaged per FBF measurement. Forearm vascular resistance 
(FVR) was calculated from simultaneously measured MAP and FBF (MAP/FBF) and 
expressed as arbitrary units (AU). The mean calculated FVRs and hemodynamic 
parameters obtained during the last 4 minutes of saline infusion or during the last 2 
minutes of each drug infusion were taken as the response and used for further 
analysis. Benzodiazepine-induced effects on vascular tone were expressed as 
absolute difference from baseline and analyzed using a paired student t-test. The 
vasodilator response to adenosine was expressed as the percentage change in FVR 
from the preceding saline infusion or benzodiazepine infusion. To avoid multiple 
comparison, the effect of the benzodiazepines on adenosine-induced vasodilation 
were assessed with repeated measures ANOVA. The presence of benzodiazepine 
and adenosine doses were used as within subject factors. The statistical analyses 
were performed using the SPSS personal computer software package (SPSS Corp., 
Gorinchem, The Netherlands). 
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Results 
 
 
Pilot studies: 
 
The pilot experiments did not reveal any signs of possible benzodiazepine induced 
arterio-toxicity, and none of the participants experienced drowsiness. Baseline 
vascular tone was not influenced by infusion of diazepam nor midazolam. The mean 
plasma-concentrations at the end of the thirty minutes infusion of the highest doses 
in the pilot experiments were 1.1 mg diazepam·L-1 (n=3) and 0.7 mg midazolam·L-1 
(n=4). As we aimed to reach high therapeutic plasma concentrations of about 2 mg 
diazepam ·L-1 and 1 mg·L-1 midazolam, the infused benzodiazepine doses were 
adjusted to 21 nmol·dl-1·min-1 diazepam and 23 nmol·dl-1·min-1 midazolam for the final 
experiment.  
 
 
Adenosine-benzodiazepine studies: 
 
In the absence of diazepam, adenosine increased forearm blood flow (FBF) from 
2.5±0.6 at baseline to 2.9±0.8, 5.5±1.3, 11.1±1.8 and 18.3±3.1 ml·min-1·dl-1 during the 
four incremental adenosine doses respectively. Recontrol values for FBF or FVR did 
not significantly differ from baseline (2.5±0.6 vs 3.2±0.7 ml·min-1·dl-1; 45.4±6.5 vs 
38±6.2 AU; p>0.1; n=9). Subsequent infusion of diazepam did not significantly affect 
FBF (3.2±0.8 ml·min-1·dl-1) or FVR (42.3±9.3 AU, n=9, p>0.1 vs recontrol). In the 
presence of diazepam, adenosine increased FBF from 3.2±0.8 at baseline to 3.4±0.8, 
6.8±1.3, 12.9±1.8 and 18.4±3.3 ml·min-1·dl-1 during the four increasing adenosine 
doses respectively (p>0.1 versus adenosine response in absence of diazepam, n=9). 
Similar results were obtained when expressed as percentage change in FVR (see 
figure 2). The mean cumulative diazepam dose was 2.1±0.3 mg (n=9). Diazepam 
plasma concentrations were obtained in 7 from 9 participants. Diazepam 
concentrations amounted 1.1±0.2 at baseline, 0.9±0.3 after the second and 0.5±0.2 
µg·ml-1 after the last adenosine dose respectively. This decrease in concentration is 
due to adenosine-induced vasodilation; at a constant infusion-rate of diazepam, an 
adenosine-induced increase in forearm blood flow results in increased dilution of 
diazepam. During the last minute of the experiment, diazepam could be detected in 
the control arm in 5 of 7 participants, with a mean value of 0.04±0.01 µg·ml-1. None of 
the volunteers in this experiment with diazepam experienced drowsiness.  
Likewise, in the absence of midazolam, adenosine increased FBF from 2.1±0.4 at 
baseline to 2.2±0.5, 4.8±0.9, 7.9±1 and 13±1.1 ml·min-1·dl-1 during the four 
incremental adenosine doses respectively. Recontrol values for FBF or FVR did not 
significantly differ from baseline (2.1±0.4 vs 1.9±0.3 ml·min-1·dl-1; 51.4±8.2 vs 
57.5±10.1 AU; p>0.1; n=7). Subsequent infusion of midazolam did not significantly 
affect FBF (2±0.3 vs 1.9±0.3 ml·min-1·dl-1) or FVR (57.5±10.1 vs 64.7±13.4 AU, n=7, 
p>0.1 vs recontrol). In the presence of midazolam, adenosine increased FBF from 
2.1±0.4 at baseline to 2.2±0.5, 4.8±0.9, 7.9±1 and 13±1.1 ml·min-1·dl-1 during the four 
increasing adenosine doses respectively (p>0.1 versus adenosine response in 
absence of midazolam, n=7). Similar results were obtained when expressed as 
percentage change in FVR (see figure 2). All but two participants in the midazolam-
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adenosine study experienced drowsiness. In the experimental arm, midazolam 
plasma concentrations changed from 2.5±0.2 at baseline to 2.7±0.4 and 1.2±0.4 
mg·L-1 during the second and last adenosine dose. The mean cumulative midazolam 
dose that was infused was 3.2±0.8 mg (n=8). During the last minute of the 
experiment, midazolam could be detected in the control arm of all volunteers, with a 
mean value of 0.04 mg·L-1. Infusion of midazolam 23 nmol·min-1·dl-1 changed FVR 
from 57±10 at recontrol to 65±13 AU (n=7, p>0.1, paired samles t-test). In the 
absence resp. presence of midazolam, the percentage decrease in FVR was 1±6, 
55±5, 74±3 and 84±2% resp.11±11, 59±2, 80±3 and 87±2% (p>0.1, n=7). 
Diazepam nor midazolam-infusion induced significant changes in blood pressure or 
heart rate. The course of FVR in the control arm did not change significantly during 
the studies.  
 
 
Discussion 
 
This study showed that adenosine-induced vasodilation in the human forearm can 
not be augmented by concomitant intra-arterial infusion of diazepam or midazolam in 
a dose that results in high therapeutic forearm concentrations. We were interested in 
a possible benzodiazepine-induced augmentation of adenosine effects because such 
an interaction could be exploited in cardiovascular diseases and during anesthesia.  
In a previous study, we showed that the dose-response curve for adenosine-induced 
vasodilation in the human forearm is reproducible [15]. The explanation for the 
discrepancy between our data and previous reports by others is that benzodiazepine 
concentrations in the forearm have been too low to induce significant inhibition of 
adenosine transport. Indeed, benzodiazepines have been shown to have a relative 
low affinity (IC50>1µM) for nucleoside transport in for example human erythrocytes, 
contrasting with the nanomolar affinity of the prototypical transport blocker 
dipyridamole [20]. We actually reached micromolar plasma concentrations of 
benzodiazepines, which does not rule out a concentration problem however, since 
we measured total plasma concentrations. Diazepam and midazolam have a high 
plasma protein binding (>90%). The study of the influence of higher doses of 
diazepam in our study was hampered by potential toxic effects on the vascular wall 
[17;21;22]. For midazolam, drowsiness in our volunteers was the dose limiting side 
effect in these studies. We can not rule out a possible interaction at supra-therapeutic 
levels of the benzodiazepines from the present study, but this lacks clinical 
significance. Finally, we performed experiments on peripheral tissues which does not 
rule out a possible benzodiazepine-induced inhibition of adenosine transport in the 
central nervous system. 
We did not observe any vasodilator action of the tested benzodiazepines, indicating 
that a possible blood pressure lowering action of these drugs as observed during 
anaesthesia [23] can not be explained by a direct action on peripheral vascular tone. 
We conclude that adenosine-induced vasodilation in the forearm vascular bed of 
human volunteers can not be augmented by diazepam or midazalam concentrations 
at the upper end of the clinical relevant range.  
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Figure 2. Effect of diazepam (left) and midazolam (right) infusions on adenosine- (0.6, 6, 20 
and 60 nmol·min-1·dl-1) induced change in forearm blood flow (FBF, ml·dl-1 FAV·min-1, mean ± 
SE), and expressed as percentage change (mean±SE) in forearm vascular resistance (FVR) 
from preceding baseline (saline or saline with benzodiazepine). Solid line: with concomitant 
saline infusion; dashed line: with concomitant benzodiazepine infusion. P-value indicates 
level of significance between the curves with and without concomitant benzodiazepine 
infusion (ANOVA for repeated measures).  
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Abstract  
 
The purine nucleotide adenosine-5`-triphosphate (ATP) exerts pronounced effects on 
the cardiovascular system. The mechanism of action of the vasodilator response to 
ATP in humans has not been elucidated yet. Proposed endothelium derived relaxing 
factors (EDRFs) were studied in a series of experiments, using the perfused forearm 
technique. 
Adenosine 5`-triphosphate (0.2, 0.6, 6 and 20 nmol·dl-1 forearm volume·min-1) evoked 
a dose-dependent forearm vasodilator response which could not be inhibited by the 
separate infusion of the non-selective COX inhibitor indomethacin (5 µg·dl-1·min-1, 
n=10), the blocker of Na+/K+-ATPase ouabain (0.2 µg·dl-1·min-1, n=8), the blocker of 
KCa-channels tetraethylammonium-chloride (TEA, 0.1 mg·dl
-1
·min-1, n=10), nor by the 
KATP-channel blocker glibenclamide (2 µg·dl
-1
·min-1, n=10). All blockers, except 
glibenclamide, caused a significant increase in baseline vascular tone. The obtained 
results might be due to compensatory actions of unblocked EDRFs. Combined 
infusion of TEA, indomethacin and L-NMMA (n=6) significantly increased baseline 
forearm vascular resistance. The ATP-induced relative decrease in Forearm 
Vascular Resistance was 48 ± 5, 67 ± 3, 88 ± 2 and 92 ± 2 % in the absence and 23 
± 7, 62 ± 4, 89 ± 2 and 93 ± 1 % in the presence of the combination of TEA, 
indomethacin and L-NMMA (p<0.05, repeated measures ANOVA, n=6). A similar 
inhibition was obtained for sodium nitroprusside (SNP, p<0.05 repeated measures 
ANOVA, n=6), indicating a non-specific interaction due to the blocker induced 
vasoconstriction.  
ATP-induced vasodilation in the human forearm can not be inhibited by separate 
infusion of indomethacin, ouabain, glibenclamide or TEA, or by a combined infusion 
of TEA, indomethacin and L-NMMA. Endothelium-independent mechanisms and 
involvement of unblocked EDRFs, such as CO, might play a role, and call for further 
studies. 
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Introduction 
 
Adenosine-5`-triphosphate (ATP) is an endogenous purine nucleotide consisting of a 
purine base (adenine), ribose and 3 phosphate groups. ATP is released from 
aggregating thrombocytes [1;2], endothelium [3], sympathetic nerve endings [4;5], 
and ischemic muscle cells [6]. Extracellular ATP exerts potent and diverse effects on 
the cardiovascular system via activation of P2 receptors [6;7]. In general, P2x and 
P2y receptors on vascular smooth muscle cells (VSMCs) mediate vasoconstriction, 
while stimulation of P2y receptors on endothelial cells causes vasodilation. This dual 
action of ATP on vascular tone may have important clinical consequences: during 
thrombocyte aggregation at sites of severe atherosclerosis, locally released ATP 
might induce vasoconstriction mediated by P2x-receptors located on VSMCs, which 
is unopposed by P2y-receptors mediated vasodilation because of endothelial 
damage [8]. Local vasoconstriction will then further aggrevate ischemia. Therefore, 
better understanding of ATP-induced vasodilation may reveal new targets for 
pharmacological intervention to reduce or prevent vasospasm, thrombus formation, 
and ischemia. 
The exact mechanism of ATP-induced endothelium-dependent vasodilation in 
humans is still a matter of debate. In vitro studies that explored the vasomotor effect 
of ATP in the presence and absence of an intact endothelium revealed an important 
role of the endothelium in ATP-induced vasodilation.  
The proposed Endothelium Derived Relaxing Factors (EDRFs) are NO, prostacyclin 
and Endothelium Derived Hyperpolarizing Factors (EDHFs) [9-12]. 
The exact nature of EDHF is stil uncertain, although its mechanism of action through 
opening of potassium channels and/or activation of Na+/K+-ATPase has been well 
established [13-16]. A study in isolated mesenteric rat-arteries showed that the 
prolonged phase of vasorelaxation to ATP was attenuated by ouabain and by 
glibenclamide, indicating direct or indirect involvement of Na+ /K+-ATPase and KATP -
channels [17]. In-vivo studies on ATP-induced vasodilation are rare. Former 
experiments by our group revealed that the ATP-induced vasodilation in the human 
forearm exceeds the vasodilation induced by equimolar adenosine infusion, which is 
the degradation product of ATP with the highest P1-purinergic receptor agonist 
activity [18]. This demonstrates that the metabolite adenosine hardly contributes to 
the ATP-induced vasodilation in the human forearm. This is further supported by the 
fact that the P1-purinoceptor antagonist theophylline did not affect the vasodilator 
response to ATP [18]. It was shown previously that ATP-induced vasodilation in the 
human forearm can not be inhibited by the competitive NO-synthase antagonist NG-
monomethyl-L-arginine (L-NMMA) [18;19]. Finally, previous experiments by our 
group have demonstrated that the vasodilator response to intra-arterial ATP in the 
forearm is not limited by any vasoconstrictor action, including vasoconstriction that 
could theoretically have resulted from P2x receptor stimulation on vascular smooth 
muscle cells [18]. 
The aim of this study was to identify a possible role for cyclo-oxygenase products 
and endothelium derived hyperpolarizing factor(s) (EDHF) in ATP-induced 
vasodilation. Cyclo-oxygenase mediates the formation of the intermediate compound 
prostaglandin H2 (PGH2), the precursor for several prostaglandins, such as 
prostacyclin (PGI2) and thromboxane A2 (TXA2 , an endothelium derived contracting 
factor). Prostacyclin acts on receptors on VSMCs mediating vasodilation by increase 
of intracellular cAMP via stimulation of adenylate cyclase [20]. In this study, 
cyclooxygenase activity was blocked with indomethacin. 
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Other arachidonic acid metabolites that might be partly responsible for EDHF activity 
are epoxides (EET`s, formed by cytochrome-P-450) and hydroxyeicosatraenoic acid 
(HETE, formed by lipoxygenases). EET`s and HETE mediate relaxation of VSMCs by 
opening calcium-dependent potassium channels [21;22]. Another compound that 
mediates vasodilation by opening calcium-dependent potassium channels (KCa -
channels) in VSMCs is endothelium derived hydrogen peroxide (H2O2) [23]. In this 
study, KCa -channels were blocked with tetraethylammonium (TEA). ATP-sensitive 
potassium channels (KATP -channels) also play a role in mediating vasodilation by 
hyperpolarizing VSMCs [24]. Glibenclamide was used to block KATP -channels. 
Finally, potassium itself acts as EDHF by inducing hyperpolarisation of VSMCs by 
activation of Na/K-ATPase [25]. The role of Na+ /K+-ATPase was studied by 
concomitant infusion with ouabain, a compound that inhibits Na+ /K+-ATPase and has 
been shown to block the relaxation and hyperpolarization caused by EDHF [26]. In 
vitro [27;28] and in vivo studies [29] have shown that EDRFs can compensate for 
inhibition of formation or function of a single EDRF. The same might be true for ATP-
induced vasodilation in the human forearm, which was studied in an additional 
experiment, by combined infusion with TEA, indomethacin and L-NMMA. 
 
 
Methods 
 
 
Subjects 
 
The study protocol was approved by the local ethics comittee, and all participants 
signed written informed consent before their participation. The investigation conforms 
with the principles outlined in the declaration of Helsinki. Demographic data are 
shown in table 1. The experiments were performed in healthy, normotensive male 
and female volunteers. They did not use concomitant medication except for oral 
contraceptive drugs. All participants underwent a physical examination, laboratory 
screening (total cholesterol, triglycerides and glucose) and electrocardiography 
before entering the study. Participants were asked to abstain from caffeine-
containing beverages and alcohol for 24 hours before the experiment, and to abstain 
from food-intake 2 hours prior to the study.  
 
 
General outline of the procedure 
 
The experiments were performed in the morning in a quiet room with stable 
temperature (23°C), with the subjects in supine position. After local anesthesia 
(xylocaine 2%), the brachial artery of the non-dominant arm was cannulated 
(Angiocath, 20 gauge, Deseret Medical, Becton Dickinson Sandy, UT, USA) for drug 
infusion (syringe infusion pump, type STC-521, Terumo Corp., Tokyo, Japan) and 
intra-arterial blood pressure measurement (Hewlett Packard monitor, type 78353B, 
Hewlett Packard GmbH, Böblingen, Germany). Drug- and volume infusion rates were 
calculated per deciliter of forearm tissue, which was measured for each person by 
water displacement.  
In protocols involving glibenclamide, a deep antecubital vein of the infused arm was 
cannulated for blood sampling. Bilateral forearm blood flow (FBF) was measured by 
ECG triggered mercury-in-silastic strain gauge plethysmography, as described before 
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[30], while the hand circulation was occluded using wrist cuffs [31]. All experiments 
started 30 minutes after intra-arterial cannulation with the measurement of baseline 
blood flow, obtained during infusion of saline (NaCl 0.9%). Thereafter, increasing 
doses of ATP were co-infused with saline. Each ATP dose was infused for 5 minutes, 
together with saline or a blocker. The succeeding ATP-doses were interrupted once 
by a 10 min drug free interval. This was done because prolonged occlusion of the 
hand circulation can cause discomfort leading to changes in blood pressure and 
heart rate. The rate of infused volume and the amount of connected syringes was 
kept constant throughout each experiment.  
 
 
The effect of indomethacin on ATP-induced forearm vasodilaton (n=12) 
 
In this study we used three increasing doses of ATP (0.6, 6 and 20 nmol·dl-1 
FAV·min-1). Forty-five minutes after infusion of the highest dose, baseline recordings 
were repeated during infusion of saline folllowed by indomethacin (5 µg·dl-1·min-1) 
respectively. Subsequently, ATP infusions were repeated in the presence of 
indomethacin.  
 
  
The effect of TEA on ATP-induced forearm-vasodilation (n=10) 
 
After baseline measurements, ATP 0.2, 0.6, 6 and 20 nmol·dl-1 FAV·min-1 were 
infused. Baseline recordings were repeated after a 30 minute drug-free interval. TEA 
(0.1 mg·dl-1·min-1) was infused for thirty minutes, followed by co-infusion with the 
increasing ATP-doses. 
 
 
The effect of glibenclamide on ATP-induced forearm-vasodilation (n=16) 
 
In the first glibenclamide study (n=10), we infused ATP 0.2, 0.6 , 6 and 20  
nmol·dl-1·min-1. After 30 minutes, recontrol values were obtained and glibenclamide (2 
µg·dl-1·min-1) was subsequently infused. Ten minutes after the start of glibenclamide, 
ATP-infusions were repeated. Venous blood samples were collected from the 
experimental arm to measure the effect of glibenclamide on glucose-, insulin-, and C-
peptide concentrations and to determine the concentration of glibenclamide during 
the course of the study. To check the validity of an observed small effect of 
glibenclamide on ATP-induced vasodilation, the protocol was repeated but now with 
ATP 0.1, 0.2, 0.4 and 0.8 nmol·dl-1·min-1 (n=6). 
 
 
The effect of ouabain on ATP-induced forearm-vasodilation (n=8) 
 
The outline of this study is similar to the glibenclamide study. Ouabain was infused 
instead of glibenclamide, in a concentration of 0.2 µg·dl-1·min-1.  
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The influence of combined infusion of TEA, indomethacin and L-NMMA on ATP-
induced forearm-vasodilation (n=6) 
 
After baseline measurements, four increasing doses of ATP were infused (0.2, 2, 6 
and 20 nmol·dl-1·min-1). The second half of the experiment started 30 minutes after 
cessation of the highest ATP-dose. Saline infusions were subsequently replaced by 
infusion of TEA (0.1 mg·dl-1·min-1), indomethacin (5 µg·dl-1·min-1), and L-NMMA (0.2 
mg·dl-1·min-1). A graphic presentation of the protocol is provided in figure 1. 
Since this combination of antagonists increased FVR significantly and reduced the % 
change in FVR in response to ATP, a similar protocol was used in a separate group 
of 6 volunteers but now ATP was replaced by nitroprusside as a vasodilative control 
(SNP; 0.02, 0.1, 0.2, and 0.6 µg·dl-1·min-1). 
Blood samples were collected in three of the six participants during the second half of 
the infusion schedule to determine oxygen consumption before and during the 
combined antagonist infusion. A venous and arterial blood sample were taken at the 
end of placebo infusion (t =100, see figure 1) and during antagonist infusion (t =130) 
for determination of oxygen saturation and hemoglobin. Oxygen consumption was 
calculated by measuring the arterio-venous difference in the product of saturation 
(%), blood flow (ml·dl-1 FAV·min-1) and hemoglobin (mM), expressed in Arbitrary 
Units. 
 
 
Figure 1. Infusion protocol of the ATP study with combined infusion of TEA, indomethacin 
and L-NMMA.  
 
cannulation
-30 100  105  110  115  120  125  130  135  140  145  150  155  160 165  1700      5     10    15    20    25    30    35    40    45   50    55    60    65   70
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Infusion rate: 50 µl.dl -1 FAV.min-1
NaCl 0.9 %
Infusion rate: 100 µl.dl -1 FAV.min-1
ATP 0.1, 0.3, 3 and 10 µg.dl -1 FAV.min-1
Infusion rate: 50 µl.dl -1 FAV.min-1
Insufflation of the wrist cuffs and FBF measurements
TEA 0.1 mg. dl -1 FAV.min-1
Infusion rate: 100 µl.dl -1 FAV.min-1
Indomethacin 5 µg. dl -1 FAV.min-1
Infusion rate: 50 µl dl -1 FAV.min-1
L-NMMA 0.2 mg dl -1 FAV.min-1
Infusion rate: 50 µl dl -1 FAV.min-1
Blood sampling
Time (minutes)
TEA
indomethacin
L-NMMA
NaCl 0.9%
NaCl 0.9%
NaCl 0.9%
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Drugs and solutions 
 
All solutions were freshly prepared. ATP (Striadyne, Wyeth Laboratories) was diluted 
to reach the necessary concentrations. Indomethacin (GenRX-Mosby Inc., St. Louis, 
MO, USA), TEA (Sigma Chemical Co, St. Louis, MO, USA), glibenclamide (Hoechst 
AG, Frankfurt, Germany), L-NMMA (Sigma Chemical Co, St. Louis, MO, USA) and 
ouabain (Pharmachemie, Haarlem, the Netherlands) were diluted in NaCl 0.9% to 
reach final syringe concentrations of 5 µg (indomethacin), 50 µg (TEA), 2 µg 
(glibenclamide), 0.2 mg (L-NMMA) and 0.2 µg (ouabain) per 50 µL respectively. 
Lyophilized SNP (Nipride, Roche Nederland, Mijdrecht, the Netherlands) was diluted 
in glucose 5% and protected against light.  
 
 
Analytical procedures 
 
Insulin and C-peptide concentrations were determined in our laboratories using 
specific radioimmunoassays. In the insulin assay standard and tracer insulin was 
prepared from mono-component human insulin (Novo, Zoeterwoude, the 
Netherlands). Insulin concentrations below 5.0 mE·L-1 remained undetected. C-
peptide was measured with a standard kit (D.P.C., Los Angeles, Calif., USA). The 
detection limit for glibenclamide was below 5.0 ng·ml-1. Plasma glucose 
concentrations were assessed in our laboratories with a Hitachi 747 (Roche 
diagnostics, Indianapolis, IN, USA). Glibenclamide was measured by high 
performance liquid chromatography (HPLC) [32]. Hemoglobin concentrations were 
assessed with the Advia 1650 (Bayer diagnostics, Leverkusen, Germany). Oxygen 
saturation was determined with the Rapidlab 248 (Bayer diagnostics). 
 
 
Statistical analysis 
 
Mean arterial blood pressure (MAP) was measured continuously during each 
recording of FBF and averaged per FBF measurement. Forearm vascular resistance 
(FVR) was calculated from simultaneously measured MAP and FBF (MAP/FBF) and 
expressed as arbitrary units (AU). The calculated FVRs and hemodynamic 
parameters obtained during the last 4 minutes of saline infusion or during the last 2 
minutes of each drug infusion were averaged to one value. Drug-induced effects 
were expressed absolute (t-tests for the effect of an antagonist on baseline values) or 
as the percentage change from preceding saline infusion or antagonist infusion. All 
results are mean ± SE, unless indicated otherwise. Based on reproducibility data 
from a previous study by our group [18], it can be estimated that for a dose of 6 
nmol·dl-1 forearm volume, a minimal difference in percentage change in forearm 
vascular resistance from baseline can be detected of 21 % (N=10) or 31% (N=6) with 
a power of 0.9 and an alpha of 0.05 (paired t-test). To avoid multiple comparison, the 
effect of antagonists on ATP and SNP-induced vasodilation were assessed with 
repeated measures ANOVA. The presence of antagonists and vasodilator doses 
were used as within subject factors. To explore the effect of previous vasodilator 
treatment on the vasoconstrictive effect of combined infusion of TEA, indomethacin 
and L-NMMA, the vasodilator was used as between group factor. T-tests were 
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applied as post hoc tests when applicable. P<0.05 (two sided) was considered 
statistically significant. 
 
Results 
 
The demographic data of the participants are shown in table 1. The course of FVR in 
the infused arm is shown in figure 2 for each experiment. The course of FVR in the 
control arm was not significantly affected by any of the blockers or vasodilators used. 
Recontrol values for FVR did not differ from baseline. 
 
 
 
 
The effect of the antagonists on baseline FVR 
 
Apart from glibenclamide, all used blockers induced a vasoconstrictor response. This 
response was most pronounced for the combined infusion of TEA, indomethacin, and 
L-NMMA (see table 2). The vasoconstrictor action of TEA was only significant after 
previous infusion of ATP but not after SNP (see table 3) and significantly differed 
between the ATP and SNP pretreated group. In the ATP-study with combined 
infusion of TEA, indomethacin and L-NMMA calculated values for oxygen 
consumption were 2.9, 7.1 and 7.2 versus 6.4, 6.1 and 6.5 AU in the absence and 
presence of antagonists respectively. Forearm oxygen consumption was not affected 
by simultaneous infusion of TEA, L-NMMA and indomethacin, which argues against 
vasoconstriction-induced ischemia. 
 Indomethacin 
 
TEA 
 
Glibenclamide 
Glibenclamide + 
low dose 
ATP  
Ouabain 
TEA  + 
Indomethacin 
+ L-NMMA 
 
SNP control 
study 
N 12 10 10 6 8 6 6 
M/F 12 / 0 4 / 6 6 / 4 4 / 2 4 / 4 1/5 1/5 
Age (year) 22.9 ±  6.0 22.6 ±  3.2 22.5 ±  2.2 21.8 ±  2.5 22.3 ±  2.1 20.8 ±  0.4 21.2 ±  3.6 
BMI (kg m-2 ) 21 ±  1.6 22.7 ±  2.1 23.1 ±  2.1 21.5 ±  1.4 23.0 ±  2.4 21.6 ± 2.9 22.1 ±  1.5 
SBP (mmHg) 129.3 ±  9.0 122.5 ±  9.3 122.8 ±  7.7 123.5 ±  9.5 120.1 ±  8.5 129 ±  10.2 115.3 ±  9.3 
DBP (mmHg) 70.9 ±  8.2 69.4 ±  6.5 76.2 ±  8.9 72.2 ±  7.8 76.4 ±  4.4 76.3 ±  5.7 67.0 ±  6.3 
HR (bpm) 69.1 ±  12.3 60.7 ±  11.4 60.8 ±  9.5 62.7 ±  15.2 61.5 ±  8.0 68.3 ±  7.0 59.8 ±  6.3 
Glc (mmol L-1) - 4.4 ±  0.2 4.5 ±  0.4 4.4 ±  0.6 4.5 ±  0.3 4.1 ±  0.5 4.8 ±  0.7 
Chol (mmol L-1) - 4.0 ±  0.6 4.0 ±  0.4 3.9 ±  0.6 3.8 ±  0.5 4.0 ±  0.4 4.1 ±  0.8 
TG (mmol L-1) - 1.0 ±  0.5 0.8 ±  0.5 0.8 ±  0.2 0.9 ±  0.4 1.1 ±  0.5 0.8 ±  0.1 
 
Table 1:  Baseline characteristics of the study groups (mean ± SD) 
 
M/F; Male/Female, BMI; Body Mass Index; SBP; Systolic Blood Pressure, DBP; Diastolic Blood 
Pressure, HR; Heart Rate, Glc; glucose, Chol; cholesterol, TG; triglycerides. 
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Table 2. Effect of the antagonists on baseline vascualr tone (FVR, absolute value, mean ± SE): 
 
mean ± SE Saline Antagonist 
 
Indomethacin* 
 
53 ± 9 
 
61 ± 9 
 
TEA* 30 ± 2 62 ± 13 
 
Glibenclamide 56 ± 11 47 ± 6 
   
Glibenclamide 
(low dose ATP) 
44 ± 5 49 ± 9  
 
    
Ouabain* 49 ± 6 63 ± 9 
   
T + I + L* 34 ± 8 92 ± 10 
 
T + I + L* 48 ± 3 85 ± 10 
(SNP) 
 
  
 
ATP-and SNP doses are expressed in nmol·min
-1
·dl
-1
 Forearm Volume. 
T = TEA; I = Indomethacin; L = L-NMMA 
*: p < 0.05 for baseline versus antagonist (paired t-test) 
 
 
 
 
Table 3. FVR (AU, mean ± SE) and % change during subsequent combination of antagonists: 
 
FVR, AU 
(% change in FVR) 
 Baseline Recontrol T T+I T+I+L 
 
 
ATP (N = 6) 
 
 
 
37 ± 7  
 
34 ± 8 
 
46 ± 8* 
(39 ± 6#) 
 
77 ± 5† 
(109 ± 57) 
 
92 ± 10 
(21 ± 13) 
 
SNP (N = 6) 
 
41 ± 4 
 
48 ± 3 
 
54 ± 4 
(12 ± 5) 
 
63 ± 5† 
(19 ± 7)  
 
 85 ± 10¶ 
 (35 ± 12) 
 
 
 
 
 
T = TEA; I = Indomethacin; L = L-NMMA 
#
: p<0.05 for between group comparison of relative responses (ATP group with SNP group) 
*: p<0.05 vs recontrol (paired t-test) 
†: p<0.05 vs T (paired t-test) 
¶
: p<0.05 vs T + I (paired t-test) 
 
 
 
Influence of the antagonists on ATP-induced forearm vasodilation  
 
Indomethacin, TEA and ouabain (infused seperately) did not reduce ATP-induced 
forearm vasodilation (see figure 2). ATP- (0.2, 0.6 , 6 and 20 nmol·dl-1·min-1) induced 
vasodilation was significantly reduced by glibenclamide (p<0.05 for the interaction 
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between ATP and glibenclamide). This effect was solely due to the lowest ATP-dose, 
and could not be reproduced in an additional study with ATP infused in a lower dose 
range: ATP 0.1, 0.2, 0.4 and 0.8 nmol·dl-1·min-1 reduced FVR by 31.1±5.9, 52.9±6.9, 
62.7±5.6 and 72.2±2.6 % versus 27.6±10.8, 52.1±6.8, 65.8±5.9 and 70.9±2.9 % in 
the absence and presence of glibenclamide respectively (p>0.1, n=6). 
Glibenclamide concentrations were measured before start of the glibenclamide 
infusion, after the third ATP dose and after the last ATP dose. Concentrations were 
1.5±0.3, 0.2±0.03 and 0.2±0.02 (ATP 0.2, 0.6 , 6 and 20 nmol·dl-1·min-1) and 1.2±0.1, 
0.5±0.03 and 1.2±0.1 µg·mL-1 (ATP 0.1, 0.2 , 0.4 and 0.8 nmol·dl-1·min-1) respectively. 
Glucose concentrations did not alter significantly : 4.5±0.1 vs 4.3±0.1 (samples taken 
before resp. during glibenclamide infusion) versus 4.4±0.1 vs 3.6±0.1 mmol·L-1 
(higher vs lower ATP dose range). Plasma insulin concentration increased 
significantly from 6.4±0.5 to 11.9±1.4 (higher ATP dose range, p<0.05) and 7.2±0.7 
to 13.8±0.5 mE·L-1 (lower dose range, p<0.05). C-peptide also increased significantly 
during the course of the study: from 0.4±0.1 to 0.6±0.1(higher ATP doses, p<0.05) 
and 0.3±0.02 to 0.6±0.01 (lower ATP dose range, p<0.05).  
Combined infusion of TEA, indomethacin and L-NMMA inhibited ATP- as well as 
SNP induced forearm vasodilation to a similar extent (figure 2). This inhibition is 
therefore considered as a non-specific effect due to the vasoconstrictive response to 
the infused antagonists.  
  
 
Discussion 
 
This study showed that all blockers, except glibenclamide, caused a significant 
increase in baseline vascular tone. ATP-induced vasodilation in the human forearm 
could not be inhibited by concomitant infusion of indomethacin, TEA, glibenclamide 
or ouabain alone, or by a combined infusion of TEA, indomethacin and L-NMMA.  
 
The effect of antagonists on baseline vascular tone. 
 
Human data on the influence of the used blockers on baseline vascular tone are very 
scarce. This is remarkable, because they have nevertheless become established and 
widely used compounds in pharmacological research. Data on animal experiments 
vary depending on species and vascular bed as will be indicated hereafter. 
Indomethacin-induced increase of FVR suggests that continuous release of 
prostacyclin plays a role in the maintenance of resting forearm blood flow. Wilson 
and Kapoor [33] and Duffy et al. [34] previously detected that inhibition of 
cyclooxygenase with aspirin or indomethacin decreased resting forearm blood flow 
by 20-30%. Prostacyclin also contributes to metabolic vasodilation [35;36] as well as 
to resting and metabolic vasodilation in coronary arteries [37]. 
The effect of KCa channel inhibition on basal vascular tone differs depending on the 
experimental setting. Increase in baseline tone has been reported in cerebral arteries 
[38]. In guinea-pig resistance arteries no change was found [39;40]. In the current 
study, TEA increased the FVR of the forearm vascular bed 30 minutes after infusing 
ATP and this vasoconstrictor response significantly differed from the effect of TEA 
after pretreatment with SNP. Pickers et al. also found that TEA had no significant 
effect on baseline vascular tone after SNP infusion [41]. TEA also had no influence 
on baseline vascular tone after infusion of hydrochlorothiazide [42] and C-type 
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natriuretic peptide [43]. FVR at recontrol, just before start of TEA-infusion, did not 
differ from baseline values, which makes it unlikely that the observed vasocontrictor 
action of TEA is due to vanishing ATP-induced vasodilation by a carry over effect, but 
can not be excluded. Although the difference in TEA-response between SNP and 
ATP pretreated groups was small and should not be overemphasized, this 
observation may indicate a pharmacodynamic carry over effect of the previous ATP 
infusions on the maintenance of vascular tone, possibly by inducing the release of an 
alternative EDRF that could affect KCa channels at baseline.  
Our finding that glibenclamide had no influence on basal vascular tone in the human 
forearm vascular bed is consistent with previous findings [44-46]. Glibenclamide had 
no influence on basal vascular tone of carotid, femoral and mesenteric endothelium-
denuded strips from rats [47]. However, infusion of glibenclamide into the coronary 
vasculature of anesthetized dogs and in isolated rabbit hearts resultated in significant 
increase in coronary resistance. 
Ouabain infusion alone induced vasoconstriction, which has been reported before 
[48-50]. Baseline activity of Na+K+-ATPase apparently contributes to resting vascular 
tone, probably by maintaining membrane polarity. 
  
Why was ATP-induced vasodilation not inhibited by any of the antagonists we used ? 
 
First, in vivo, ATP might induce its vasodilation via an endothelium independent, 
instead of the proposed endothelium dependent, mechanism. Few in vitro studies 
have already shown that ATP exerts vasodilation partially via endothelium 
independent mechanisms [51-54]. Vascular smooth muscle cells express P2y 
receptors which may mediate vasodilation [55].  
Second, the infused concentrations of the antagonists might have been insufficient to 
inhibit the actions of EDRFs that are released in response to ATP. This is unlikely for 
any of the blockers used, however. Previously in our laboratory, Pickkers and de 
Hoon showed that indomethacin at a concentration of 5 µg·dl-1 FAV·min-1 was able to 
inhibit cyclooxygenase: in a set of experiments they confirmed adequate 
cyclooxygenase inhibition by the absence of thromboxane-B2 formation in blood 
drawn from an antecubital vein of the indomethacin infused forearm, determined by 
RIA (unpublished results). The observed vasoconstrictive effect of indomethacin and 
its clinical use as treatment for patent ductus arteriosus in preterm infants further 
support blockade of vascular cyclo-oxygenase. Likewise, TEA 0.1 mg·dl-1 FAV·min-1 
has been shown to inhibit vasodilation in the human forearm to the endothelium 
dependent vasodilator bradykinin [56], which acts via EDHFs. TEA was also able to 
inhibit the C-type natriuretic peptide (CNP)-induced vasodilation (43) and the 
vasodilation induced by acetazolamide [41] in the human forearm; both openers of 
KCa channels. The infused concentration of 2.0 µg glibenclamide ·dl
-1 FAV·min-1 was 
based on a study previously performed in our laboratory that showed that a 
concentration seven times lower was capable of effectively blocking KATP channels 
[45]. The significant rise in insulin and C-peptide during the course of the studies with 
glibenclamide indicates systemic spill of glibenclamide with subsequent stimulation of 
insulin secretion. However, the course in FVR in the control arm was not significantly 
affected by the glibenclamide infusion, indicating that the systemic changes of 
humoral parameters did not interfere with forearm vascular tone. Ouabain was 
infused at a concentration of 0.2 µg·dl-1 FAV·min-1, based on studies from our 
research group demonstrating that this concentration effectively blocked Na+K+ 
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ATPase [50;57]. We have previously confirmed that L-NMMA 0.1 mg·dl-1 FAV·min-1 
significantly inhibits acetylcholine induced vasodilation [18]. As we used a dose of L-
NMMA twice as high it is unlikely that NO-synthase was insufficiently inhibited. The 
studies regarding these references were all done under the same conditions as the 
currently reported experiments. We conclude that the lack of effect of the used 
antagonists on ATP-induced vasodilation was not due to insufficient doses. 
Third, we may not have blocked the action of all EDHFs. Several EDHFs have been 
suggested, like metabolites of arachidonic acid produced through the cytochrome 
P450 (CYP 450) monooxygenase pathway and reactive oxygen species (ROS) 
[58;59]. Their mechanism of action has in all cases been directly or indirectly linked 
to potassium channels and Na+K +ATPase. In the current study, we only blocked the 
KCa channels by TEA. TEA antagonizes various types of potassium channels with 
different degrees of potency, but the compound has been shown to block KCa 
channels selectively at concentrations below 1 mM [60]. TEA at an infusion rate of 
0.1 mg·dl-1 FAV·min-1 results in a local plasma concentration of approximately 0.5 
mmol·L-1. ATP sensitive potassium channels (KATP channels) and voltage-dependent 
potassium (KV) channels can be blocked by TEA at a concentration of respectively 7 
and 10 mM [60]. Thus the concentration we used was not sufficient to block these 
channels. EDHFs might, however, also exert their effects via KATP, Kv and KIR 
(inwardly rectifying potassium) channels, although their role in EDHF-induced 
vasodilation is uncertain. Furthermore, glibenclamide did not inhibit ATP-induced 
vasodilation. Fourth, a redundancy of vasodilator mechanisms of ATP could 
potentially have prevented inhibition of ATP- induced vasodilation by interruption of a 
single vasodilator pathway. However, use of a combination of substances that affect 
NO, COX, and EDHF still did not reveal a reduction in ATP-induced vasodilation. It is 
of interest for further experiments to combine infusion of bariumchloride (blocker of 
KIR-channels) and ouabain, which might have a greater inhibitory effect on ATP-
induced vasodilation than ouabain alone. Finally, there might be a different 
mechanism of vasodilation/EDRF besides NO, prostacyclin and EDHFs that 
contributes to the ATP-induced vasodilation in-vivo. For instance, evidence is 
accumulating that carbon monoxide (CO) can be an important vascular paracrine 
factor [61]. 
In conclusion, the present findings do not support a role for NO, prostacyclin or 
EDHFs that act by opening K ATP channels, KCa channels, or by activation of Na/K-
ATPase in ATP-induced vasodilation. In humans, the role of endothelium-
independent mechanisms and involvement of unblocked EDRFs remains to be 
explored. 
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Figure 2. Relative response in FVR (infused arm) during infusion of ATP and (last graph) of 
SNP with and without antagonists as indicated. T = TEA, I = Indomethacin, L = L-NMMA. For 
doses: see text. P-values indicate ANOVA for repeated measures for the effect of the 
antagonist(s) on the vasodilator response curve. 
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Abstract 
 
Experimental data derived from animal models suggest that the endogenous 
nucleoside adenosine has important cardioprotective properties. The potent 
vasodilator effects of adenosine may contribute to this cardioprotection as ischemia-
induced release of endogenous adenosine has been suggested to adjust local blood 
flow to the metabolic demands of the tissue. Interestingly, the vascular effects of 
adenosine appeared to be impaired in animal models for diabetes mellitus. This 
observation may be of importance with respect to the increased cardiovascular 
mortality in diabetes. Therefore, we investigated the in vivo vasodilator effects of 
adenosine in insulin-dependent diabetic patients.  
In twelve uncomplicated insulin-dependent male diabetic patients and twelve healthy 
male age-matched subjects, the brachial artery was cannulated for infusion of 
adenosine (0.15, 0.5, 1.5, 5, 15 and 50 µg·100 ml-1·min-1) and for measurement of 
mean arterial pressure (MAP). Forearm blood flow (FBF) was measured by venous 
occlusion mercury-in-silastic strain gauge plethysmography. Maximal vasodilation 
was assessed by standardized post occlusive reactive hyperaemia (PORH). Baseline 
forearm blood flow was 2.7 ± 0.4 and 1.8 ± 0.2 ml·100 ml-1·min-1 for the diabetic 
patients and control group respectively. In the diabetic patients, adenosine infusion 
raised forearm blood flow to 2.4 ± 0.4, 2.6 ± 0.4, 4.4 ± 0.7, 6.3 ± 1.0, 9.8 ± 1.5 and 
14.2 ± 2.1 ml·100 ml-1·min-1 for the respective dosages. In the control group these 
values were 1.7 ± 0.2, 1.9 ± 0.3, 3.2 ± 0.8, 6.0 ± 1.2, 10.9 ± 2.1 and 17.1 ± 3.4 ml·100 
ml-1·min-1 respectively (p>0.1 for between group comparison). Forearm blood flow at 
the contralateral side was not significantly affected by the placebo and adenosine 
infusions. Comparable results were obtained when results were expressed as 
changes in forearm vascular resistance or forearm blood flow ratio (FBF infused 
arm/FBF control arm). Maximal vasodilation did not differ between the two groups.  
We conclude that the forearm vasodilator response to adenosine is preserved in 
uncomplicated insulin-dependent diabetic patients. This observation argues against a 
primary role of a reduced adenosine responsiveness in the cardiovascular sequelae 
of diabetes. 
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Introduction 
 
Adenosine has potentially important cardioprotective properties like inhibition of 
neutrophil activation with subsequent reduced free radical formation, inhibition of 
thrombocyte aggregation, vasodilation, presynaptic inhibition of norepinephrine 
release, and opening of potassium channels [1]. These effects are mediated by 
adenosine receptors, located on the outer cell membrane. In animals, myocardial 
infarct size is reduced when adenosine is infused either before ischaemia or during 
the reperfusion period [2-4]. In addition, adenosine reduces the incidence of 
ischaemia-induced arrhythmias [5]. Infusion of a selective adenosine receptor 
antagonist increases infarct size, indicating a role for endogenous adenosine as a 
cardioprotective autacoid [6]. Since the vasodilator action of adenosine is thought to 
play a role in the local adjustment of oxygen demand to oxygen supply [7;8], this may 
contribute to the cardioprotective properties of adenosine. 
Interestingly, an impaired responsiveness to the vasodilator effect of adenosine has 
been observed in animal models for diabetes mellitus [9;10]. Several mechanisms 
may be responsible for this reduced responsiveness to adenosine. Animal and 
human data have indicated both fascilitating as well as inhibiting interactions 
between adenosine and the sympathetic nervous system [11-16]. Furthermore, 
human and animal studies show that adenosine-induced vasodilation is at least 
partially mediated by the endothelium [17-19]. Since insulin alters sympathetic 
nervous system activity [20;21] and diabetes mellitus has been associated with 
reduced endothelium-dependent vasodilation [22-25], both neural and endothelial 
mechanisms may be involved in the reduced reactivity to adenosine in these 
descriptive animal studies. Additionally, direct actions of adenosine on cardiac and 
vascular muscle cells may be reduced in patients with diabetes mellitus. 
Although vascular reactivity in human diabetes has been studied extensively over the 
past few years [22-25], no human data are available on the responsiveness to the 
endogenous nucleoside adenosine. Since diabetes is an independent risk factor for 
developing cardiovascular disease [26], and is often associated with concomitant 
hypercholesterolaemia and hypertension which further attributes to an increased risk 
of ischaemic heart disease [27;28], an impairment in adenosine responsiveness may 
be of clinical interest. Pharmacological compounds are currently being developed to 
potentiate the action of endogenous adenosine at sites of ischemia [13]. In this 
context it is valuable to know if diabetic patients exhibit decreased responses to 
adenosine. Furthermore, a reduced vascular responsiveness to adenosine may also 
be of importance in the metabolic control of patients with diabetes mellitus since 
adenosine enhances glucose uptake in some animal models [29;30]. This metabolic 
effect of adenosine may in part be due to its effect on blood flow [31]. Therefore, we 
evaluated the vasodilator response to adenosine in patients with uncomplicated 
insulin dependent diabetes mellitus and compared these observations with a 
carefully matched control group. 
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Patients and methods 
 
 
Patients 
 
After approval of the local ethics committee, twelve normotensive nonsmoking 
caucasian male patients with insulin-dependent diabetes mellitus were selected from 
our outpatient population. Diabetes mellitus was diagnosed at least 5 years before 
participation to this study. Patients with evidence of macro- or microvascular disease 
were excluded from the study because these vascular complications would result in a 
nonspecific impairment of the reactivity to any vasodilator substance. Macrovascular 
disease was assessed by taking their history (no coronary artery disease, heart 
failure, cerebrovascular disease, peripheral vascular disease or foot ulcers), physical 
examination and a twelve lead electrocardiogram. Microvascular disease was 
excluded by demonstrating the absence of orthostatic hypotension and peripheral 
loss of sensibility, by a normal fundoscopy, and by an albumin excretion ratio less 
than 20 µg·min-1. None of the patients used medication other than subcutaneous 
insulin injection. Only patients with a glycosylated haemoglobin concentration 
(HbA1c) between 7 and 10 % as measured during insulin treatment were included. 
 
 
Table 1. Demographic characteristics of the study groups (mean±SD) 
 
  
Diabetic subjects 
 
Healthy subjects 
   
N 
 
12 12 
Male/female 
 
12/0 12/0 
Age (years) 
 
Body Mass Index (kg·m
-2
) 
 
34.6 ± 5.9 
 
23.6 ± 2.4 
34.8 ± 6.0 
 
23.3 ± 2.4 
Systolic blood pressure (mmHg)* 
 
123 ± 10.4 118 ± 8.2 
Diastolic blood pressure (mmHg)* 
 
63.2 ± 8.6 62.4 ± 4.9 
Mean arterial pressure (mmHg)* 
 
85.2 ± 9.8 82.4 ± 6.8 
Heart rate (beats per minute)# 
 
67.3 ± 16.8 57.4 ± 9.6 
HbA1c (%) 
 
8.5 ± 0.9  
Time after diagnosis (years) 
 
16.2 ± 8.3  
Glucose (mmol·L
-1
)@ 
 
13.0 ± 5.1  
 
*: Intra-arterially measured during placebo infusion; #: Measured by electrocardiographic 
recordings during placebo infusion; @: Determined during the experiment; for each subject 
the 6 determinations were averaged to one value.  
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The control group consisted of twelve male non-smoking healthy caucasian 
volunteers.These subjects were carefully matched for age, blood pressure and body 
weight.They had no history of diabetes mellitus and did not use concomitant 
medication. Physical examination and twelve lead electrocardiography did not reveal 
any abnormalities. Demographic data of the study groups are shown in table 1. 
 
 
Methods 
 
Before the start of the study, the subjects were asked to abstain from caffeine-
containing products for at least 24 hours, because caffeine is a potent adenosine 
receptor antagonist [32]. In all participating subjects, the plasma caffeine 
concentration was below the limit of detection as measured in a sample that was 
collected immediately before starting the experiments (reversed phase HPLC; 
minimal level of detection: 0.2 µg·ml-1 [33]. All tests were performed in a temperature 
controlled laboratory (22-23 ºC), with participants in the supine position, after an 
overnight fast, starting at 8.00 am.  
From a methodological point of view, the level of plasma insulin and glucose 
concentrations throughout the study is a very important issue. Recent studies have 
convincingly shown that baseline skeletal muscle flow in humans is not affected by 
hyperglycemia [34], whereas hyperinsulinemia induces an obvious increase in 
baseline skeletal muscle flow as well as in forearm vascular reactivity [35-38]. To 
avoid confounding of our results by insulin-mediated vasodilation, we instructed the 
diabetic subjects to skip their morning dose of insulin and not to use a breakfast. This 
was done in order to achieve low and steady state plasma insulin levels during the 
time of experiments. Although even lower insulin levels would have been reached by 
also skipping the long-acting insulin injection of the evening before the experiment, 
this would have introduced the risk of the development of ketosis or keto-acidosis, a 
factor which would certainly have affected the results. Since no insulin was 
administered in the morning hours, we had to accept the varying fasting glucose 
levels throughout the experiments, since correcting the glucose levels would 
inevitably have increased insulin levels. As stated above, recent data have 
convincingly shown that plasma glucose levels up to 15 mmol·l-1 do neither affect 
baseline forearm blood flow nor vascular reactivity of the forearm vascular bed [34]. 
After local anaesthesia (Xylocaïne, 2%), the left brachial artery was cannulated with a 
20-gauge catheter (Angiocath, Deseret Medical, Inc., Becton Dickinson and Co, 
Sandy, UT, U.S.A.) for both intra-arterial adenosine infusion (automatic syringe 
infusion pump, type STC-521, Terumo Corporation, Tokyo, Japan) and blood 
pressure recording (Hewlett Packard GmbH, Böblingen, Germany). Forearm blood 
flow was registered simultaneously on both forearms by electrocardiography-
triggered venous occlusion plethysmography using mercury-in-silastic strain gauges 
(Hokanson EC4, D.E. Hokanson, Inc., Washington, U.S.A). The upper arm collecting 
cuff was inflated using a rapid cuff inflator (Hokanson E-20, D.E. Hokanson, Inc., 
Washington, U.S.A.). At least one minute before the FBF measurements, the 
circulation of the left hand was occluded by inflation of a wrist cuff to 200 mmHg. 
Forearm blood flow was recorded three times per minute during the four minute 
placebo infusion and during the last two minutes of each adenosine infusion.  
The experiment started with the measurement of baseline forearm blood flow during 
placebo infusion (NaCl, 0.9%). Apart from the course in the forearm blood flow, figure 
1 shows the schedule of the several drug infusions. The effect of six increasing 
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dosages of adenosine (Sigma Chemical Co., St Louis, MO, U.S.A.; 0.15, 0.5, 1.5, 5, 
15 and 50 µg·100 ml-1 forearm·min-1) were compared with placebo (NaCl 0.9%). 
Prolonged occlusion of the hand circulation can cause discomfort with subsequent 
effects on blood pressure and heart rate. Therefore, a 5-minute rest period with 
desufflation of the wrist cuffs was allowed between the placebo infusion and the first 
adenosine dose and between the third and fourth adenosine dose.  
 
 
 
Figure 1. The course in forearm blood flow (FBF) before and during the intra-arterial infusion 
of adenosine is presented for the diabetic patients and the control group. There was no 
statistically significant difference between the groups (ANOVA for repeated measurements: 
P=1.0). 
 
 
During all procedures, total volume infusion was adjusted to forearm volume as 
measured by water displacement and kept at a constant rate of 100 µl·100 ml-1 
forearm·min-1. Placebo and each adenosine dosage were infused during 4 minutes.  
To exclude structural vascular changes in the diabetic patients, maximal vasodilation 
was measured during post occlusive reactive hyperaemia (PORH) according to the 
well-established method of Pedrinelli et al [39;40] twenty minutes after the end of the 
final adenosine infusion. A cuff applied to the left upper arm was inflated to 300 mm 
Hg for 13 minutes. During the last minute of ischaemia the subjects were asked to 
perform repeated hand contractions. Immediately after desufflation of the upperarm 
cuff, FBF measurements were started for at least 2 minutes with occluded hand 
circulation. 
30 40 50 60 70
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The lowest forearm vascular resistance (MAP/FBF) was considered to represent 
maximal vasodilation.  
In the diabetic group, blood glucose concentrations were determined 6 times: 
immediately after arterial cannulation, after infusion of placebo, after the third and 
after the sixth adenosine dose, just before the test of maximal vasodilation and just 
before decannulation (Accutrend, type 1284851, Boehringer, Mannheim, Germany). 
Prior to the intra-arterial adenosine infusions, 10 ml arterial blood was collected with 
Li-heparin as anti-coagulant in 9 diabetic patients and in 4 control subjects for the 
determination of plasma insulin and detection of insulin antibodies. Plasma insulin 
was measured by radioimmunoassay using a specific antiserum raised in a guinea 
pig against human insulin. A second antibody was used to separate the antibody-
bound and free fractions. Insulin antibodies were detected by incubation of the 
samples with 125I-insulin and subsequent precipitation with polyethyleneglycol [41]. 
 
 
Statistics 
 
Mean arterial pressure (MAP) was measured continuously during each recording of 
forearm blood flow (FBF) and averaged per FBF registration. Forearm vascular 
resistance (FVR) was calculated from simultaneously measured MAP and FBF 
(MAP/FBF) and expressed as arbitrary units (AU). Additionally, the ratio of each 
simultaneously measured FBF (FBF infused arm/FBF control arm) was calculated. 
Forearm blood flows, the calculated flow ratios and FVR's obtained during each four 
minutes of placebo infusion or during the last two minutes of each drug infusion were 
averaged to one value. Adenosine-induced effects were expressed both as absolute 
and percentage change from preceding placebo infusion. Differences in responses to 
adenosine between the two study groups were analysed with an ANOVA for 
repeated measurements with the adenosine dosage as within-subject factor and the 
presence of diabetes mellitus as between-subject factor. Differences in baseline 
values were assessed with the unpaired Student t-test. Correlations were performed 
using the Pearson correlation coefficient. Since plasma insulin concentrations did not 
show a Gaussian distribution, group differences in insulin levels were analyzed by 
the Mann-Whitney U test. All results are expressed as mean±SE unless indicated 
otherwise; P<0.05 (two sided) was considered to indicate statistical significance. 
 
 
Results 
 
Baseline FBFs in the infused arm were 2.7 ± 0.4 and 1.8 ± 0.2 ml·100 ml-1 
forearm·min-1 for the diabetic patients and control group respectively (P=0.07). In the 
control arm these values were 2.4 ± 0.4 and 1.5 ± 0.1 ml·100 ml-1 forearm·min-1 
(P=0.05). During the adenosine infusions, FBF in the infused arm of the diabetic 
patients amounted 2.4 ± 0.4, 2.6 ± 0.4, 4.4 ± 0.7, 6.3 ± 1.0, 9.8 ± 1.5 and 14.2 ± 2.1 
ml·100 ml-1 forearm·min-1 for the respective adenosine dosages of 0.15, 0.5, 1.5, 5, 
15 and 50 µg adenosine·100 ml-1 forearm·min-1. In the control group these values 
were 1.7 ± 0.2, 1.9 ± 0.3, 3.2 ± 0.8, 6.0 ± 1.2, 10.9 ± 2.1 and 17.1 ± 3.4 ml·100 ml-1 
forearm·min-1, respectively (see figure 1). In both groups, FBF in the control arm was 
not significantly affected during the placebo and adenosine infusions. Overall, 
repeated measures ANOVA did not reveal a significant difference between the two 
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groups (between subject effect: P=1.0). Comparable results were obtained when 
results were expressed as absolute or relative changes in FBF from baseline. 
Baseline FVRs in the infused arm were 39.6 ± 5.2 and 57.5 ± 7.6 AU for the diabetic 
patients and controls, respectively (P=0.07). In the control arm these values were 
45.7 ± 6.3 and 63.7 ± 5.9 AU, respectively (P<0.05). During adenosine infusion, 
FVRs in the infused arm of the diabetic patients were 44.6 ± 6.6, 41.9 ± 5.4, 29.9 ± 
7.1, 20.5 ± 4.6, 16.6 ± 5.7 and 12.2 ± 5.7 AU for the six increasing adenosine 
dosages, respectively. In the controls, these values were 57.5 ± 7.6, 58.5 ± 7.2, 56.1 
± 7.7, 45.8 ± 9.0, 24.6 ± 5.5, 16.0 ± 4.6 and 13.2 ± 5.2 AU, respectively. Overall, the 
course of FVR in the infused arm did not significantly differ between the two groups 
(between-subject effect: P=0.2). In both groups, FVR in the control arm was not 
affected. Comparable results were obtained when adenosine-induced changes in 
FVR were expressed as absolute or relative changes from baseline (see figure 2). 
 
 
 
Figure 2. Adenosine-induced forearm vasodilation in controls (open symbols) and diabetic 
patients (closed symbols) expressed as absolute and percentage change in forearm vascular 
resistance (FVR) from baseline. P values indicate the level of significance for between group 
effects (ANOVA for repeated measurements). 
 
 
Because we observed slight differences in baseline FBF- and FVR-values between 
the diabetic patients and the control group, we also analyzed the results of the FBF-
ratio (FBFinfused arm divided by FBFcontralateral arm). Assessment of the percent 
changes of this ratio has been shown to be an appropriate method to analyze dose 
response curves [22;42]. During placebo infusion, the FBF-ratio was equal in both 
groups and numbered 1.2 ± 0.1. 
In the diabetic patients, the FBF-ratios increased to 1.0 ± 0.1, 1.2 ± 0.1, 2.1 ± 0.4, 4.4 
± 1.0, 5.9 ± 1.2 and 9.2 ± 2.5 during the six increasing adenosine dosages, 
respectively. In the controls, these values were 1.3 ± 0.1, 1.5 ± 0.2, 2.2 ± 0.4, 4.2 ± 
0.8, 8.9 ± 1.5 and 14.7 ± 2.1, respectively. Overall, the course of the ratio did not 
significantly differ between the two groups (between-subject effect: P=0.2). 
Comparable results were obtained when adenosine-induced changes in the ratio 
were expressed as absolute or relative changes from baseline.  
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The minimal FVR that occurred during post-occlusive reactive hyperaemia did not 
differ between diabetic patients and controls: 3.2 ± 0.2 versus 3.4 ± 0.3 AU (P=0.6). 
The individual courses of blood glucose concentration are shown in figure 3. Within 
each individual, glucose levels remained reasonably stable. However, between the 
patients a high variation in averaged glucose level existed ranging from 3.4 to 20.6 
mmol·L-1. There was no correlation between the individual plasma glucose 
concentration and the vascular responsiveness to adenosine in the diabetic patients 
(r=-0.2, P=0.5). Plasma insulin concentration was 21.8 ± 2.5 mE·L-1 (N=9) in the 
diabetic patients versus 6.5 ± 1.3 mE·L-1 (N=4) in the controls (P<0.01). In four 
diabetic patients, insulin antibodies could be detected. After exclusion of these 
patients, plasma insulin concentration was still significantly higher in the diabetic 
patients as compared with the control subjects (20.8 ± 3.8 versus 6.5 ± 0.9 mE·L-1; 
P<0.05).  
 
 
 
Figure 3. Individual courses of blood glucose concentrations, demonstrating the large inter-
individual variability as well as the small intra-individual variability during the experiments. 
 
 
Discussion 
 
This study was performed to investigate whether the forearm vasodilator response to 
adenosine is affected in patients with insulin-dependent diabetes mellitus. 
Normotensive non-smoking diabetic patients without evidence of macro- or 
microvascular complications were selected to prevent possible confounding by 
structural arteriolar or microvascular changes. Maximal forearm vasodilation in the 
diabetic patients appeared to be equal to that of the age-matched control group 
confirming the absence of structural abnormalities in the forearm vascular bed of the 
diabetic subjects. In these carefully selected patients, we observed a preserved 
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vasodilator response to adenosine in the forearm vascular bed. This observation 
argues against a primary role of reduced adenosine responsiveness in the 
cardiovascular sequellae of diabetes. 
The current results are in contrast with several observations in animal models for 
diabetes [9;10] that studied the responsiveness of the heart and coronary vasculature 
to adenosine. We can not exclude the possibility that diabetes mellitus differentially 
affects the coronary and forearm vascular bed in humans. However, other possible 
explanations should be discussed as well. 
It has to be emphasized that animal models for diabetes represent a true 
insulinopenic state. In contrast, as a result of subcutaneous administration of insulin 
as opposed to the physiological release of insulin into the portal vein, the levels of 
insulin are elevated in treated patients with insulin-dependent diabetes mellitus. As 
such, treated patients with insulin-dependent diabetes do not represent an 
insulinopenic state, not even in the fasting state when plasma insulin concentrations 
reach their trough level. This may well explain the preserved adenosine 
responsiveness in our patients, because treatment of diabetic animals with insulin 
also restored the impaired responses to adenosine [9]. Since we did not study the 
effects of adenosine in a true insulinopenic state, our data do not exclude an 
interaction between insulin and adenosine. Nonetheless, our present results do allow 
the conclusion that the vascular responsiveness to adenosine is preserved in 
patients with diabetes mellitus who are regularly treated with insulin. 
In the diabetic patients, baseline forearm blood flow and forearm vascular resistance 
were slightly different from that of the control subjects. This interesting phenomenon 
has been described before [22] and is not only confined to the forearm but has also 
been shown for the retinal, renal and cutaneous circulation [43-45]. It already exists 
in the early course of the disease before diabetic complications have developed 
[22;45]. Although the exact mechanism of this 'hyperdynamic circulation' in diabetic 
patients is not known, it may be related to the development of complications like 
diabetic nephropathy and diabetic microangiopathy [45]. Especially because of this 
difference in baseline forearm blood flow, we also included the results on the FBF-
ratio (see method section). For the FBF-ratio, the diabetic patients and the control 
group had exactly the same baseline values. Using this parameter, statistical 
analysis of the adenosine responses revealed no difference between the two groups. 
The main observation of the present study is that adenosine-mediated forearm 
vasodilation is not significantly affected in insulin-dependent diabetic patients. The 
response to the two highest adenosine dosages tended to be slightly reduced in the 
diabetic patients, but this difference did not reach statistical significance. In contrast 
to the two highest dosages, the responses to the lower dosages were very similar 
between the two groups. We regard these lower dosages more representative for the 
local physiological increases in adenosine concentration which are probably needed 
for the small adjustments of local flow in order to constantly balance tissue oxygen 
demand and supply. 
The effect of intra-arterially supplied adenosine is determined by the adenosine 
concentration, adenosine receptor density and receptor function. Adenosine 
concentrations depend on the rate of cellular adenosine uptake. In theory, diabetes 
mellitus may impair this cellular uptake of adenosine [46]. Therefore, a reduced 
adenosine receptor density or function could have been masked by differences in 
adenosine kinetics between the two groups. However, the clinical significance of a 
possible receptor dysfunction is limited when the overall vasodilator effect of 
adenosine is not reduced in vivo as shown in the present study.  
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In conclusion, the vasodilator response to adenosine is preserved in patients with 
insulin-dependent diabetes mellitus who are regularly treated with insulin. This 
observation argues against a primary role of impaired adenosine responsiveness in 
the cardiovascular sequelae of diabetes. 
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The studies described in this thesis were meant to study adenosine kinetics in  
humans in-vivo, and dealt with the following questions:  
 
1. What is the effect of intra-arterially infused dipyridamole and adenosine on 
interstitial and intravascular adenosine concentrations (chapter 2). 
From the observations described in chapter 2, we conclude that intra-arterially 
infused adenosine does not enter the interstitium of skeletal muscle in humans in 
vivo. This observation is in agreement with in-vitro studies that have shown that the 
endothelium serves as a metabolic barrier for adenosine to reach the interstitial 
space. This finding supports the concept that the local actions of intra-arterially 
administered adenosine, such as vasodilation, presynaptic inhibition of 
norepinephrine release from forearm sympathetic nerve endings and stimulation of 
sympathetic afferents which elicit generalized sympatho-excitation, are mediated by 
adenosine-induced release of endothelial factors.  
Dipyridamole reduced clearance of both intravascular and interstitial adenosine, 
providing direct biochemical evidence that dipyridamole inhibits cellular uptake of 
adenosine from these compartments. To our surprise however, interstitial access of 
intra-arterial adenosine was not increased by simultaneous inhibition of nucleoside 
transporters with dipyridamole. As yet, we do not have a clear explanation for this 
observation. Possibly, dipyridamole insensitive nucleoside transporters on 
endothelial cells are responsible for the endothelial metabolic barrier for adenosine.  
Another observation that is difficult to explain is why dipyridamole did not increase 
baseline interstitial and/or intravascular adenosine levels, despite our finding that 
dipyridamole-induced vasodilation is inhibited by adenosine receptor blockade (see 
below). Most likely, baseline adenosine formation occurs within the vascular wall (i.e. 
endothelial cells) at a site that is not accessible for interstitial or intravascular 
microdialysis catheters. Alternatively, a small rise in interstitial adenosine during 
infusion of dipyridamole remains below the limit of detection with the used 
microdialysis technique but is sufficient to induce vasodilation. Our finding that the 
endothelium in the human forearm constitutes a barrier impeding the delivery of 
intravascular adenosine into the underlying interstitium was described previously in a 
recent publication from Gamboa et al. [1]. In contrast with our results, intravenous 
dipyridamole-infusion enhanced the delivery of adenosine into the interstitium during 
intra-arterial infusion of adenosine. Differences in experimental set up may explain 
these contrasting results. Gamboa et al administered dipyridamole intravenously at a 
dose that is likely to result in a generalized sympatho-excitation, which may have 
resulted in increased perivascular release of the co-transmitter ATP and subsequent 
increased formation of interstital adenosine. Alternatively, differences in the 
technique to quantify dialysate adenosine could in theory have resulted in the 
contrasting results.     
 
2. What is the role of adenosine in the pressor response to exercise in healthy 
volunteers (chapter 2). 
Infusion of dipyridamole into the brachial artery did not augment the pressor 
response to hand grip exercise. This lack of potentiation of the exercise-pressor 
reflex was observed despite a proven inhibition of clearance of extracellular 
endogenous adenosine from the skeletal muscle interstitial compartment. Taken 
together, these findings argue against a role for endogenous adenosine in the blood 
pressure response to non-ischemic exercise in healthy volunteers. This study does 
not exclude a role for adenosine in the pressor response to ischemic exercise in 
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healthy volunteers or in the pressor response to exercise in patients with reduced 
perfusion of exercising muscle such as patients with heart failure. 
 
3.  Is there a difference in the mechanism of vasodilation between interstitial and 
intravascular adenosine (chapter 2 and 3). 
After the effect of dipyridamole on adenosine kinetics was described biochemically in 
chapter 2, the vasodilator action of dipyridamole was further characterized and 
compared with the vasodilator action of adenosine in chapter 3. First, further 
evidence for the inhibitory action of dipyridamole on cellular uptake of extracellular 
adenosine was provided by showing a potentiating effect of dipyridamole on 
adenosine-induced vasodilation. We hypothesized that dipyridamole induces 
vasodilation by increasing the extracellular concentration of adenosine, resulting in 
adenosine receptor stimulation at sites of endogenous adenosine formation. 
This concept was supported by an experiment in which the forearm vasodilator 
response to both adenosine and dipyridamole was antagonized by the adenosine 
receptor antagonist theophylline. We speculated that endogenous adenosine 
formation primarily occurs within the vascular wall and interstitial space, a 
compartment that is not well accessible for intravascular adenosine (see paragraph 
1). Therefore, we further reasoned that infusion of dipyridamole into the brachial 
artery may stimulate adenosine receptors on vascular smooth muscle cells whereas 
infusion of adenosine stimulates these receptors on the endothelium. The post-
adenosine-receptor pathways that are involved in vasodilation may differ between 
endothelium and vascular smooth muscle. In particular the role of ATP-sensitive 
potassium channels could differ between the two cell types. Therefore, we studied 
the effect of glibenclamide, a blocker of ATP-sensitive potassium channels, on the 
forearm vasodilator response to adenosine and dipyridamole infusion into the 
brachial artery of healthy volunteers. Our findings support this concept by 
demonstrating that glibenclamide inhibits the vasodilator response to dipyridamole 
but not to adenosine. This observation has potentially clinical relevance in patients 
who use glibenclamide. When these patients are evaluated for cardiac ischemia with 
Thallium scintigraphy, our results suggest that adenosine should be preferred over 
dipyridamole to prevent underestimation of ischemia. The forearm-studies described 
in this thesis do not enable to draw a conclusion on this issue. Studies on the effects 
of chronic glibenclamide treatment on adenosine- and dipyridamole induced coronary 
vasodilation in humans are scarse and conflicting. Farouque et al. [2] found a dose-
dependent reduction of basal coronary flow and adenosine-induced hyperemia, 
whereas coronary flow reserve was unaffected. Reffelmann et al. [3] found no effect 
of glibenclamide on basal coronary flow, adenosine-stimulated hyperemia or flow 
reserve. In the work by Reffelmann, hyperinsulinemia was induced by the 
administration of intravenous glibenclamide wich may have blurred the results by 
inducing a vasodilatory action.  
Finally, results from glibenclamide-studies can not be translated to newer 
sulfonylurea drugs with a lower affinity for to the vascular KATP channels without 
further evidence [4;5] . 
 
4. What is the vasomotor action of AP5A in humans, and what is the role of 
adenosine in AP5A-induced changes in vascular tone (chapter 4). 
In contrast to animal studies, our data clearly show that intra-arterial infusion of AP5A 
does not evoke vasoconstriction. The observed vasodilator response to this 
diadenosine is explained by degradation to adenosine as evidenced by interaction 
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studies with dipyridamole and theophylline. Our study disproves the concept that the 
vasomotor action of thrombocyte-derived AP5A plays a causal role in hypertension.  
Over the last years, research on diadenosine polyphosphates has not yielded 
clinically relevant results. Holla et al [6] described that thrombocyte concentrations of 
AP5A and AP6A are elevated in patients with essential hypertension. He 
hypothesizes that vasoconstriction caused by release of AP5A and AP6A from 
thrombocytes may contribute to the increase of vascular resistance in hypertensive 
patients. A causal relationship is lacking however. Recently, AP4 was isolated from 
human ventricular cells [7]. AP4 is a possible metabolite of AP5A. AP4 exerted 
vasodilation via endothelial P2Y1 receptors and vasoconstriction via P2X receptors 
on vascular smooth muscle cells. The role of AP4 in the forearm vasodilator response 
to AP5A is currently not known. 
 
5. Do benzodiazepines inhibit cellular adenosine uptake in the human forearm 
(chapter 5). 
In contrast to dipyridamole, clinically relevant concentrations of diazepam or  
midazolam did not augment the forearm vasodilator response to adenosine. This  
observation excludes an important interaction of these benzodiazepines with the  
nucleoside transporter. The apparent discrepancy with in-vitro data in the literature is  
most likely explained by the used concentrations of benzodiazepines which is higher  
in the reported in-vitro studies. Interestingly, we did not observe a vasodilator  
response to locally infused benzodiazepines, suggesting that a decrease in blood  
pressure that is often observed after intravenous infusion of benzodiazepines results  
from actions of these drugs in the central nervous system, unrelated to  
inhibition of nucleoside transport. 
 
6. What is the mechanism of ATP-induced vasodilation in the human forearm 
(chapter 6). 
The forearm vasodilator response to intra-arterial infusion of ATP appeared to be 
remarkably resistant to our pharmacological attempts to inhibit NO-synthase, cyclo-
oxygenase, Na/K-ATPase, ATP sensitive potassium channels and Ca2+-sensitive 
potassium channels. Therefore, the mechanism of vasodilation of this ubiquitous 
endogenous purine remains enigmatic in humans in vivo. We speculate that a 
currently unknown endothelium-derived relaxing factor is involved in this powerful 
vasodilator response to ATP. Further studies are needed to reveal this substance. 
 
7. Is the vasodilator response to adenosine reduced in patients with 
uncomplicated insulin dependent diabetes mellitus (chapter 7). 
Our study did not reveal a significant impairment of the vasodilator response to 
adenosine in patients with type 1 diabetes. Therefore, A2-adenosine receptor 
responsiveness seems to be intact in these patients. The main drawback of our study 
is that the experiments were performed in a hyperinsulinemic state, but we can still 
conclude that the vascular responsiveness to adenosine is preserved in patients with 
diabetes mellitus who are regularly treated with insulin. Whether A1-adenosine 
receptor-mediated protection against ischemia-reperfusion injury is reduced in these 
patients remains an unanswered question that needs to be addressed in further 
studies.  
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In summary, the experiments that are described in this thesis provide three 
independent lines of evidence that dipyridamole inhibits cellular uptake of 
extracellular adenosine in humans in vivo: (1) dipyridamole reduces the clearance of 
interstitial and intravascular adenosine as assessed by microdialysis, (2) 
dipyridamole-induced vasodilation is inhibited by the adenosine receptor antagonist 
theophylline and (3) dipyridamole augments the vasodilator response to exogenous 
adenosine.  
Based on these results, dipyridamole was used as a pharmacological tool to study 
the role of adenosine in the exercise-pressor reflex and in the vasodilator response to 
AP5A. Our observations indicate that adenosine does not play an important role in 
the blood pressure response to non-ischemic handgrip exercise in healthy 
volunteers. Dipyridamole augmented the vasodilator response to AP5A, indicating 
important involvement of adenosine, a degradation product of AP5A. The latter 
conclusion was further substantiated by an inhibitory action of theophylline on AP5A-
induced vasodilation and in-vitro data supporting rapid degradation of AP5A to 
adenosine.  
The observed difference between dipyridamole and adenosine-induced vasodilation 
with respect to their interaction with glibenclamide can be explained by differences in 
distribution between endogenous and exogenous adenosine and may have clinical 
importance in patients with type 2 diabetes who are treated with glibenclamide and 
are scheduled for a stress-Thallium scan of the heart. 
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De experimenten die in dit proefschrift worden beschreven zijn opgezet om de 
kinetiek van adenosine in de humane in-vivo situatie te bestuderen, en zijn 
toegespitst op de volgende vragen: 
 
1. Wat is het effect van intra-arteriëel geinfundeerd dipyridamol en adenosine op 
de interstitiële en intravasculaire adenosine-concentraties (Hoofdstuk 2).  
Gebaseerd op de resultaten beschreven in hoofdstuk 2, concluderen we dat intra-
arteriëel geïnfundeerd adenosine in de humane in-vivo situatie het interstitium van 
skeletspierweefsel niet bereikt. Deze bevinding komt overeen met in-vitro studies 
waaruit bleek dat het endotheel een metabole barrière vormt die adenosine 
belemmert om het interstitium te bereiken. Deze bevinding ondersteunt het concept 
dat de lokale effecten van intra-arteriëel toegediend adenosine, zoals vasodilatatie, 
presynaptische remming van noradrenaline-afgifte uit sympathische zenuweinden in 
de onderarm, en stimulatie van sympathische afferenten leidend tot 
gegeneraliseerde sympathicus-activatie, gemedieerd worden door adenosine-
geinduceerde afgifte van endotheliale factoren.  
Dipyridamol verminderde de klaring van zowel intravasculair als interstitiëel 
adenosine, hetgeen direct biochemisch bewijs vormt dat dipyridamol de cellulaire 
uptake van adenosine uit deze compartimenten remt. Verrassend was echter dat de 
interstitiële toegang van intra-arteriëel adenosine niet vergroot werd door gelijktijdige 
remming van nucleosidetransporters met dipyridamol. Vooralsnog hebben wij geen 
goede verklaring voor deze bevinding. Mogelijk zijn dipyridamol-ongevoelige 
nucleosidetransporters op endotheel-cellen verantwoordelijk voor de endotheliale 
metabole barrière voor adenosine.  
Een andere bevinding die moeilijk verklaarbaar is, is waarom dipyridamol geen 
toename gaf van de basale interstitiële en/of intravasculaire adenosine-
concentraties, ondanks de observatie dat dipyridamol-geïnduceerde vaatverwijding 
geremd wordt door adenosinereceptorblokkade (zie onder). Waarschijnlijk vindt 
basale adenosineproduktie plaats in de bloedvatwand (in het endotheel) op een 
plaats die niet toegankelijk is voor interstitiële of intravasculaire microdialyse 
catheters. Een alternatieve verklaring is dat een geringe toename van interstitiëel 
adenosine tijdens infusie van dipyridamol onder de detectie grens blijft van de 
toegepaste microdialyse-techniek, maar wel toereikend is om vasodilatatie te 
induceren. Onze bevinding dat het endotheel in de humane onderarm een barrière 
vormt voor de toegang van intravasculair adenosine tot het interstitium is reeds 
beschreven in een recente publicatie door Gamboa et al. [1]. In tegenstelling tot onze 
resultaten, induceerde intraveneuze dipyridamol-infusie een toename van de 
interstitiële adenosineconcentratie tijdens intra-arteriële infusie van adenosine. Deze 
contrasterende resultaten kunnen verklaard worden door een verschil in 
experimentele set-up. Gamboa et el. dienden dipyridamol intraveneus toe in een 
dosering waarvan aannemelijk is dat het geleid heeft tot gegeneraliseerde sympatho-
excitatie, hetgeen geresulteerd kan hebben in toegenomen perivasculaire release 
van de co-transmitter ATP, en vervolgens toegenomen vorming van interstitiëel 
adenosine. Een alternatieve verklaring kan gezocht worden in verschil in techniek ter 
kwantificering van het dialysaat-adenosine, wat in theorie geleid kan hebben tot de 
contrasterende resultaten.  
 
2. Wat is de rol van adenosine in de “pressor respons” op inspanning bij 
gezonde vrijwilligers (Hoofdstuk 2). 
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Infusie van dipyridamol in de arteria brachialis gaf géén toename van de 
bloeddrukstijging o.i.v. inspanning. Het onbreken van potentiëring van deze 
bloeddrukstijging werd waargenomen ondanks een bewezen remming van de klaring 
van extracellulair endogeen adenosine uit het interstitiële skeletspiercompartiment. 
Samen pleiten deze bevindingen tegen een rol voor endogeen adenosine in de 
bloeddrukrespons op niet-ischemische inspanning bij gezonde vrijwilligers. De 
huidige bevindingen sluiten een rol voor adenosine in de “pressor respons” op 
ischemische inspanning bij gezonde vrijwilligers of bij patiënten met verminderde 
perfusie van contraherende skeletspieren (zoals patiënten met hartfalen) echter niet 
uit.  
 
3.  Is er verschil in het vaatverwijdende mechanisme tussen interstitieel en 
intravasculair adenosine (Hoofdstuk 2 en 3). 
Nadat het effect van dipyridamol op adenosinekinetiek biochemisch is beschreven in 
hoofdstuk 2, wordt het vaatverwijdende effect van dipyridamol nader onderzocht in 
hoofdstuk 3, en vergeleken met het vaatverwijdende effect van adenosine. Op de 
eerste plaats werd aanvullend bewijs verkregen voor het remmende effect van 
dipyridamol op de cellulaire uptake van extracellulair adenosine, doordat werd 
aangetoond dat dipyridamol het vaatverwijdende effect van adenosine versterkt. De 
veronderstelling was dat dipyridamol vaatverwijding induceert doordat het de 
extracellulaire adenosine-concentratie verhoogt, resulterend in stimulatie van de 
adenosinereceptor op plaatsen waar endogeen adenosine gevormd wordt. Deze 
veronderstelling werd ondersteund door een test waarbij de vaatverwijdende respons 
in de onderarm op zowel adenosine als dipyridamol geantagoneerd werd door de 
adenosinereceptorantagonist theophylline. Mogelijk vindt endogene 
adenosinevorming voornamelijk plaats binnenin de vaatwand en in de interstitiële 
ruimte, een compartiment dat niet goed toegankelijk is voor intravasculair adenosine 
(zie paragraaf 1). In dat geval zou infusie van dipyridamol in de arteria brachialis 
adenosinereceptoren op gladde spiercellen stimuleren terwijl infusie van adenosine 
deze receptoren op het endotheel stimuleert. De signaaltransductie voor 
vasodilatatie zou verschillend kunnen zijn voor endotheel en voor vasculair glad 
spierweefsel. In het bijzonder zou de rol van KATP-kanalen verschillend kunnen zijn 
voor de twee celtypen. Daarom werd het effect van glibenclamide bestudeerd (een 
blokker van KATP-kanalen) op de vaatverwijdende respons in de onderarm op 
adenosine en dipyridamol-infusie in de arteria brachialis van gezonde vrijwilligers. De 
resultaten steunen de veronderstelling omdat bleek dat glibenclamide wel de 
vaatverwijdende respons op dipyridamol maar niet die op adenosine remt. Deze 
bevinding is van potentieel klinisch belang voor patiënten die glibenclamide 
gebruiken. Wanneer deze patiënten geëvalueerd worden onder verdenking van 
cardiale ischemie door middel van Thallium scintigrafie, suggereren onze resultaten 
dat adenosine de voorkeur heeft boven dipyridamol om onderschatting van de ernst 
van de ischemie te voorkomen. Uit de studies uitgevoerd met het `onderarmsmodel`, 
beschreven in Hoofdstuk 3 van dit proefschrift, kan hierover echter geen conclusie 
getrokken worden. Onderzoek naar de effecten van chronische 
glibenclamidebehandeling op adenosine- en dipyridamol geinduceerde coronaire 
vasodilatatie bij mensen zijn spaarzaam en de resultaten zijn niet eensluidend. 
Farouque et al. [2] vonden een dosis-afhankelijke reductie van de basale coronaire 
flow en van adenosine-geinduceerde hyperemie, terwijl de coronaire flow reserve 
onveranderd bleef. Reffelmann et al. [3] vonden geen effect van glibenclamide op de 
basale coronaire flow, op adenosine-gestimuleerde hyperemie of flow reserve. In het 
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onderzoek door Reffelmann, werd hyperinsulinemie geinduceerd door de toediening 
van intraveneus glibenclamide hetgeen de resultaten vertekend kan hebben doordat 
hyperinsulinemie vaatverwijding induceert.  
Tot slot kunnen resultaten van onderzoek uitgevoerd met glibenclamide niet zonder 
meer vertaald worden naar nieuwere sulfonylureum-derivaten met een lagere 
affiniteit voor de vasculaire KATP-kanalen [4;5] . 
  
4. Wat is het vasoactieve effect van AP5A bij de mens, en wat is de rol van 
adenosine bij AP5A-geïnduceerde veranderingen in vaattonus (Hoofdstuk 4). 
In tegenstelling tot dierexperimentele studies, laten onze data duidelijk zien dat intra-
arteriële infusie van AP5A geen vasoconstrictie veroorzaakt. De waargenomen 
vaatverwijdende respons op dit diadenosine-polyfosfaat wordt verklaard door 
degradatie tot adenosine, zoals blijkt uit interactie-onderzoek met dipyridamol en 
theofylline. Ons onderzoek pleit tegen het concept dat het vasomotore effect van 
AP5A afkomstig uit thrombocyten, een causale rol speelt bij hypertensie.  
Onderzoek op het gebied van de diadenosinepolyfosfaten heeft de afgelopen jaren 
geen klinisch relevante resultaten opgeleverd. Hollah et al. [6] beschreven dat 
thrombocyten-concentraties van AP5A en AP6A verhoogd zijn bij patiënten met 
essentiële hypertensie. Zijn hypothese is dat vasoconstrictie veroorzaakt door 
release van AP5A en AP6A uit thrombocyten kan bijdragen aan de toename in 
vaatweerstand bij patiënten met hypertensie. Een causale relatie is echter niet 
aangetoond. Recent werd AP4 geisoleerd uit humane ventrikulaire cellen [7]. AP4 is 
een mogelijke metaboliet van AP5A. AP4 induceerde vaatverwijding via endotheliale 
P2Y1 receptoren en vasoconstrictie via P2x receptoren op vasculaire gladde 
spiercellen. De rol van AP4 in de AP5A-gemedieerde vaatverwijdende respons in het 
skeletspiervaatbed van de onderarm is nog niet bekend. 
 
5. Hebben benzodiazepine-derivaten een remmend effect op de cellulaire 
adenosine uptake in de onderarm in de humane in-vivo situatie (Hoofdstuk 5). 
In tegenstelling tot dipyridamol, veroorzaakten diazepam en midazolam in klinisch 
relevante concentraties geen toename van adenosine-gemedieerde vaatverwijding in 
de onderarm. Deze waarneming pleit tegen een relevante interactie van deze 
benzodiazepinen met de nucleoside-transporter. De ogenschijnlijke discrepantie met 
in-vitro data in de literatuur wordt waarschijnlijk verklaard door de gebruikte 
benzodiazepineconcentraties, die hoger liggen in de in-vitro studies. We zagen geen 
vaatverwijdende respons op lokaal geïnfundeerde benzodiazepinen, hetgeen 
suggereert dat de bloeddrukdaling die vaak waargenomen wordt na intraveneuze 
infusie van benzodiazepinen veroorzaakt wordt via het centrale zenuwstelsel, en 
geen verband heeft met remming van de nucleosidetransporter. 
 
6. Wat is het mechanisme van ATP-geinduceerde vaatverwijding in de onderarm 
bij gezonde vrijwilligers (Hoofdstuk 6). 
De vaatverwijdende respons in de onderarm op intra-arteriële infusie van 
ATP bleek opvallend resistent tegen farmacologische pogingen tot remming van NO-
synthase, cyclo-oxygenase, Na/K-ATPase, KATP-kanalen en KCa2
+-kanalen. Het 
vaatverwijdende mechanisme van dit endogene purine in het door ons gebruikte 
model blijft dus nog onopgehelderd. Mogelijk is een nu nog onbekende “endothelium-
derived relaxing factor” betrokken bij de krachtige vaatverwijdende respons op ATP. 
Verder onderzoek is nodig om deze stof op te sporen. 
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7. Is de vaatverwijdende respons op adenosine verminderd bij patiënten met 
ongecompliceerde insuline-afhankelijke diabetes mellitus (Hoofdstuk 7). 
Ons onderzoek liet geen significante afname zien van de vaatverwijdende respons 
op adenosine bij patiënten met type 1 diabetes. De A2-adenosine receptor 
gevoeligheid lijkt daarom intact te zijn bij deze patiënten. Het grootste bezwaar van 
ons onderzoek is dat de experimenten werden uitgevoerd in een 
hyperinsulinemische toestand. In elk geval kan geconcludeerd worden dat de 
vasculaire gevoeligheid voor adenosine bewaard gebleven is bij patienten met 
diabetes mellitus die behandeld worden met insuline. Of A1-adenosine receptor-
gemedieerde bescherming tegen ischemie-reperfusie schade afgenomen is bij deze 
patiënten is door ons niet onderzocht.  
 
 
Samengevat biedt het onderzoek dat beschreven staat in dit proefschrift drie 
onafhankelijke bewijzen dat dipyridamol de cellulaire uptake van extracellulair 
adenosine bij gezonde vrijwiligers in-vivo remt. (1) Dipyridamol vermindert de klaring 
van interstitiëel en intravasculair adenosine zoals gemeten met microdialyse. (2) 
Dipyridamol-geinduceerde vaatverwijding wordt geremd door de 
adenosinereceptorantagonist theophylline en (3) dipyridamol versterkt de 
vaatverwijdende respons op exogeen adenosine.  
Gebaseerd op deze bevindingen, werd dipyridamol als farmacologisch middel 
gebruikt om de rol van adenosine te bestuderen in de “exercise-pressor reflex” en bij 
de vaatverwijdende respons op AP5A. Onze resultaten wijzen erop dat adenosine 
geen belangrijke rol speelt in de bloeddrukrespons op niet-ischemische inspanning 
bij gezonde vrijwilligers. Dipyridamol versterkte de vaatverwijdende respons op AP5A, 
wat wijst op substantiële betrokkenheid van adenosine, een degradatie produkt van 
AP5A. Deze laatste conclusie is bovendien aannemelijk omdat theofylline AP5A-
geinduceerde vaatverwijding remt en omdat in-vitro data een snelle degradatie van 
AP5A tot adenosine ondersteunen.  
Het waargenomen verschil tussen dipyridamol en adenosine-geïnduceerde 
vaatverwijding met betrekking tot hun interactie met glibenclamide kan verklaard 
worden door verschil in distributie tussen endogeen en exogeen adenosine en zou 
klinisch van belang kunnen zijn bij patiënten met type 2 diabetes die behandeld 
worden met glibenclamide en een stress-Thallium scan van het hart moeten 
ondergaan. 
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